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Abstract
The recent development in quantitative measurements and access to interaction
databases facilitate the construction of detailed molecular interaction maps of cellular
processes. Such networks serve as a knowledge-base and being machine readable are
amenable to computational analysis. Studying biochemical networks as a non-linear
dynamical system is challenging due to a large number of components and complex
network structures including feedback/feedforward loops.
In this thesis, I propose an integrative workﬂow to study large-scale biochemical
networks by combining techniques from bioinformatics and systems biology. It
integrates heterogeneous sources of biological information with network structure and
dynamical systems analysis to unravel mechanisms underlying diseases. To this end, we
constructed a comprehensive interaction map for the transcription factor E2F1 to
understand its functional role in diﬀerent traits of cancer, such as drug resistance and
epithelial-mesenchymal transition (EMT). The network contains 1,015 nodes and 4,180
interactions. Further, the network structural analysis revealed a large number of
feedback and feedforward loops. To make such a large, complex network suitable for
dynamical analysis, I developed a ﬂexible and extendible workﬂow based on
multi-objective optimization function. It combines network structural properties with
high-throughput and biomedical data to identify smaller modules which I refer to as
core-regulatory networks that are amenable for analysis with dynamical systems
theory. Using the proposed workﬂow, I identiﬁed core-regulatory networks from the
E2F1 molecular interaction map underlying EMT in bladder and breast cancer. I
carried out dynamical analyses of the core-regulatory networks using logic-based
modeling. Using in silico stimulus-response and perturbation experiments, I detected
molecular signatures and potential drug targets for each cancer type. The in silico
predictions were validated with patient data and through in vitro experiments.
Moreover, I developed a hybrid modeling framework that combines ordinary
diﬀerential equation models with logic-based models as a strategy to analyze the
dynamics of large-scale non-linear biological systems. Using the proposed hybrid
modeling strategy, I simulated the known dynamical features of the
E2F1-p73/DNp73-miR205 network in drug resistance for diﬀerent concentrations of the
transcription factor E2F1 and receptor molecules. Further, the results of hybrid model
analyses suggest that cancer cells might become independent of growth factors when
E2F1 is highly expressed.
This thesis is a contribution to interdisciplinary cancer research, providing a
methodology for the analysis of large-scale networks in molecular and cell biology.
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Zusammenfassung
Die jüngste Entwicklung quantitativer Messungen und der Zugang zu
Interaktionsdatenbanken ermöglichen die Erstellung detaillierter molekularer
Interaktionskarten zellulärer Prozesse. Solche Netzwerke dienen als Wissensbasis und
sind maschinenlesbar und können rechnerisch analysiert werden. Die Untersuchung
biochemischer Netzwerke als nichtlineares dynamisches System ist aufgrund einer
großen Anzahl von Komponenten und komplexen Netzwerkstrukturen, einschließlich
Rückkopplungs-/Vorwärtskopplungsschleifen, eine Herausforderung.
In dieser Arbeit schlage ich einen integrativen Workﬂow vor, um biochemische
Netzwerke in großem Maßstab zu untersuchen, indem Techniken aus der Bioinformatik
und der Systembiologie kombiniert werden. Es integriert heterogene biologische
Informationsquellen in die Netzwerkstruktur und die Analyse dynamischer Systeme, um
Mechanismen aufzudecken, die Krankheiten zugrunde liegen. Zu diesem Zweck haben
wir eine umfassende Interaktionskarte für den Transkriptionsfaktor E2F1 erstellt, um
seine funktionelle Rolle bei verschiedenen Krebsmerkmalen wie Arzneimittelresistenz
und epithelial-mesenchymal transition (EMT) zu verstehen. Das Netzwerk enthält
1.015 Knoten und 4.180 Interaktionen. Ferner ergab die Netzwerkstrukturanalyse eine
große Anzahl von Rückkopplungs- und Vorwärtskopplungsschleifen. Um ein so großes,
komplexes Netzwerk für dynamische Analysen geeignet zu machen, habe ich einen
ﬂexiblen und erweiterbaren Workﬂow entwickelt, der auf der Funktion zur Optimierung
mehrerer Ziele basiert. Es kombiniert Netzwerkstruktureigenschaften mit
Hochdurchsatzdaten und biomedizinischen Daten, um kleinere Module zu identiﬁzieren,
die ich als "Kernregulierungsnetzwerke" bezeichne, die für die Analyse mit der Theorie
dynamischer Systeme geeignet sind. Unter Verwendung des vorgeschlagenen Workﬂows
identiﬁzierte ich aus der molekularen E2F1-Wechselwirkungskarte, die der EMT bei
Blasen- und Brustkrebs zugrunde liegt, zentrale regulatorische Netzwerke. Ich habe
dynamische Analysen der Kernregulierungsnetzwerke mit logikbasierter Modellierung
durchgeführt. In silico Stimulus-Response- und Störungsexperimenten entdeckte ich
molekulare Signaturen und potenzielle Wirkstoﬀtargets für jeden Krebstyp. Die in silico
Vorhersagen wurden mit Patientendaten und durch In-vitro-Experimente validiert.
Darüber hinaus entwickelte ich ein hybrides Modellierungsgerüst, das gewöhnliche
Diﬀerentialgleichungsmodelle mit logikbasierten Modellen kombiniert, um die Dynamik
nichtlinearer biologischer Großsysteme zu analysieren. Unter Verwendung der
vorgeschlagenen Hybridmodellierungsstrategie simulierte ich die bekannten
dynamischen Merkmale des E2F1-p73 / DNp73-miR205-Netzwerks hinsichtlich der
Arzneimittelresistenz für verschiedene Konzentrationen des Transkriptionsfaktors E2F1
und der Rezeptormoleküle. Ferner legen die Ergebnisse von Hybridmodellanalysen
nahe, dass Krebszellen von Wachstumsfaktoren unabhängig werden könnten, wenn
E2F1 stark exprimiert wird.
Diese Dissertation ist ein Beitrag zur interdisziplinären Krebsforschung und liefert eine
Methodik zur Analyse von großräumigen Netzwerken in der Molekular- und Zellbiologie.
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Chapter1
Introduction
Large parts of this chapter were published in a book chapter:
 Khan F.M., Sadeghi M., Gupta S.K., Wolkenhauer O. (2018) A Network-Based
Integrative Workﬂow to Unravel Mechanisms Underlying Disease Progression. In:
Bizzarri M. (eds) Systems Biology. Methods in Molecular Biology, vol 1702. Humana
Press, New York, NY. https://doi.org/10.1007/978-1-4939-7456-6_12.
Synopsis
In this chapter, I describe the prospects and challenges of analyzing large-scale
biochemical networks to discover and characterize key regulatory mechanisms underlying
complex diseases (e.g., cancer). The large number and the nonlinear nature of
interactions hamper the analysis of biochemical networks. Here, I discuss methods for
structural and dynamical analysis of biochemical networks and propose an integrative
workﬂow that combines these analyses with high throughput and clinical data to unravel
mechanisms underlying diseases. Finally, I outline the structure of this thesis, the
objective of each chapter, and summarize the contribution of my work to the ﬁeld.
1.1. Motivation and objectives
In order to investigate the complex behavior of cancers, such as tumor invasion and
drug resistance, interdisciplinary collaborations often start with the gathering of
information from the literature and databases, summarizing components and their
interactions relevant for the processes under consideration. The machine-readable
representation of this information typically leads to interaction maps composed of a
large number of components that are involved in signaling, gene regulation and
metabolism. These interaction maps serve as a knowledge base and are amenable for
computational analysis to generate new hypotheses. Analyzing the structure of
biochemical networks provides useful information including network hubs [1], regulatory
motifs [2], and often global features like small world organization [3] of the system. The
analysis of regulatory motifs, especially feedback and feedforward loops, can provide
1
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novel insights into the regulatory mechanisms controlling the normal and disease states
of the cell [2, 4]. Their nonlinear dynamics, however, not only challenge human
intuition but also limit the application of conventional data analysis tools [5, 6].
Moreover, for large scale biochemical networks a dynamical analysis is particularly
diﬃcult with mechanistic (e.g., ordinary diﬀerential equation (ODE) based) approaches
from the theory of dynamical systems. In order to exploit the advantages of large-scale
biochemical networks in combination with mechanistic modeling, we need integrative
approaches and computational workﬂows that combine diﬀerent systems biology and
bioinformatics tools to integrate heterogeneous sources of biological information. This
can allow us to identify disease speciﬁc small regulatory modules that can be subjected
to a more detailed analyses, followed by the prediction of molecular signatures and
therapeutic targets.
In this thesis, I developed a new integrative workﬂow to study large-scale biochemical
networks by combining techniques from bioinformatics and systems biology, in
combination with the integration of experimental and clinical data to understand and
unravel mechanisms underlying diseases. In this context, I constructed a comprehensive
interaction map of the transcription factor E2F1 to understand its functional role in
drug resistance and epithelial-mesenchymal transition (EMT). To make such large
networks suitable for dynamical analysis, I developed a ﬂexible and extendible method
that combines network structural analysis with high throughput data and biomedical
data to identify smaller `modules' for speciﬁc disease phenotypes. I hereafter refer to
these as core-regulatory networks [7, 8] that are amenable for an analysis with
dynamical systems theory. A mathematical model (e.g., ODE-based, logic-based or
hybrid model) of the identiﬁed smaller modules can be constructed to give mechanistic
insights into diseases and propose new hypotheses, which are subjected to experimental
validation. Using the proposed workﬂow, I analyzed the large-scale molecular
interaction network of E2F1 and identiﬁed core-regulatory networks for EMT processes
in bladder and breast cancers. Further, I developed logic-based models of the
core-networks and using in silico stimulus response analyses, I detected molecular
signatures that render non-invasive cancer into invasive. Furthermore, I carried out in
silico perturbation experiments and predicted therapeutic targets that can reduce the
invasive behavior of cancer cells. The model predictions were validated experimentally
and through patient data.
Systems biology approach oﬀers mathematical modeling formalisms suitable for
biological systems at diﬀerent abstraction levels depending on the size, structure and
type of data or information available. ODE-based kinetic models are well established
approaches for detailed quantitative analyses of small, nonlinear systems, while
logic-based models are well appreciated for coarse-grained qualitative analyses of large
systems. I developed a hybrid modeling framework that combines kinetic models with
logic-based models as a strategy to model large-scale, nonlinear biochemical
networks [9]. The hybrid model characterized the nonlinear dynamics of the
2
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E2F1-p73/DNp3-miR205 network in drug resistance and revealed that cancer cells
might get independent of growth factors when the transcription factor E2F1 is highly
expressed.
Ultimately, the proposed integrative workﬂow provides a powerful foundation to
decipher the mechanisms underlying complex diseases that would lead to a better
prognosis and an eﬀective therapeutic intervention.
The speciﬁc objectives of this thesis are:
 Construction of an E2F1 interaction map (Chapter 2)
 Identiﬁcation of tumor-speciﬁc core regulatory networks (Chapter 2)
 Logic-based modeling of tumor invasion (Chapter 3)
 ODE-based and hybrid modeling of drug resistance (Chapter 4)
1.2. The Systems Biology Approach
Biological processes are complex, composed of a large variety and number of components
that interact in a nonlinear fashion in space and time. Non-linear processes in particular
induce counter-intuitive behavior, which is impossible to understand by unaided human
observations. The systems biology approach combines experiments with computational
tools and methods to understand such complex processes [10, 11]. We consider the
systems biology approach as an interdisciplinary collaboration that realizes an iterative
cycle of data-driven modeling and model-driven experimentation (Figure 1.1). A research
project taking a systems biology approach, often starts by gathering information about
a biological process from literature and databases. The information is organized and
represented in a form of machine-readable network which is a formalized representation
of a large number of individual experimental results. The network is then computationally
analyzed, for example modeled (mathematically) with a certain modeling formalism to
perform dynamical system analyses. After calibration with experimental data, the model
should mimic the biological phenomena under consideration, and could perform stimulus
response and perturbations analyses, which are used to formulate/reﬁne hypotheses and
therefore, supports the design of new experiments. If experiments justify the hypothesis,
it will generate new knowledge, which may be used for developing another model. In
this way, the systems biology approach cycles between data-driven modeling and model-
driven experimentation. More speciﬁcally, we can divide this approach into four main
stages:
(i) Setting the context: This step starts with the formulation of a biological question
that is to be investigated. For example, a general question could be: What are the
regulatory mechanism(s) underlying breast tumor metastasis or drug resistance?. This
deﬁnes the project boundaries and gives directions to collect information from literature
and databases. The collected information is then converted into a machine readable
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format (i.e., in the form of a network) for computational analysis. With the help of
domain experts or using computational methods, project-speciﬁc network components
or modules are then chosen.
(ii) Representation of a sub-/system: Mapping out the interactions among
biochemical entities, like genes, proteins, or miRNAs, as a network provides a platform
for structural and dynamical analysis of the system. A large set of network
visualization tools (e.g., CellDesigner [12], Cytoscape [13], VANTED [14] and
SBGN-ED [15]) are used to construct these networks, representing biological processes
from abstract to more detailed levels depending on the requirements of the biological
question and available knowledge. Based on available knowledge and the domain
expert's opinion the directions of the interactions (e.g., activation or inactivation)
among molecular entities are deﬁned or hypothesized. Depending on network size and
kinetic details, a suitable modeling formalism is chosen to analyze the dynamics of a
system for stimulus response behavior and diﬀerent perturbations.
(iii) Model construction: This step starts with the detailed description of the
molecular interactions providing the biochemical and biophysical information. For
example, biochemical interactions characterize the activation/inactivation in terms of
phosphorylation/dephosphorylation and biophysical interactions describe what enzyme
or catalyst regulates the reaction. For dynamical system analyses the interactions can
be represented by: (i) a system of mathematical equations, which we refer to as the
mathematical model e.g., system of ODEs, or (ii) a system of computational entities
forming computational model e.g., Petri Nets [16]. Each equation in mathematical
model contains variables and parameters. Variables are the quantity of interest in a
model, which changes over time e.g., concentrations of proteins in a cell. Parameters
characterize the speciﬁc quantitative behavior of a model and are ﬁxed quantities for a
given computational experiment. Model parameter values are identiﬁed and
characterized by model calibration with data [17, 18], and from available biological
information and databases like SABIO-RK [19] and BioModels [20].
(iv) Validation and experimentation: After the identiﬁcation of model parameter
values, analytical tools (e.g., bifurcation and sensitivity analysis) are used to
identify/investigate the model's dynamical behavior. Model simulations reproduce the
known aspects of biological reality and develop new hypotheses, which help to unravel
unknown regulatory mechanisms underlying complex processes. Hypotheses made by
model simulations need to be validated by designing new experiments. If the model
predictions are validated by experiments it will provide a reasonable explanation of the
underlying mechanisms and sharpen our understanding of the complex processes.
4
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Figure 1.1. The systems biology approach. An iterative process of data-driven
modeling and model-driven experimentation.The ﬁgure is taken from Khan et al.,
2018 [21].
1.3. Biochemical networks
To elucidate the structure and functional roles of interacting components in a given
cellular (mal)function, it is essential to have a blueprint of these interactions in the form
of a network, which is a collection of nodes (genes, proteins, metabolites etc.) and edges
(reactions, physical relation, conversion, transport step etc.). These networks serve as
knowledge base and provide a foundation for computational analysis and, furthermore,
give valuable insights into the interactions (mechanisms) among components that realize
a certain functionality. Various types of interaction networks (including protein-protein
interactions, metabolic, signaling, transcription and gene-regulatory networks) can be
constructed by gathering the relationship data (i.e., interactions) from individual studies
and high-throughput screening (Figure 1.2).
Signal transduction networks are composed of nodes representing signaling proteins
that generate and process information in response to external changes or stimuli
(Figure 1.2a). The edges are chemical reactions that are often reversible modiﬁcations
5
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where the signals are internally propagated in the form of, for example, protein
phosphorylation or dephosphorylation cascades, which ultimately results in the
activation or deactivation of a transcription factor. Numerous databases (e.g., PID [22],
BioCarta [23], SPIKE [24], WikiPathways [25], CST Signaling Pathways [26], The Cell
Collective [27], iHOP [28], SignaLink [29] and NetPath [30]) are available that collect
and organize data about signal transduction. These can be used to construct a signal
transduction network.
P
P
P
Ligand
receptor
Cascade
Transcription factors
Genes
a Signal transduction network
Transcription factors
Genes
mRNA
Protein
Degradation
miR1 miR2
b Gene regulatory network
Metabolites
c Metabolic network
Proteins
A
Interactions
d Protein-protein interactions network
Figure 1.2. Visualization of biochemical networks. Various types of biochemical
networks can be constructed based on physical or causal interactions among the
interacting components. The ﬁgure are adopted from Khan et al., 2018 [21].
Gene regulatory networks (GRNs) are modeled as directed graphs where nodes are
either transcription factors or genes and edges are the interactions between transcription
factors and the genes that they regulate (Figure 1.2b). A GRN is a structured set of
information that speciﬁes how the transcription machinery responds to biological signals
that accordingly change the expression of genes, allowing the cell to make the proteins
they need at appropriate time and amount. This transcriptional regulation also works in
a cascade fashion; an initial stimulus can transcribe a gene which triggers the expression
of large gene sets in turn. For a GRN construction one can derive information from
databases such as KEGG [31], TRANSFAC [32], TRRUST [33], HTRIdb [34], TRED [35]
and TransPath [36]. Further, GRN also contains microRNAs (miRNAs), small RNA
molecules that regulate the expression of certain genes by interacting with their mRNA
targets and are involved in the modulation of various cellular functions [37]. miRNAs
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interact with their targets (miRNA-target gene interactions) and the transcription factors
(TF-miRNA interactions). miRNA-target gene interactions repress the translation of
mRNAs into proteins or degrade the mRNA expression of the target. In TF-miRNA
interactions, miRNA's are up or down-regulated by diﬀerent transcription factors. For
each type of interaction a number of public databases (e.g., for miRNA-target gene
interactions: miRecords [38], TarBase [39], miRTarBase [40], miRWalk [41], miRGen [42];
and for TF-miRNA interactions: TransmiR [43] and UCSC browser [44]) are available to
provide such information.
Metabolic networks are composed of metabolites that are connected through
biochemical reactions (i.e., conversion between the metabolites catalyzed by enzyme,
special type of proteins that regulate chemical reactions) (Figure 1.2c). Usually,
metabolic reactions yield the production of energy exchange (ATP
production/consumption) and synthesis of the biomolecules such as amino acids,
sugars, and lipids which the cell needs for growth, reproduction, self-maintenance or
communication with other cells. Some important databases that accumulate data for
metabolic network reconstruction are KEGG [31], BioCyc [45], MetaCyc [46],
BRENDA [47], BiGG [48], metaTIGER [49] etc.
Protein-protein interaction (PPI) networks represent the physical interaction
among proteins, if they bind with each other (Figure 1.2d). It is a common practice to
infer PPIs from experimental data [50]. The main experimental techniques to infer
these networks are yeast two-hybrid screening and co-immunoprecipitation. There are
plenty of databases (including BioGrid [51], HPRD [52], STRING [53], IntAct [54],
PID [22], and MIPS [55]) that provide genome scale information about PPIs of various
species. These databases provide undirected PPIs. In directed PPI networks, the
interactions are labeled as either positive or negative based on the causal relationship of
interacting proteins. A positive interaction indicates one of the interacting proteins
being activated, while a negative interaction corresponds to an inactivated state.
Recently, Vinayagam et al. developed a systematic method by integrating PPI
networks with genetic screens to predict the `signs' for large-scale PPIs1 [56]. Further, a
databases called SIGNOR2 is also available to retrieve directed PPIs. Characterizing
activation-inhibition relationships between interacting proteins can be used as a scaﬀold
for understanding the mechanisms underlying complex biological processes.
All the described networks are interdependent and overlap with each other; and are
likewise collectively responsible for cellular behavior. For example, the external signal
activates the signaling pathway by ligand binding to receptors and the signal
propagates subsequently from surface to nucleus by means of protein
phosphorylation/dephosphorylation in the form of cascades. These cascades may
activate or inhibit transcription factors that regulate the expression of genes to produce
mRNA molecules. Certain sets of proteins can act as enzymes to catalyze the metabolic
1http://www.ﬂyrnai.org/SignedPPI/
2https://signor.uniroma2.it/
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reactions; and some of the de novo metabolite can in turn interact with transcription
factors to regulate gene expression.
Eﬀorts to represent interaction maps in an unambiguous and standard format, together
with access to expression data have led to a common practice of developing comprehensive
interaction maps that collect and organize molecular details to study complex cellular
processes in normal and disease states [5759]. These maps serve as knowledge-base
and being machine-readable are amenable for computational analysis to formulate new
hypotheses that can subsequently be tested by experiments.
1.4. Graphical representations of biochemical networks
Biochemical networks are not just drawings but a formalized representation of
numerous experimental studies carried out in labs around the world that are amenable
to analyze through computational tools. They are large and complex containing a
variety of biochemical entities having large numbers of interactions. In order to
uniformly organize and visualize such information, it requires a standardized encoding
scheme. Several network representation and visualization formalisms have been
proposed [6064]. Among them the Molecular Interaction Map (MIM) named as `Kohn
Map' [64] and the Kitano's `process diagram' [60] are the most popular ones. A MIM is
a diagram convection for the representation of complex biochemical networks,
containing multi-protein complexes, protein modiﬁcations, and enzymes that are
substrates of other enzymes. MIMs provide an organized knowledge-base for all
possible types of molecular interactions but due to graphical complexity and lack of
software support their use is quite scarce. Kitano's proposed graphical notation made
several improvements to the Kohn Map and provides a well deﬁned and clearly visible
notations system, powered by the `process diagram', which helps to understand the
temporal sequences of reactions. It is worth mentioning that the Kohn Map and the
improvements made by Kitano provide the foundation for standard graphical
representations of biological systems.
The Systems Biology Graphical Notation (SBGN) is adopted as a standard graphical
representation which facilitates an unambiguous representation and easy exchange of
complex biological knowledge in the form of standardized pathway maps [65]. SBGN
consist of three visual languages: (i) Entity Relationship (ER), (ii) Process Description
(PD), and (iii) Activity Flow (AF). The SBGN ER is largely inspired by MIM diagram
convention to represent all the relationships in which an entity participates regardless
of the temporal aspect. Kitano's Process Diagrams [66] and CellDesigner [12] are tools
that adopted the SBGN Process Description (SBGN PD) to represent mechanistic and
temporal relationships among entities involved in a biological process. It contains detailed
process information and can easily be converted into standardized machine readable code
such as Systems Biology Markup Language (SBML) [67] for computational analysis,
including computer simulations. The SBGN Activity Flow (SBGN AF) represents the
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causal relationship (e.g., stimulation, inhibition, state transitions) between molecules in
an abstract manner. Including CellDesigner, many pathways tools (see the list at3) are
already using the SBGN notation (Figure 1.3) for graphical representation. In this study,
we used CellDesigner for the construction of the E2F1 regulatory map.
3http://sbgn.github.io/sbgn/software_support/
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Figure 1.3. Glyphs of the graphical notation used by CellDesigner. The
diagram illustrates the main graphical symbols used by CellDesinger (Version 4.4) for
the representation of network components. The size and color of each symbol are
conﬁgurable. Source http://celldesigner.org/documents/StartupGuide41.pdf.
10
1.5 Network analysis
1.5. Network analysis
After gathering and managing information regarding biological systems in the form of
interactions networks, structural and dynamical analyses provide useful information
about the network architecture and dynamics. The structural analysis of networks
allows the identiﬁcation of functional modules, regulatory motifs (including feedback
and feed-forward loops) and node properties (including node degree (ND) and
betweenness centrality (BC)). The node degree is the number of edges (or links)
connected to a node. For example, in Figure 1.4 node `B' has six edges, thus its degree
is six (i.e., ND(B) = 6). The betweenness centrality of a node is the number of shortest
paths from all nodes to all others that pass through that node. In a network, a node
which occurs in many of the shortest paths has a high betweenness centrality. In
biochemical networks, nodes can be proteins, genes, miRNAs or metabolites etc.
Node properties have a signiﬁcant role in the network topology [6871]. For example,
networks with a node degree distribution follows a power law P (ND) = ND r are
called scale-free networks, where r is an approximated parameter whose value ranges
2 < r < 3. There are two important characteristics of scale-free networks; ﬁrst, they
contain `hubs', nodes comprising many more connections than others; secondly, these
networks are considered robust against single random perturbations [72, 73]. Similarly,
betweenness centrality indicates the centrality of a node in a network. A node with a
high BC serves as a gate keeper in the communication between diﬀerent parts of a
network. For example in Figure 1.4 node `A' connects the top and bottom part of a
network; it has the highest BC value [72].
Further, it is established that biological networks contains modules. A module is an
aggregations of densely interconnected neighboring nodes as shown by the green box in
Figure 1.4. It was shown that functionally akin nodes are located in close proximity
and, thus, form functional modules [74, 75]. These functionally related genes can be
associated with the same biological pathway and can have similar eﬀects on certain
disease phenotypes and may be targeted by structurally similar drugs [76, 77]. Further,
biological networks are enriched in recurring structural patterns called network
motifs [2]. Feedback and feed-forward loops are important network motifs which
induces non-intuitive behavior and play a crucial role in system dynamics [2, 78]. I
describe network motifs in detail in Section 2.1.4 on Page 26.
Network structure analysis revealed that the functioning and regulation of a network
are governed by a certain set of organizing principles [68]. To understand the
mechanisms of these organizing principles, mechanistic dynamical models are used to
analyze the systems. The dynamical properties of a network characterize the temporal
behavior of a network under certain conditions, which can help to explain the nature of
regulation of interacting components in response to stimuli/perturbations that aﬀect
the functionality of cells, and ultimately their consequences on the cellular phenotype.
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Figure 1.4. Properties of a molecular interaction network. In ﬁgure the circles
represent nodes of a network connected by edges. Node `A' has highest the betweenness
centrality, most of the shortest parts that connect each pair of nodes in this network
passes through node `A'. Node `B' has highest degree (i.e., the large number of edges
going in and out of this node). The green box represents a module, which is a cluster
of highly inter-connected nodes. If these nodes are involved in the regulation of a
particular cellular function it is called functional module.
1.6. Selection of mathematical modeling formalisms
Mathematical models are a well-established tool to elucidate the counter-intuitive
nonlinear dynamical features of complex biochemical networks in living cells. Models
are an abstract representation of the reality, and thereby their validity and usefulness
depend strongly on the context and the assumptions being made. Modelling is the art
of making appropriate assumptions. A variety of modeling formalisms have been
proposed [6, 79] and are applied depending on the availability of data, the type of
research question as well as the size and the structure of the system (Figure 1.5). Two
commonly used modeling formalisms are: (i) detailed quantitative models of (small)
functional modules using, for instance, ordinary diﬀerential equations
(ODEs) [4, 80, 81]; and (ii) coarse grained qualitative models of (large) sub-cellular
processes which can be encoded through logic-based formalisms [82].
ODE-based modeling: If the detailed kinetic information of relevant components
in a network are largely known, for a small-scale network a number of modeling
formalisms are used, such as, ODE-based models, stochastic models or agented-based
models [79, 83]. Among them, ODE-based models are widely used to analyze the
functional role of nonlinear biochemical networks [4, 80, 81]. In such models the
reactions are represented by a set of diﬀerential equations describing the change in
quantity (such as concentration) of reactants to products and vice versa in case of
reversible reactions. Based on reaction rates and kinetic parameters such models
usually yield high quality predictions of the system's dynamics with quantitative
information about molecular concentrations. We used ODE-based models to explain
the nonlinear dynamics induced by the E2F1-p73/DNp73-miR205 network of drug
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resistance in melanoma (for details see Section 4.3 on Page 64). These models however,
require accurate kinetic parameters, which is often infeasible for large networks,
therefore, ODE-based models of large biochemical systems are very diﬃcult if not
impossible to obtain/generate. In such cases a Boolean/logic-based models are a
suitable option [84, 85].
Logic-based modeling: Logic-based modeling is a popular approach to describe
the qualitative temporal behavior of large systems of interactions where experimental
data are sparse (not all can be measured, few time points) and uncertain (lack of
replicates and precision) [86]. Logic-based models are qualitative and do not require
detailed quantitative parameters which make them suitable for large-scale biochemical
networks [6, 82, 84, 8792]. In this modeling formalism, a network is represented as a
graph with nodes and edges, where a node represents any molecular species and edges
depict the type of eﬀect that one species exert on the state of another in terms of
activation/inactivation. The state of each species is determined by a logic-based
function that links the incoming eﬀect to a state. Logic-based models can provide
predictive testable hypotheses, which are especially valuable in poorly understood
large-scale systems [93, 94]. I used a logic-based model to analyze the stimulus-response
behavior of tumor-speciﬁc EMT regulatory networks in bladder and breast cancer. The
in silico analysis identiﬁed molecular signatures for each cancer type which were
validated by patient data and through shRNA-based experiments (for details see
Section 3.2 on Page 43). Logic-based models are qualitative and can not capture the
network dynamics where small variations can produce an entirely diﬀerent
state/behavior. Therefore, the choice for an appropriate modeling formalism for
biochemical networks which are large and have complex structures composed of
multiple regulatory loops, is challenging. I proposed a modeling strategy, which I here
refer to as hybrid models [9], that combines ODE-based and logic-based models to
accommodate a large-scale, nonlinear system of interactions.
Hybrid models: Hybrid models combine diﬀerent modeling formalisms to handle
systems that contain multiple aspects; for example discrete and continuous, linear and
non-linear dynamics. The biological system of the cell cycle is an appealing example that
contains discrete and continuous aspects [95, 96]. Alﬁeri et al. modeled the cell cycle as
a hybrid system using hybrid automata where the R-point (a point in G1 phase at which
the cell committed to the cell cycle) transition was modeled as a discrete event while the
mitogenic stimulation of the system was realized as a continuous state by ODEs [96]. In
Khan et al., I proposed a hybrid modeling formalism that combines the features of ODEs
and logic-based formalisms to provide an eﬃcient solution to model large-scale, non-
linear biochemical networks [9]. Using such a hybrid modeling approach, the network
is organized and divided into diﬀerent parts with distinctive regulatory features and
each part is modeled with the suitable modeling formalism (Figure 1.5). For instance
sub-networks that are enriched with feedback and feed-forward loops, and are therefore
expected to display a highly nonlinear behavior are modeled using ODEs, whereas target
13
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gene modules that represent an activation or inactivation regulation of dozens to hundreds
of genes are modeled using a logic-based formalism. Using a hybrid model, I performed
the stimulus-response analysis of the E2F1-p73/DNp73-miR205 network. It accurately
captured the eﬀect of nonlinear dynamics of regulatory motifs on a set of genes involved
in drug resistance in melanoma. Further, model simulations revealed that with high
expression of the E2F1 and EGFR receptors, tumor cells get independent of ligands (for
details see Section 4.4, Page 66). A hybrid model provides a good compromise between
quantitative/qualitative accuracy and scalability when considering large networks.
The standard representation of these models in the form of the Systems Biology
Markup Language (SBML), SBML qual package in case of logic-based models, and the
Systems Biology Graphical Notation (SBGN) allows for re-usability and exchange.
Databases such as the BioModels Database [20], and the CellML [97] and
SABIO-RK [19] repositories are used for model storage and exchange.
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Figure 1.5. Mathematical modeling formalisms. The core regulatory network
is modeled using ordinary diﬀerential equations (ODEs), the target genes module is
modeled using discrete logic-based modeling (Boolean or multi-valued logic), while the
phenotypical read-outs are encoded in ODEs or discrete logic-based modeling (multi-
valued logic). The ﬁgure is adopted from Khan et al., 2018 [21].
1.7. An integrative workﬂow to unravel mechanisms
underlying diseases
Recent technological advancements in biology yield remarkable amounts of data on
biological organisms but the mechanisms behind diseases remain largely elusive,
preventing the development of eﬃcient diagnostic and therapeutic measures. Towards
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mechanistic understanding, the systems biology and bioinformatics proposed many
computational methods and tools to process data in the functional context of a
biological system; but the inherent complexity associated with interacting components,
for example regulatory circuits and cross-talks among pathways, and massive network
size pose a methodological challenge to these methods. For example: (i) Transcriptomic
data analysis tools identify associated gene expression patterns for normal to disease
states; but due to genetic heterogeneity it can not explain the causes that induce such
patterns; (ii) graph theoretical analyzes of biological systems that are translated into
biochemical networks identiﬁes important hub nodes and small recurring regulatory
motifs but their utility is conﬁned only to static analysis; and (iii) dynamical systems
theory oﬀers a large number of modeling formalisms to simulate the dynamics of
biological systems for diﬀerent stimuli and perturbations but each modeling formalism
has its own limitations (see Figure 1.5). To overcome these limitations, we need
strategies that combine the strength of diﬀerent methods or tools, here named as
"integrative workﬂows", with the goal to eﬀectively analyze massive and complex
networks to understand the functionality of biological systems. The wide applicability
of high-throughput data and network-based analyses (i.e., network structure and
dynamics analysis) enables workﬂows to address biological and biomedical questions
where individual conventional methods are not performing well.
These integrative methods in systems biology are scarce but highly demanded. A
number of integrative methods are proposed that successfully identify key network
elements in diseases. Some are based on integrating data and networks to identify
regulatory modules in diseases [98100]. Others integrate network structural properties
with expression data to identify potential regulators for a disease [101103]. The recent
reviews by Mitra et al. [75] and Gustafsson [104] discuss integrative approaches, in
particular networks and data, to identify modules in regulatory networks underlying
disease.
Here, I propose an integrative workﬂow that combines techniques from systems
biology and bioinformatics, in combination with the integration of experimental and
clinical data to analyze large-scale biochemical networks with the aim to investigate
complex mechanisms underlying diseases (Figure 1.6). The workﬂow combines network
structural analysis with high-throughput and biomedical data to identify tumor-type
speciﬁc core-regulatory networks that are amenable for analysis with dynamical
systems theory. Using suitable modeling formalism, the core networks can be analyzed
to detect disease-speciﬁc molecular signatures (i.e., sets of network derived
diagnostic/prognostic biomarkers). The proposed molecular signatures are validated by
clinical data which are further subjected to in vitro experiments. The proposed
workﬂow was applied to our reconstructed E2F1 molecular interaction map and was
able to identify core-regulatory networks in invasive bladder and breast cancer (see
Chapter 2). Using a logic-based modeling formalism, I analyzed the stimulus response
behavior of the core networks to identify distinctive molecular signatures for EMT
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regulation in both cancer types. Further, I performed in silico perturbations of the core
network and determined possible drug targets (see Table 3.3, Page 49), which can
render high invasiveness in cancer cells (for details see Chapter 3). The model
predictions were validated with patient data which were further veriﬁed by in vitro
experiments.
The integrative workﬂow cannot provide an exact representation of cellular events but
it guides the formulation of hypotheses and their validation in experiments.
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Figure 1.6. Integrative workﬂow. An integrative workﬂow to study large-
scale biological networks to unravel regulatory mechanisms underlying diseases.
The workﬂow combines network analysis with high-throughput transcriptomic data
and biomedical information to identify disease speciﬁc core-regulatory networks
that are amenable for analysis with dynamical systems theory. Using a suitable
modeling formalism, the core-networks can be analyzed for diﬀerent input-stimuli
and perturbations to identify molecular signatures for diseases that are subject to
experimental validation. The ﬁgure is adopted from Khan et al., 2018 [21].
1.8. Outline of the thesis
The present work is a development of an integrative workﬂow to study large-scale
biochemical networks to understand and unravel mechanisms underlying complex
diseases, such as cancer. Figure 1.7 on Page 18 illustrates an outline of the thesis,
which is organized in the following chapters:
Chapter 2 is divided into two parts. In the ﬁrst part (Part A) I describe the steps
to collect and organize the disperse knowledge for a certain biological phenomenon in a
format amenable to computer simulations. I list numerous databases that can be used
to extract information for diﬀerent types of interactions e.g., protein-protein
interactions. We construct a comprehensive interaction map of transcription factor
E2F1 by deriving and incorporating information from literature and databases. The
map is constructed in the pathway diagram editor CellDesigner and visualized in SBGN
format. The second part (Part B) of the chapter describes the design of a
methodology that integrates network structural properties, speciﬁcally centrality
measures and feedback/feed forward loops, with expression data and other biomedical
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knowledge to identify a tumor-speciﬁc core regulatory network. Using the proposed
methodology, I derive tumor speciﬁc core-networks from the large-scale E2F1
interaction map for epithelial-mesenchymal transition (EMT) regulation in bladder and
breast cancer. The core-networks contain critical molecular interactions and regulatory
motifs that may drive a cancerous phenotype.
Chapter 3 & 4 focus on the methods of dynamical analysis, namely ODE-based
kinetic models, logic-based models and hybrid models, to provide mechanistic insights
into disease progression. Speciﬁcally, in Chapter 3, I describe the development of
logic-based models to analyze the dynamics of core-regulatory networks, previously
identiﬁed in Chapter 2. The models are calibrated with expression data and the in
silico simulations predict molecular signatures for EMT regulation in bladder and
breast cancer. Further, model analysis based on in silico perturbations identiﬁed
potential therapeutic targets for each cancer type. The model predictions were
validated using TCGA patient data and in vitro by shRNA-based experiments.
Chapter 4 contains ODE-based and hybrid models of chemoresistance. In this
chapter, I provide a motivation for hybrid models, which combine ODE-based and
logic-based modeling. Section 4.2 describes ODE-based models, the law of mass-action
kinetics, and the type of analysis that can be carried out by ODE models. In
Section 4.3, I describe the ODE model-based detection of molecular signatures for
chemoresistance in a network around E2F1. Model analyses identiﬁed a signature that
includes the transcription factor E2F1, two isoforms of the transcription factor TP73
(P73 and DNp73) and the microRNA miR-205. An unbalance in the
E2F1-P73/DNp73-miRNA205 circuitry can mediate chemoresistance in melanoma cells.
Further, in Section 4.4, I describe the development of a hybrid model that combines
ODEs and logic-based models as a strategy to model large-scale, nonlinear biochemical
networks. As a proof of principle, I derive a hybrid model of the E2F1 chemoresistance.
Model simulations recapitulate chemosensitivity and chemoresistance of tumor cells
depending on the concentrations of growth factors, E2F1 and TGFB, as well as the
level of induced genotoxic-stress. For high expression levels of E2F1 and TGFB-1 alone
or in combination, the in silico experiments show resistance against anti-cancer drugs,
which are in consensus with our kinetic model and other biological evidences in the
literature.
Chapter 5 concludes and discusses how the methods developed during the course of
this thesis can be used in the ﬁeld for other studies. Finally, I preview possible future
directions and open questions that could be addressed to improve the eﬀectiveness of
similar integrative workﬂows in computational biology.
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Figure 1.7. Thesis outline. Studies presented in this thesis are organized in
the following chapters: (i) Chapter 2 has two parts where Part A illustrates the
construction of biochemical networks; and Part B describes the methodology of tumor
speciﬁc core-regulatory network identiﬁcation, (ii) Chapter 3 includes logic-based
modeling as a dynamical systems analysis tool to perform in silico experiments of the
core-regulatory networks identiﬁed in Chapter 2 to unravel mechanisms (e.g. identify
molecular signatures and therapeutic targets) underlying EMT regulation in bladder
and breast cancer, and (iii) Chapter 4 describes the hybrid modeling approach as
a strategy to simulate large-scale nonlinear network as dynamical systems. The blue
rounded rectangles represent the methods developed, the light green rectangles list
the possible inputs to respective methods to produce the output, listed in dark green
rectangles.
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Chapter2
Construction and analysis of the E2F1
molecular interaction map (MIM)
The methodology for the network construction and subsequent analysis is published in
the following publications:
 Khan FM, Marquardt S, Gupta SK, Knoll S, Schmitz U, Spitschak A, Engelmann D, Vera
J, Wolkenhauer O, Pützer BM. Unraveling a tumor type-speciﬁc regulatory core underlying
E2F1-mediated epithelial-mesenchymal transition to predict receptor protein signatures.
Nat Commun. 2017 Aug 4;8(1):198. https://doi.org/10.1038/s41467-017-00268-2.
 Khan FM, Sadeghi M, Gupta SK, Wolkenhauer O. (2018) A Network-Based Integrative
Workﬂow to Unravel Mechanisms Underlying Disease Progression. In: Bizzarri M. (eds)
Systems Biology. Methods in Molecular Biology, vol 1702. Humana Press, New York, NY.
https://doi.org/10.1007/978-1-4939-7456-6_12.
 Khan FM, Gupta SK, Wolkenhauer O. Integrative workﬂows for network analysis. Essays
in biochemistry. 2018 Oct 26;62(4):549-61. https://doi.org/10.1042/EBC20180005.
Synopsis
Processes in living cells are carried out by a large number of interactions whose
dysregulations result in complex diseases like cancer. Networks are the blue print
representation of these interactions and their analyses provide useful insights into
diseases. The massive size and complex nature of interactions hamper conventional
computational tools to decipher networks for disease mechanisms. In this chapter, I
propose an integrative workﬂow to analyze large networks. This chapter is divided into
two parts: (A) Construction of the E2F1 molecular interaction map; and (B) The
identiﬁcation of tumor type-speciﬁc core-regulatory networks. The ﬁrst part includes the
list of databases and repositories used for retrieving information about molecular
interactions. Brief descriptions of the modules in the map, and the annotation of
molecular species and interactions are provided. The second part contains the
development of a workﬂow that integrates network structural properties with
high-throughput and biomedical data through a multi-objective optimization function to
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identify tumor type-speciﬁc core-regulatory network, which are amenable for analysis
using dynamical systems theory.
2.1. Part A: Construction of the E2F1 MIM
2.1.1. Background and motivation
Cellular processes are regulated by a large number of interactions among biological
entities such as genes, proteins, RNAs, mRNAs, enzymes, transcription factors and
other molecules. To understand the mechanisms behind normal and malfunctioned
(linked to diseases) execution of these processes, it is essential to initially organize data
and knowledge about them in a network representation (i.e., vertices connected by
edges). Such networks (e.g., molecular interaction maps) are a formalized
representation of information that can subsequently be analyzed with computational
algorithms. They serve as knowledge-bases, which help in: (i) gathering disperse
information about complex biological systems in one place, (ii) managing and
organizing information in a standard pathway diagram format that is helpful to
conceptually analyze and intuitively visualize the network components, (iii) provide
information about the interactions to develop hypotheses that can experimentally be
tested, and (iv) provide a foundation to derive mathematical models to analyze the
dynamics of interacting components.
The construction of networks includes phases of manual curation, validation and
encoding. Various approaches are used to map out molecular interactions underlying
certain biological processes. A number of computational techniques have been
developed, to infer biochemical networks from experimental data [105] and high
throughput data [106, 107]. Despite their importance, they face many challenges, for
example false positive and false negative interactions. More detailed and highly focused
networks, centered around a particular disease [5759] or cellular process [108110], can
be constructed by domain expert knowledge (functional and structural information),
diligent manual search of published literature and publically available databases (e.g.,
KEGG [31], BioCyc [45], HPRD [52], IntAct [54], DIP [22] and miRTarBase [40]). To
avoid the laborious manual curation for network construction, some methods were
developed to automatically reconstruct networks by retrieving interactions or
sub-networks from existing maps and models [111, 112], and some Cytoscape `Network
Generation' plugins including Bisogenet [113], OmniPath [114] etc. Combining
automatic network reconstruction with domain knowledge, manual literature search and
data retrieval from public repositories would provide a reasonable strategy to construct
detailed and fully annotated large-scale biochemical networks (see Figure 2.1). Further,
for the construction of a interaction network, one can introduce more regulatory layers,
which contain, for example, transcriptional or post-transcriptional interactions.
Databases providing information about transcriptional interactions include
TRANSFAC [32], TRRUST [33] and HTRIdb [34]. Resources for post-transcriptional
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interactions include miRTarBase [40], miRWalk [41] and TriplexRNA [115]).
Network-based studies are becoming a popular approach to collect and organize
molecular details and get insights into the mechanisms underlying dysregulated
processes in diseases. For example, the Parkinson's disease (PD) map by Fujita et al.
containing detailed molecular information on various aspects of PD pathogenesis [57].
Matsuoka et al. created a large detailed pathway map of the inﬂuenza A virus (IAV)
replication cycle [58]. The map is annotated with around 500 scientiﬁc articles, includes
information from previous inﬂuenza maps, and incorporates pathway information from
KEGG, PANTHER and Reactom databases. This study was intended to develop a
broader picture of the functional mechanism of IAV and its associated host response.
Further the map was used for in silico analysis to identify several critical targets in the
IAV life cycle. Calzone et al. constructed a comprehensive map of RB/E2F pathway
interactions in the regulation of the cell cycle [109]. They identiﬁed diﬀerent structural
modules in the map based on clusters of regulatory cycles.
Figure 2.1. Scheme for biochemical network construction. More detailed and
highly focused networks, centered around a particular disease or process, can be
constructed using expert domain knowledge (functional and structural information),
manual search and curation of published literature and publically available databases
(e.g., HPRD, IntAct, DIP, BioCyc, KEGG, REACTOME and miRTarBase). The
ﬁgure is taken from Khan et al., 2018 [21].
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To mechanistically understand the role of E2F, a family of transcription factors, in
cancer, more speciﬁcally in drug resistance, tumor invasion and metastasis, we
constructed a molecular interaction map (MIM) by retrieving information from
literature and interaction databases. The map contains state-of-the-art knowledge on
signaling, transcriptional, post-transcriptional, and protein-protein interactions around
the E2F family. All the interactions are carefully curated with references and validated
by domain experts.
2.1.2. E2F1 interaction map
E2F1 is the most prominent member of the E2F family, involved in a number of
essential cancer-related cellular processes such as proliferation, apoptosis and
diﬀerentiation [116]. E2F1 is a remarkable example of a network hub as this protein
interacts with many genes, proteins, and other transcription factors through a variety
of regulatory mechanisms. In the context of solid tumors, unbalanced E2F1 regulation
can lead to the emergence of aggressive tumor cell phenotypes, which drives cancer
progression, resistance to anti-cancer drugs and the rise of metastatic lesions [117121].
To understand how E2F1 interacts with diﬀerent molecules and how it mediates cancer
related processes upon activation of diﬀerent receptors, we constructed a detailed
molecular interaction map (Figure 2.2) based on information retrieved from published
literature and databases as well as E2F1 cofactors [122] recently identiﬁed by our
colleagues from the Institute of Experimental Gene Therapy and Cancer Research
(IEGT)1 headed by Prof. Brigitte M. Pützer. More speciﬁcally, we retrieved data on
protein-protein interactions from STRING [53] (v9.1), IntAct [54], and HPRD [52]
(release 9). Transcription factors and their target genes were retrieved from
TRANSFAC [32] and relevant literature. Moreover, we included miRNA-target
interactions, which were extracted from the miRTarBase [40] database (release 4.5), a
database of validated miRNA-target interactions. Transcription factors of miRNAs
have been extracted from the TransmiR [43] database (v1.2). Additionally, we searched
PubMed for publications about validated E2F transcription factors, their
post-translational modiﬁcations, molecular interactions and connections to certain
diseases, especially to cancer. Furthermore, we manually curated interactions (for
assigning directions to the interactions, i.e., activation/inhibition, and relevant
references) that were retrieved semi-automatically from databases like STRING,
HPRD, IntAct, KEGG, or the EMBL-EBI search engine PSICQUIC [123] and the text
mining tool iHop [28]. In order to assure the accuracy of the network, we randomly
selected 10 percent of the interactions and asked independent domain experts to
cross-validate them. Over 98% of the interactions were derived correctly.
The E2F1 regulation and activity map constructed in this thesis is based on manual
exploration of over 800 publications related to E2F1 and E2F family proteins, as well as
1http://www.iegt-rostock.de/en/
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connected pathways playing a role in cancer-related cellular processes. The map, shown
in Figure 2.2, contains 873 nodes (including miRNAs, which are not visualized in the
Figure 2.2) and 2315 interactions. In order to improve the visualization, we modularized
the map into diﬀerent modules: (i) Extra-/intracellular receptor signaling (n = 113); (ii)
Post-translational modiﬁers of E2F1 (n = 24); (iii) Regulators of E2F1 transcriptional
activities (n = 66), where n the number of factors in each layer. Furthermore, there
are seven functional modules: (i) Cell cycle (n = 145); (ii) Quiescence (n = 29); (iii)
DNA repair (n = 33); (iv) Metabolism (n = 11); (v) Apoptosis (n = 89); (vi) Survival
(n = 52); and (vii) EMT/Invasion/Angiogenesis (n = 69). Where n is the number of
nodes in each module.
Figure 2.2. A comprehensive map of E2F1 interactions in tumor progression
and metastasis. The map is organized into diﬀerent functional and regulatory
modules. This ﬁgure is taken from Khan et al., 2017 [124]. For better visualization,
transcription and translation processes are condensed into one reaction directly leading
from gene (yellow boxes) to protein (green or blue boxes with round edges). In the
map we pool proteins of the same family into one node (e.g., FGFR for FGFR1-
4, FGF for FGF1-23, ITGA and ITGB for alpha and beta integrins). The miRNA
layer is not included in this CellDesigner diagram, but for network analysis, the
Cytoscape version of map, includes all the family members of place holders and
miRNAs (Figure A.3 in Appendix A). The interactive E2F1 interaction map can be
accessed at https://navicell.curie.fr/pages/maps_e2f1.html.
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2.1.3. Graphical representation
The E2F1 interaction map (in Figure 2.2) was built with the process diagram editor
CellDesigner [12] (v4.3) and visualized as a SBGN (Systems Biology Graphical
Notation) compliant diagram [65]. We created diﬀerent regulatory and functional parts
based on the role of molecules in inﬂuencing E2F1 activities and determining cell fates.
Next, I incorporated into the map detailed text-based annotations including Oﬃcial
name, HGNC ID, Entrez ID, and UniProt ID for nodes, and PubMed reference IDs for
reactions. HGNC ID is an identiﬁer assigned by HUGO Gene Nomenclature
Committee [125]. Entrez ID is a unique identiﬁer assigned by National Center for
Biotechnology Information (NCBI), which provides detailed information about every
gene, such as genomic location, gene products and their attributes, markerf, phenotypes
and links to citations [126]. UniProt ID is a unique identiﬁer for each protein assigned
by UniProt database, a resource for protein sequence and functional information [127].
All this information is stored in the Notes section of CellDesigner. We used complex
formation and dissociation information to accommodate activities of protein monomers,
dimers and oligomers. By assigning web links to the annotations in the map, we turned
it into an interactive resource. A complete list of the E2F1 CellDesigner map
interactions with corresponding PubMed references can be downloaded at2.
Web version: I created web version of the map using a pathway browser platform
called NaviCell [128], which can be accessed at3, where users can browse its contents.
NaviCell uses the graphical representation of maps created in CellDesigner. It provides
4 levels of zooming for visualization and facilitates an easy navigation of the network
components. If annotations are provided in the CellDesigner .xml ﬁle, users can see it
by clicking on the biological entities. It also provides web-blog, which allow users to
contribute in reﬁnement and update of the map.
I created four images of diﬀerent zoom levels: (i) detailed zoom level, it is the original
representation of map, (ii) hidden-details zoom level, which hides the entity modiﬁcation,
complex names and reaction numbers, (iii) pruned zoom level, shows only major routes
in the map, and (iv) top-level zoom view, which is an abstract representation of the map.
All these zoom levels are separately created by JavaScript provided in the NaviCell user
guide4. In order to create the NaviCell web map, zoomed images and the CellDesigner
.xml ﬁles are converted into html and JavaScript ﬁles using NaviCell factory, which is a
java-based software embedded into Cytoscape plugin BiNoM [129].
2.1.4. Network structural analysis
To evaluate the structural properties of the E2F1 interaction map, we converted the E2F1
map into a format suitable for analytical tools such as Cytoscape [13]. Towards this, all
types of reactions were categorized into activation; inhibition and neutral interaction
2https://sourceforge.net/projects/khan-phd/ﬁles/Supplementary-ﬁle-1.xlsx/download
3https://navicell.curie.fr/pages/maps_e2f1.html
4https://navicell.curie.fr/doc/usersguide.pdf
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(a complete list of interactions in a format suitable for analysis in Cytoscape can be
downloaded at5). Moreover, complexes that take part in a reaction were dissected and
separate reactions were established for their components, for example: a reaction for
complex `AB' that activates `C' was split into two separate interactions: (i) `A' activates
`C'; and (ii) `B' activates `C'. The purpose to dissect the complexes into separate reactions
was to add the post-transcriptional regulatory layer (miRNAs) and map expression data
on the map. While in the CellDesigner map (Figure 2.2) proteins of the same family
are pooled in one node, the Cytoscape map (see Figure A.3 in Appendix A) contains
all respective family members and interactions among them, thereby allowing the use of
existing tools for data integration and network analysis. The Cytoscape ﬁle of the map
can be accessed at6.
Topological properties of the E2F1 map
The E2F1 molecular interaction map in Cytoscape format contains 1,015 nodes and
4,180 interactions. I determined topological properties (see Table 2.1) of the network
using the Cytoscape plugin `NetworkAnalyzer' [130]. The average number of neighbors
for each node in the network is 7.89, which indicates that the network is well-connected.
I calculated the average clustering coeﬃcient of the network (C = 0:226) and the network
diameter (D = 8). The clustering coeﬃcient indicates the density of connections among
the neighbors of a node [131]. The comparably large value of C and large diameter
of the network indicate the modular organization of nodes in the network [70, 132].
Furthermore, I ﬁtted a power law of the form y = a + x r to the clustering coeﬃcient
distribution (Figure A.2 in Appendix A). The results a = 0:906; r = 0:710 indicate a
hierarchical structure of the network [72, 132]. The small average characteristic path
length (l_G = 3:258) and large average clustering coeﬃcient indicate that the network
has a small world architecture [3, 72, 131]. The small world property reveals that signals
can propagate very fast through the whole network. The values of important topological
properties for each node are listed in Supplementary-ﬁle-2 at7.
Some of the node properties (node degree and betweenness centrality) of the E2F1
interaction map were mapped to visual properties in Figure A.3 in Appendix A. In this
representation the node size is determined by its degree, i.e., number of edges connected
to the node and node color denotes the betweenness centrality (green: low; red: high),
i.e., the amount of control that a node exerts over the interactions of other nodes in the
network. Since the network was constructed by focusing on interactions around E2F1,
it is no surprise that E2F1 represents the largest node followed by other members of the
E2F family (E2F2/3). Other nodes with very high node degree are TP53 and MYC,
which are known for their role in tumorigenesis. E2F1 has also the highest betweenness
centrality value (Cb(E2F1) = 0:4222) indicating that E2F1 plays a central role for the
5https://sourceforge.net/projects/khan-phd/ﬁles/Supplementary-ﬁle-2.xlsx/download
6https://sourceforge.net/projects/khan-phd/ﬁles/E2F1-map-in-Cytoscape.xml/download
7https://sourceforge.net/projects/khan-phd/ﬁles/Supplementary-ﬁle-2.xlsx/download
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signal ﬂow in this network. By determining these topological properties one can identify
important nodes as potential candidates for therapy design [72, 133].
Further, I ﬁtted a power law of the form y = a+ x b to the degree distribution of the
network nodes (Figure A.1 in Appendix A), where y indicates the number of nodes that
share a particular degree x (a = 320:15 and b = 1:249). From this result, I conclude that
the network has a scale-free topology, which is consistent with the fact that the network
contains few high-degree nodes also known as hubs. Networks containing few hubs are
generally heterogeneous in terms of node degree and are considered to be robust against
single random perturbations [72, 73].
Topological parameters Values
Number of nodes 1015
Number of edges 4174
Clustering coeﬃcient 0.226
Network diameter 8
Network radius 4
Characteristic path length 3.258
Avg. number of neighbors 7.892
Table 2.1. Topological parameter values of the E2F1 regulatory network [124].
Network motifs
Network motifs are the interaction patterns that occur signiﬁcantly more often than in
random networks [2]. These motifs are a sort of small molecular circuitry that cells use to
process information. Moreover, network motifs govern dynamical responses of the cell to
external or internal ﬂuctuations [78, 134]. Feedback loops (FBLs) and feedforward loops
(FFLs) are important regulatory network motifs. In a feedback loop, a node is directly
or indirectly regulated by it's own target. Figures 2.3a and 2.3b, for example, illustrate
the indirect activation/inhibition of a node `X' by its own target. FBLs can either be
positive or negative depending whether they have an even or odd number of negative
links in the loop. Negative FBLs have an odd number of negative links (Figure 2.3b)
and positive FBLs have an even number of negative links (Figure 2.3a). A negative FBL
exerts negative eﬀects on the evolution of their components, while a positive FBL exerts
positive eﬀects [135]. FFLs are characterized by interactions in which a node is a mutual
target of another node and its target. In Figures 2.3c and 2.3d, for example, `X' regulates
`Y', and then `X' and `Y' mutually target `Z'. FFLs can either be coherent or in-coherent
depending on the parity of negative links in the loop. A FFL is coherent (Figure 2.3c) if
the parity is even and it is in-coherent (Figure 2.3d) when the parity is odd.
Using the Cytoscape plugin NetDS [136] (v3.0), I identiﬁed a large set of three-nodes
FBLs (n = 444; 213 positive, 228 negative and 3 neutral) in the E2F1 interaction map
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(Supplementary-ﬁle-3 at8). I considered only FBLs of three nodes due to the fact that
larger sized network loops are typically composed of one or more small size loops [78].
Moreover, I have also identiﬁed feedforward loops (n = 11904) of path length 2 (i.e.,
the maximum path from source to target is 2). In intracellular regulatory networks,
FBLs provide stability and robustness against intrinsic and extrinsic noise, homeostasis
or even all-or-nothing patterns of activation [2, 78, 134]. Very often, these network
motifs are disrupted or abnormally regulated in cancer and, therefore their
computational analysis can provide important clues to the emergence of cancer
phenotypes. However, the identiﬁcation of important feedback/feedforward loops,
which are more relevant in certain biological context of a highly connected network, is a
methodological challenge.
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Figure 2.3. Feedback and feedforward loops. a-b All possible 3-node feedback
loops. c-d All possible of path length 2 (or 3-node) feedforward loops. The ﬁgures are
adopted from Khan et al., 2018 [21].
8https://sourceforge.net/projects/khan-phd/ﬁles/Supplementary-ﬁle-3.xlsx/download
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2.2. Part B: Identiﬁcation of a tumor-speciﬁc core
regulatory network
2.2.1. Background and motivation
The set of mutated, deregulated or epigenetically modiﬁed cancer genes is highly
tumor-type speciﬁc. More importantly, these genes are integrated in a small set of
modules and regulatory pathways [137]. Furthermore, it has been found that such
modules and pathways are enriched in regulatory motifs to shape and ﬁne-tune basic
cellular phenotypes that are subverted in diseases like cancer [78]. The advance in
sequencing and omics technologies provides us with data that can be used to identify
and characterize cancer and tumor-speciﬁc regulatory motifs. The analysis of these
motifs has the potential to give insights into various aspects of carcinogenesis, tumor
progression and metastasis [138140]. Regulatory motifs, including feedback and
feedforward loops are a source for nonlinear regulatory behavior [2, 68], therefore, for
their analysis dynamical system theory is inevitable [5, 6]. But large-scale biochemical
networks contain a large number of regulatory loops, which make a dynamical analysis
diﬃcult, particularly with mechanistic (e.g., ODE-based) approaches.
In order to exploit the advantages of large-scale biochemical networks, in
combination with mechanistic modeling for disease understanding, we require
integrative approaches and computational workﬂows to identify disease-speciﬁc small
regulatory/functional modules that can be subjected to a more detailed analysis,
followed by the prediction of molecular signatures and therapeutic targets. Towards
this, I have developed a ﬂexible and extendible integrative workﬂow based on a
multi-objective optimization function that combines network structural analysis with
high-throughput and biomedical data to identify smaller `modules' for speciﬁc disease
phenotypes. I hereafter refer to these as core-regulatory networks, which are amenable
for analysis with dynamical systems theory [4]. For the validation of my workﬂow, I
applied it to the E2F1 molecular interaction map (shown in Figure A.1 in Appendix A)
and identiﬁed core-regulatory networks for the regulation of the epithelial-mesenchymal
transition (EMT) in bladder and breast cancer.
2.2.2. Methodology for the identiﬁcation of a tumor-speciﬁc core network
I have developed a novel method to prioritize recurring structures in a network (i.e.,
motifs including feedback/feedforward loops) with respect to the disease phenotype
under investigation (Figure 2.4). More speciﬁcally, the method incorporates: (a)
topological properties, node degree (ND) and betweenness centrality (BC ), (b) the
gene prioritization (GP) scores, (c) relatedness to disease pathway (DP), and (d) gene
expression fold-change (FC ) data. GP is inspired by the well-established
`guilt-by-association' concept [141], which assumes that genes which are physically or
functionally close to each other tend to be involved in the same phenotype/disease. GP
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ranks important genes for a certain disease based on the network structure and known
disease markers using network propagation methods, e.g., random walk with restart.
(DP) accounts the association of motifs with a certain disease by checking if any of the
nodes in a motif is part of the pathway:
n(Mj \DP) (2.1)
where n is the number of nodes in a motif Mj present in a disease pathway, and its
value is (0  n  length of a motif), and j = 1; : : : ;m, for m number of motifs Mj .
Associating network components with DP can provide a foundation to explain genetic
heterogeneity across patients [142]. (FC ) accounts for data from a normal to disease
phenotype which makes the methodology speciﬁc to a disease or phenotype.
Here, I refer to (ND + BC ), GP , DP , and FC as four prioritization sub-functions
(objective functions) (fl; l = 1; : : : ; 4), which are used in the multi-objective optimization
function [143] to optimize the ranking score (FM ) of a motif for a given weight wk:
FM =
4X
l=1
wlk  fl (2.2)
where wl, is the weight assigned to sub-function (fl) which is normalized by  (equal to
maximum value of fl); and k is the number of user deﬁned weighting scenarios. One can
iteratively modify the values of the weighting factors wk to optimize the function (F ) for
one or multiple sub-functions. In this case no single solution exists that simultaneously
optimizes the function (F ). Thus, one can have a number of Pareto optimum solutions. A
solution is called Pareto optimal, if none of the optimized functions (F ) can be improved
in value for a given objective functions without degrading some of the other objective
functions. For example, to optimize (maximize) F for objective function f1 and f2:
F = w1  fl + w2  f2 (2.3)
the values of w1 and w2 can be iteratively modiﬁed to maximize the functions (F ) for
respective objective function. If one wants to maximize F for f1 by assigning a higher
value to w1 than w2, it will reduce the value for f2, and vice versa. The Pareto set is
obtained by merging all the non-identical solutions. From Pareto sets, top ranked motifs
are selected based on score greater than or equal to certain cut-oﬀ (FM >= cut  off).
The core-regulatory network is obtained by taking the union of the top ranked motifs.
Using this workﬂow, I identiﬁed core-regulatory networks from the large-scale E2F1
molecular interaction map (MIM) driving the epithelial-mesenchymal transition (EMT)
regulation in bladder and breast cancer. The workﬂow involves the following steps: (i)
Network analysis, (ii) Motif identiﬁcation, (iii) Gene prioritization score, (iv)
Association of network motif with disease pathway, (v) Fold change expression proﬁle,
(vi) Motif ranking using multi-objective optimization function, and (vii) Derivation of
the regulatory core (see Figure 2.4).
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(i) Network analysis: I performed network analyses to identify the structure and
node properties, which help to identify important nodes for network organization and
information ﬂow. Topological and node properties were determined using the Cytoscape
plugin NetworkAnalyzer [130]. In particular, I ﬁrst calculated for each node the ND and
BC . The average ND and BC of each feedback loop were calculated.
(ii) Network motif identiﬁcation: I identiﬁed a large set of 3-node feedback loops
(m = 444; 213 positive, 228 negative and 3 neutral) from the E2F1 MIM using the
Cytoscape plugin NetDS [136] (v3.0). The complete lists of FBLs are provided at9.
(iii) Gene prioritization score: GP is a method to identify important genes or
proteins in a network based on the network structure and a set of known disease
markers using a global network propagation method. For the GP , I ﬁrst selected the
known EMT markers (including VIM, ZEB1, ZEB2, SNAI1, SNAI2, CDH1, TWIST1,
TWIST2) in our map as proposed in Lanouille et al. [144] and then calculated the score
for all the nodes using a random walk with restart algorithm implemented in the
Cytoscape plugin GPEC [145]. In diﬀusion methods, random walk with restart is the
most popular disease gene prediction method [146, 147], where nodes that are most
frequently traversed by random walks are assumed to be important, i.e., may be
associated with a disease or a phenotype [76]. I calculated the GP score of nodes based
on these EMT markers. Based on GP score of each node, the average GP score for
every motif is calculated, a list of high GP scores nodes is available at10.
(iv) Association with disease pathway: I chose association of a motif with DP as
one of the parameter for motif ranking. The idea is to determine the association of
motifs with a certain disease pathway by checking if any of the nodes in a motif is part
of the pathway. (DP) values range from zero to the total number of nodes in a motif.
For example, if none of the nodes in a 3-node motif is present in the disease pathway
the value of this parameter is zero. Conversely, if all the nodes are present then the
value of the parameter is 3. For this study, I used KEGG's cancer disease pathway
(KEGG: hsa05200) to ﬁnd the association of a motif with cancer and based on each node
association with the DP (the average DP score for every motif is calculated).
(v) Fold change expression proﬁle: I integrated gene expression proﬁles of two cancer
cell lines for E2F1-driven highly aggressive tumors in bladder and breast. We used the
ArrayExpress database (ArrayExpress accession number: E-MTAB-2706) [148] to ﬁnd
suitable gene expression data in non-invasive and invasive bladder and breast cancer cell
lines. In particular, we used RT-4 as non-invasive and UM-UC-3 as invasive cell lines in
bladder cancer, while MCF-7 as non-invasive and MDA-MB231 as invasive cell lines in
breast cancer. Diﬀerential expression analysis was performed using the DEseq R-package
with method = `blind0 and fitType = `local0 (v1.22.1) [149]. Furthermore, I calculated
the absolute average fold change for a motif based on the change in expression values of
each node in non-invasive to invasive phenotype.
9https://sourceforge.net/projects/khan-phd/ﬁles/Supplementary-ﬁle-3.xlsx/download
10https://sourceforge.net/projects/khan-phd/ﬁles/Supplementary-ﬁle-2.xlsx/download
30
2.2 Part B: Identiﬁcation of a tumor-speciﬁc core regulatory network
(vi) Motif ranking: Using a multi-objective optimization function (Equation 2.2), I
designed an algorithm, which calculates scores for each motif based on based on which
they are ranked. The scores are calculated based on objective functions (i.e., ND , BC ,
DP , GP and FC ) and weights wk:
FMjk =
w1k
2
 hNDij
max(ND)
+
w1k
2
 hBC ij
max(BC )
+w2k  hDPij
max(DP)
+w3k  hGPij
max(GP)
+w4k  hjFC jij
max(FC )
(2.4)
Here FMjk is the score of each motif (Mj ; j = 1; : : : ;m) for diﬀerent weighting scenarios
(wk; k = 1; : : : ; 13) as given in Table 2.2. w1k to w4k are weighting factors pounding the
importance of given objective function (ND , BC , DP , GP and FC ).
In order to have the uniform range of values for each property, the objective functions
are normalized to their maximum values. For example, for hNDij , is normalized by
dividing each value by the maximum value of ND (max(ND)) in the motif list. In order
not to over emphasize topological properties in motif prioritization, I assigned half of
the weighting factor to hNDi and hBC i. Further, to approximate the Pareto set of all
non-dominated motif rankings, I iteratively modiﬁed the values of the weighting factors
wlk and computed the score FMjk for each motif.
A complete list of the selected motifs along with structural and biomedical parameters,
as well as their scores are provided in Supplementary-ﬁle-3 at11. Further, I selected the
top ten scored motifs from each Pareto set. In this way, I obtained 32 and 28 non-
redundant motifs associated with an invasive phenotype in bladder and breast cancer,
respectively.
(vii) Derivation of the core-regulatory network: The core-regulatory network is
obtained by merging the sets of top ranked motifs resulted in three disjoint sub-networks
in both tumor types, which I connected by reviving interactions among the nodes from
the E2F1 regulatory network. In this way, tumor-speciﬁc (bladder and breast cancer)
core-regulatory networks are obtained as shown in Figure 2.5. Both core-regulatory
networks include the transcription factors E2F1-3 and the cell cycle regulators RB1,
MYC, CDKN2A, TP53/MDM2, SP1, FOXA1, FOXO3 and AKT1. Furthermore, both
contain the enzyme SIRT1, which modiﬁes targets like E2F1, TP53 and histones to silence
their function. In addition, both core networks contain the CDH1 regulators SNAI1/2
and TWIST1 and interaction partners of CTNNB1 (AXIN2, LEF1).
In bladder cancer, FGFR1 and its downstream regulatory subunits of the protein
phosphatase 2 (PP2; inhibitor of cell growth and division), and the pro-proliferative
inhibitor of PP2, KIAA1524 (CIP2A) are part of the core-regulatory network, as well
as the TGFBR1/2 downstream signaling molecules SMAD2-4 and their regulator ZEB1.
The breast cancer core network includes FN1, which is associated with migration; FLT4,
involved in angiogenesis; GSK3B, an anti-proliferative enzyme; KPNA2, a nucleopore
transporter, and the EP300 associated transcriptional activator NCOA3.
11https://sourceforge.net/projects/khan-phd/ﬁles/Supplementary-ﬁle-3.xlsx/download
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Figure 2.4. Methodology for the derivation of a core-regulatory network.
First, a molecular interaction network is constructed in a machine-readable format
(SBGN) by integrating and curating data from public repositories and the literature.
The network is then converted into a format suitable for analysis using computational
tool (Cytoscape). Network analysis is used to determine node properties (ND and
BC ), disease genes prioritization (GP), and identiﬁed network motifs.Theses network
properties are combined with gene expression fold changes (FC ) and association with
disease pathways (DP) for ranking network motifs. This is done using multi-objective
optimization function. Using diﬀerent weighting (wlk) scenarios, the ranking scores
for each motif are maximized for objective functions individually and in combinations,
which results in a Pareto set of motifs. The top 10 high scored motifs are selected
from each Pareto set. A core-regulatory network is constructed from the union of top
ranked motifs. The methodology is published in Khan et al., 2017 [124] and the ﬁgure
is adopted from Khan et al., 2018 [150].
Additionally, we observed feedback loops concerning NFKB1 regulation (CHUK,
NFKBIA; related to cell survival) in bladder cancer, and anti-apoptotic BIRC2/3 and
pro-apoptotic TRAF1 factors in breast cancer, respectively. Interestingly, both loops
are related to each other, since NFKB1 and BIRC2/3 are survival molecules and
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NFKB1 activates BIRC transcription. The regulatory cores, which we consider as the
drivers of invasive phenotypes contain 41 nodes and 107 interactions in bladder cancer
and 35 nodes and 86 interactions in breast cancer.
(a) core-regulatory network in bladder cancer (b) core-regulatory network in breast cancer
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Figure 2.5. Core-regulatory networks that drive tumor invasiveness in (a)
bladder and (b) breast cancer. The regulatory cores contain three disjoint
subnetworks (shown in pink, green and blue background colors). Blue dotted
lines represent direct interactions extracted from the comprehensive E2F1 regulatory
network to interconnect these subnetworks. The networks were generated using
Cytoscape plugin NetDS. Nodes in gray color are common in both regulatory core
networks, whereas those in white color are unique. The ﬁgures are adopted from Khan
et al., 2017 [124].
2.2.3. Weighting schemes for motif ranking
I chose ﬁve diﬀerent sets of 13 weighting scenarios (i.e., k = 1; : : : ; 13), each giving more
importance to one or another objective function in the Equation 2.4. The weighting
scenarios are shown in Table 2.2. In the ﬁrst set, only one objective function was given
importance for ranking. In the sets 2-4, I considered two, three and four objective
functions respectively and applied consistently higher weights to the absolute expression
fold change of the motif to identify tumor type/process-speciﬁc top ranked motifs. In
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the last set, we assigned equal weights to all the objective functions considered.
Sets w1 w2 w3 w4
Set 1
1 0 0 0
0 0 1 0
0 0 0 1
Set 2
1/4 0 0 3/4
0 1/4 1 3/4
0 0 1/4 3/4
Set 3
1/8 1/8 0 3/4
et 3 1/8 0 1/8 3/4
0 1/8 1/8 3/4
Set 3
1/16 1/16 1/8 3/4
et 4 1/16 1/8 1/16 3/4
1/8 1/16 1/16 3/4
Set 5 1/4 1/4 1/4 1/4
Table 2.2. Weighting scenarios for motif ranking [124].
2.3. Summary of results and discussion
Using the proposed workﬂow, I identiﬁed E2F1-mediated core-regulatory networks for the
regulation of epithelial-mesenchymal transition in bladder and breast cancer. The core-
regulatory networks are comparatively small, which makes them amenable for analysis
using dynamical systems theory to provide deeper insights into the network behavior in
response to diﬀerent stimuli and perturbations.
In the context of our work, Calzone and coauthors [109] reconstructed a comprehensive
map of the E2F transcription factor family. Their work focused on the diﬀering roles
of E2F family members in the cell cycle, reﬂecting the complex interplay between the
E2Fs, RB1, its homologs RBL1 and RBL2, the cyclins/cyclin dependent kinases, and cell
cycle arresters. In contrast, our map sets the main focus on the newly discovered role of
activating members of the E2F family (E2F1-3) in cancer development and progression,
with an emphasis on pro- and anti-apoptotic (survival), angiogenic as well as EMT
relevant functions. We included additional key players connected to E2F1 directly or
through its neighbors along with a post-transcriptional layer of miRNAs in the context
of cancer. Interestingly, the majority of the components in the map by Calzone and
co-workers are included in our map.
The underlying idea of my integrative workﬂow is that the structural and data-driven
analysis of biochemical networks allows the identiﬁcation of key functional modules,
here named core-regulatory network, composed of regulatory motifs and critical
molecular interactions, which can have signiﬁcant impact on the regulation of cellular
processes, who's dysregulation results in complex diseases. This work presents a
precedent of combining network-based high-throughput data analysis, network
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reduction and Boolean modeling. Existing work either focuses on network-based
analysis [140, 151] or Boolean network construction and simulation [152, 153]. Further,
my methodology includes an innovative element in terms of network reduction, namely
the use of an algorithm employing multi-objective optimization concepts to rank and
select key regulatory motifs, based on network-topological features, biomedical
information and expression proﬁles.
Motif identiﬁcation methods have been previously used to recognize key network
regulators. For example, Zhang and coworkers ranked network motifs using gene
expression data to detect breast cancer susceptible genes [103] and Koschützki and
coauthors used motifs with various network topological parameters to identify
important nodes in a biochemical network [154]. I here introduced a new motif ranking
scheme using a weighted multi-objective optimization function that integrates
topological (e.g., node degree and betweenness centrality) and non-topological (e.g.,
gene expression, gene prioritization) properties. Topological properties account for the
structural importance of the nodes, and non-topological properties for their cancer-type
and context-speciﬁc relevance. I used multiple weighting scenarios in the
multi-objective optimization function to provide motif ranking unbiased as much as
possible regarding the properties assessed in the function. The proposed multi-objective
optimization function and ranking scheme can easily be extended to add new
information layers in the workﬂow. Thus, I think the method proposed can be used for
investigating other cancer networks besides those focused on the E2F family discussed
here.
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Chapter3
Logic-based dynamical systems analysis
of the E2F1 tumor invasion network
The models described in this chapter are the ones published in the following publication:
 Khan FM, Marquardt S, Gupta SK, Knoll S, Schmitz U, Spitschak A, Engelmann D, Vera
J, Wolkenhauer O, Pützer BM. Unraveling a tumor type-speciﬁc regulatory core underlying
E2F1-mediated epithelial-mesenchymal transition to predict receptor protein signatures.
Nat Commun. 2017 Aug 4;8(1):198. https://doi.org/10.1038/s41467-017-00268-2.
Synopsis
Mathematical models are a well-established tool to elucidate the dynamics of complex
processes in living cells. Depending on the available information, the structure and size
of a network behind a system and the purpose of modeling, a number of modeling
formalisms are available. For a large system of interactions with sparse data, the coarse
grained qualitative models are suitable tool, which can be encoded using a logic-based
formalism. In this chapter, I present the development, calibration and analyses of a
logic-based model (in particular Boolean models and its multi-valued variant) of
epithelial-mesenchymal transition (EMT) regulation in bladder and breast cancer. In
silico simulations of stimulus-response behavior identiﬁed molecular EMT signatures for
both cancers. Further, I performed in silico perturbation experiments to predict potential
drug targets. The predicted signatures and drug targets have been validated through
patient data and by in vitro experiments.
3.1. Background and motivation
The molecular details yielded by omics technologies and the availability of databases
that collect, organize and share information about interactions among proteins, genes
and miRNAs, enable researchers to model cellular processes as molecular interaction
networks. These networks encoded in a computer-readable format (e.g., SBGN and
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SBML), using tools like Cytoscape and CellDesigner, turn them into knowledge-base
that provide useful information, such as regulatory motifs and hub
nodes [58, 59, 109, 110, 155]. However, their utility is conﬁned to a static analysis,
which does not help to explain cause and eﬀect relationships, the ubiquitous
phenomenon in biological systems [156]. Moreover, only from the network connectivity
it is impossible to dynamically characterize complex network structures, like
feedback/feedforward loops and cross-talks in network modules, which aﬀect the
regulatory behavior of a system. Nevertheless, networks are an important step towards
understanding a system and providing a foundation for the development of dynamical
models [5, 6, 79, 157]. The dynamical analysis helps in understanding the behavior of a
system upon diﬀerent stimuli; and supports the formulation of new hypotheses about
the unknown aspect of a system upon internal or external perturbations [156, 158].
Using a systems biology approach (Figure 1.1), the iterative cycle of data-driven
modeling and model-driven experimentations reﬁne formulated hypotheses until they
are validated.
Models are abstract representations of the reality, which provide a sense (i.e.,
understanding the behavior) of the original system, depending on available information
and the purpose of modeling [159]. Modeling, is the process of the creation and use of a
model [159]. Mathematical models describe certain aspects of the reality (i.e., processes
in a cell) in terms of functions or equations, which contain variables and parameters
(Equation 3.1):
v(X1; : : : ; XN ; k1; : : : ; kN ) (3.1)
where v is the function that evaluates, e.g. the temporal behavior of systems having state
variables X1,: : :,XN and parameters k1,: : :,kN . Variables are the quantity of interest in
model analysis, which typically change over time, e.g. the concentration of proteins,
RNAs or metabolites in a cell. Parameters are quantities, which are ﬁxed for a given
computational experiment to characterize a speciﬁc quantitative behavior of a model.
Parameter values are typically derived from literature, databases such as BioModels [20],
BRENDA [160] and SABIO-RK [19], or can be estimated from experimental data by
calibrating the model to recapitulate the biological processes under investigation [17,
18]. After calibrating the model with experimental data, one can perform large sets
of repetitive in silico experiments for many diﬀerent conditions, which may be time-
consuming and expensive with wet-lab experiments.
Models can be created at diﬀerent levels of abstraction, ranging from coarse grained
qualitative models of (large) sub-cellular processes to detailed quantitative models of a
(small) functional module. Logic-based models are popular to qualitatively analyze
biological systems [91, 92, 161163], where experimental data is frequently sparse (not
everything can be measured, few time points) and uncertain (lack of replicates and
precision), which make the identiﬁcation of kinetic parameters
diﬃcult [6, 82, 8789, 163]. They are qualitative and do not require detailed
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quantitative parameters [6, 82, 8792, 163]. Moreover, they provide predictive testable
hypotheses, which are especially valuable in poorly understood large-scale
systems [93, 94]. Logic-based formalisms make simplifying assumptions and assign
discrete states to components of a system based on a set of logical rules that are
derived from their regulatory interactions. The simplest logic-based model is the
Boolean model popularized by Kauﬀmann (1969) [164], where network components can
be assigned two possible state values (e.g., 1 or 0; representing active or inactive; ON or
OFF states respectively).
Being qualitative in nature, logic-based models are conceptually and computationally
simple, and are easier to calibrate against data, yet they provide the ability to capture
cause-eﬀect relationships [165, 166]. Therefore, they have received signiﬁcant
appreciation in modeling large-scale biochemical networks [86, 93, 94]. They have been
successfully used to generate hypotheses and ﬁnd explanations for various biological
processes, ranging from the cell cycle [167169] to cell diﬀerentiation [170, 171], cell
death [91, 172, 173], and cell migration [152, 174]. Further, logic-based models have
been successfully applied to identify possible alterations in pathways [162, 175] and
proposed diﬀerent combinations of drug targets through in silico
perturbations [84, 161, 176]. Such models can be integrated with patient-speciﬁc data
to derive a personalized model, which can recapitulate and analyze the gain-of-function
or loss-of-function of mutated genes in speciﬁc disease pathways. As a result these
models can aid clinical decision-making or improve therapy towards a personalized
design [177, 178]. Like other modeling formalisms, logic-based modeling consists of
three main steps: (i) model construction; (ii) model calibration; and (iii) model
analysis.
3.1.1. Model construction
In logic-based modeling a network is represented as a graph containing nodes and
edges, where nodes represent molecular species and edges depict the type of eﬀect that
one species exerts on the state of another species (e.g., activation or inactivation) see
Figure 3.1a. The state of each species is determined by a logical function that links the
incoming eﬀect to its state. In Boolean models, nodes (X1;:::;n) of a network correspond
to Boolean variables that can have values of either 1 or 0, and edges deﬁne the type of
interactions (e.g., activation or inhibition). The state of a node at the succeeding time
step X(t + 1) is determined by a Boolean function (BF) of the current state X(t) of
nodes regulating it (Equation 3.2):
Xi(t+ 1) = BF (X1(t); X2(t); : : : ; Xn(t)) (3.2)
Boolean functions determine the states of a node using Boolean operators/gates:
`NOT' (denoted by !), `OR' (denoted by _) and `AND' (denoted by ^). Where, the
`NOT' gate is used to model inhibition. For example, the ﬁrst function (BF1) in
38
3.1 Background and motivation
Figure 3.1b, BF1 encodes the negative eﬀect of X3 on X1 activity. In case of an
independent regulation of more than one molecular species on a target species, we
connected them with an `OR' gate. For example, in BF3 and BF4, X1 and X2 can
independently activate X3 and X4. Finally, an `AND' gate represents the interaction,
where more than one species collectively regulates the expression level of a mutual
target species. BF2, for example, encodes the collective inﬂuence of X1 and X3 on X2.
Multi-valued logic is used as an alternative to encode the behavior of networks, which
allows to represent the state of a node in more than two ordinal levels [91, 155]. Illustrated
in Figure 3.1c), I show how functions (MF1-4) following a multi-valued logic can be used to
model ordinal levels of a phenotypic outcome of the interaction network. The phenotype
is modeled in four ordinal levels (from 0 to 3) based on the Boolean state of factors
regulating it. Representing a phenotype in multiple ordinal levels helps to assess the
aggregated eﬀect of various network components (i.e., X2, X3, X4) on it.
Figure 3.1. Logic-based representation of a biochemical network. (a) The
network consists of four nodes (X1 4), the interactions of which are linked to a certain
phenotype. (b) Boolean functions (BF1-5) of nodes that derive their subsequent state
based on the present state of the nodes regulating them using logic operators (NOT
(denoted by !), OR (denoted by _), and AND (denoted by ^). (c) Multi-valued
logic functions represent the phenotype in more than two ordinal levels. The ﬁgure is
adopted from Khan et al., 2017 [124].
3.1.2. Model calibration
Once a biochemical system has been converted into a Boolean model using logical
operators, the next step is the model calibration against available data. Model
calibration makes the simulations match as good as possible to experimental
observations. Calibration of logic-based modeling mainly decide about the use of
`NOT', `OR' or `AND' operator in a logical function. They can be estimated either
based on prior knowledge about biological process or by training the model with
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experimental data. A number of tools and methods are available that automatically
generate and train logical models from data and prior knowledge encoded by
networks [166, 179, 180]. For example, when there is more than one activator for a
molecular species, one has to specify whether the species is active in the presence of
either regulator or only if both are present. Suppose, we have expression level changes
of genes X1, X2, X3 and X4, in a cancer versus normal condition (Table 3.1). If we
train the model shown in Figure 3.1 with this data, the Boolean function of X1(t + 1),
X2(t + 1) and X4(t + 1) will remain the same as shown in Figure 3.1b, while that of
species X3(t+ 1) will change from an `OR' operator to an `AND'. Figure 3.1 shows that
species X3 is regulated (activated) by X1 and X2. The data in Table 3.1 shows that the
expression levels of regulator X1 is up and X2 down, while X3 is also down, which
means for the activation of X3 both the regulators must be active. Such type of causal
relationship is encoded by a logic operator `AND', therefore, the `OR' operator in BF3
will be replaced by `AND' i.e., BF3: X3(t + 1) = X1(t) ^ X2(t), which will improve
model ﬁtting to the data.
Calibrating the model against data does not only enrich the biological context of the
model, but also signiﬁcantly increase its predictive power [179]. Using this approach, I
calibrated logic-based models of EMT in bladder and breast cancer against diﬀerential
expression data from non-invasive to invasive cancer cell lines. The model calibration
substantially increased the model ﬁt to the data; and their simulations successfully
identiﬁed molecular signatures for disease-speciﬁc phenotypes, which were subsequently
validated by in vitro experiments (see Section 3.2).
Species Expression level
X1 High
X2 Low
X3 Low
X4 High
Table 3.1. Hypothetical expression levels
3.1.3. Model analysis
After model construction and calibration, the next step is to dynamically analyze the
behavior of the biological system for diﬀerent stimuli or perturbations using in silico
simulations. Stability analysis is a widely used method to analyze the dynamical behavior
of the biological system, especially the input-output or the cause-eﬀect behavior [135,
181]. For a given set of inputs or initial conditions and perturbations, it describes the long
term behavior of a system over time. Such analyses are well suited for model simulations
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to recapitulate the transition from one cellular state to another [92, 173, 174, 177, 182],
which is the output of many complex processes in a biological system.
In logic-based modeling the system dynamics can be represented in the form of a
state transition graph, which shows the state of each component in the network and
the possible transitioning among them using either a synchronous or an asynchronous
update scheme. In a synchronous update, the states of all nodes update from the current
state `X(t)' to the next state `X(t + 1)', simultaneously. The transition between the
states is deterministic and each system state has at most one subsequent state [135] (see
Figure 3.2). Whereas, in the asynchronous scheme the states of a system are updated
according to the timescale of individual biological events and systems can have more than
one subsequent state (see Appendix C). Asynchronous updates can be non-deterministic
(i.e., stochastic scheme, which choses random events for a system update) or deterministic
where the timescale of every event is known (which in many cases is not possible) [181].
In stability analysis, the model starts from an initial condition and evolves over time
by transitions from one state to another until eventually reaching a ﬁxed point (steady
state) or complex attractor. An attractor is a state/condition towards which a system
tends to evolve, which in biological systems is usually correspond to steady state
activation of cellular components associated with cellular phenotypes (such as
proliferation or apoptosis) or oscillatory behavior (such as the cell cycle or circadian
rhythms) [183185]. In ﬁxed point attractors (Figure 3.2a), the states of the system get
stuck at one point and do not change over time; while in complex attractors (limit
cycle) (Figure 3.2b), the system oscillates among a set of states. René Thomas
proposed important conjectures about the structure of networks that generate either
multiple steady states or oscillation: (i) a positive circuit in the interaction graph is the
necessary condition for multiple stable states; (ii) a negative circuit in the interaction
graph is the necessary condition for oscillatory behavior [186]. The existence of a
steady state attractor does not depend on the update scheme, while complex attractors
are highly dependent on the update scheme [82, 135, 181].
In Boolean models, a network with n nodes has 2n possible states. In a review
article, Wang et al. (2012) provides a survey of applications, challenges and their
possible solutions of attractor analysis Boolean models [82]. Attractor analysis of a
system enables to study the behavior of a system in response to diﬀerent stimuli and
perturbation, which helps to predict the activity states/levels of components in a
certain phenotypical trait [173, 187]. For example, logic-based model of attractor
analysis was used to reveal the mechanism of cell fate decision in response to cytokine
stimuli, such as, TNF and FASL [173]. The attractors were correspond to survival,
necrosis and apoptotic phenotypes, which were nicely characterized by the activity
levels of speciﬁc components (i.e., genes) leading to the respective phenotypes. In
another study, a Boolean model of the p53 network used attractor analysis to
investigate the network response to DNA damage [187]. Attractors represented the p53
regulated cell fate, such as cell cycle arrest and cell death, and identiﬁed particular
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combination states of molecules that corresponded to a speciﬁc cellular outcome.
Furthermore, targeted perturbations revealed that the MDM inhibitor nutlin-3 triggers
p53 oscillation, which induced cell cycle arrest, while combining nutlin-3 with inhibition
of Wip1 resulted in sustained increase in p53 activity and triggered cell death, which
were subsequently validated in MCF7 breast cancer cell line. For large biochemical
networks, the identiﬁcation of all possible 2n attractors is diﬃcult (the number of
attractors increases exponentially) and intractable; and asynchronous update schemes
tends to make the analysis even more complicated [82]. Many methods are proposed to
tackle this problem, for example, one solution is to use network reduction techniques to
simplify the network while preserving the essential dynamics [82].
Steady state attractor
X1(t) X2(t) X1(t+1) X2(t+1)
0 0 0 0
0 1 1 0
1 0 0 1
1 1 1 1
Possible state transition graphs
01 1000 11
steady state Limit cycle
X1 X2
Boolean functions 
X1(t+1) = X2(t)
X2(t+1) = X1(t)
a Steady state attractor
Complex attractor (limit cycle)
Possible state transition graphs
00 10 11 01
Limit cycle
X1 X2
Boolean functions 
X1(t+1) = NOT X2(t)
X2(t+1) = X1(t)
X1(t) X2(t) X1(t+1) X2(t+1)
0 0 1 0
0 1 0 0
1 0 1 1
1 1 0 1
b Cyclic attractor
Figure 3.2. Attractor analysis for (a) a steady state attractor and (b) a
complex attractor. (a) The interaction graph represents a positive circuit where
molecular species X1 activates species X2, and X2 activates X1. The logical relation
for each species is represented by a Boolean function. For the synchronous state
update, the state transitions from X(t) to X(t+ 1) are shown in the state table, and
also visualized in state transition graph. State transition graphs show that the systems
has two stable states (00 and 11) which upon state updates never change. (b) The
interaction graph represents a negative feedback loop where speciesX1 activates species
X2 while X2 represses the expression of X1. The logical relation for each species is
represented by a Boolean function. Starting from the initial state 00, for synchronous
update, the sequence of states is visualized in the state transition graph. The state
transition graph depicts a limit cycle behavior of the system dynamics.
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In addition to attractor analysis, logical steady state (LSS) analysis has been
proposed [188], where steady states of the components are determined by propagating a
sustained input signal to the output layer until no further state updates occur. The
LSS of each network element is consistent with the value of its associated logical
function. Once the system reaches a LSS, no state of a node switches anymore and the
system remains in this state. The LSS of a dynamical system is equivalent for both
synchronous and asynchronous state updates. For a given set of input nodes, LSS
determines unique steady state values of nodes for large-scale biochemical networks.
LSS can be used to study how the signal propagates through the network, which helps
to explore the interplay of pathways involved in normal cellular processes, disease
states, and upon perturbations allows to determine important players for phenotype
traits [90, 174, 189]. Saez-Rodriguez et al. (2007) developed a large-scale Boolean
model for T-cell receptor signaling activation and using LSS analysis, they deciphered
the unforeseen signaling events for CD28 and Fyn perturbations, which were
subsequently validated by experiments [90]. Further, LSS analysis can explain
stimulus-response behavior of large networks [84, 91]. For example, using LSS analysis
for a given set of input stimuli, large-scale qualitative model of EGFR/ErbB receptors
predicted the necessary conditions for JNK and p38 cascade activation in response to
PI3K dependent/independent signaling pathway in primary hepatocytes and
HepG2 [84].
3.2. Logic-based model of E2F1 in tumor invasion
Cancer cells have the ability to desciminate from primary tumor, move to nearby and
distant organs, and establish new colonies [190]. Invasion and metastasis development
are highly complex, and their exact mechanisms and molecular determinants are largely
unknown. The transcription factor E2F1 has recently been identiﬁed as a key regulator
of processes involved in tumor invasiveness and metastasis [119, 122, 191]. Cells gain
migratory and invasive properties through an extremely complex process called epithelial-
mesenchymal transition (EMT) in response to various internal and external signals [192
194]. To understand the functional relatedness of E2F1 with EMT, I developed a logic-
based model of the core-regulatory networks identiﬁed in Chapter 2. I carried out logical
steady state analysis for diﬀerent expression levels of E2F1 and receptor molecules to
identify signatures for EMT in bladder and breast cancer. Furthermore, I performed in
silico perturbations to identify potential therapeutic targets, which can be manipulated
to counteract invasion.
3.2.1. Model construction
I developed logic-based models of the core-regulatory networks (shown in Figure 2.5)
of bladder and breast cancer to evaluate their input-output relationship for diﬀerent
expression levels of E2F1, receptor stimuli, and diﬀerent knock-in/out perturbations.
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I established logical rules based on the network structure and the inspection of the
available literature about the interactions using logic-based modeling formalism described
in Section 3.1.1. The obtained model contains three layers: (i) an input layer, (ii) a
regulatory layer, and (iii) an output layer representing the phenotype Figure 3.3 and 3.4.
The input layer of the logic-based models contain E2F1 and all receptors present in the
regulatory core. In bladder and breast cancer, two common receptors are part of the input
layer: (i) EGFR and (ii) the Retinoic Acid Receptor Alpha (RARA). Additionally, we
found FGFR1 only in the regulatory core of bladder cancer. The models were constructed
in the Process Modeling Tool (ProMoT) [195] and the layouts were arranged in yEd
graphical editor1.
In order to analyze the eﬀects of all possible input signals on the core-regulatory
networks, I expanded the input layers by including additional receptors present in the
E2F1 map (Figure 2.2). I took the receptors that are directly connected to nodes
constituting the regulatory cores. Thus, I included TGFBR, which is connected to
SMADs, and the Chemokine (C-X-C motif) Receptor 1 (CXCR1) connected to ZEB1
and SNAI1 in the bladder cancer model. Similarly, I expanded the breast cancer input
layer with the Hyaluronan-Mediated Motility Receptor (HMMR) connected to FN1; the
TGFBR connected to SNAI1 and SNAI2; the InterLeukin 1 Receptor type I (IL1R1)
and the Thyroid Hormone Receptor Beta (THRB) connected to TRAF1 and MYC,
respectively. For bladder cancer, I selected TGFBR1 and for breast TGFBR2 due to
their tissue-speciﬁc expression proﬁles. I derived Boolean functions for the input signals
and their propagation through the nodes constituting the regulatory layer (see
Appendix D and E).
The output layer of the models comprises a unique node that represents the EMT
process as the driver of the invasive phenotype, which is modeled by a multi-valued logic
function involving the EMT markers present in the regulatory core. Here, the multi-
valued function accepts four ordinal levels, ranging from 0 (no EMT) to 3 (high EMT).
3.2.2. Model calibration with expression data
I used qualitative information based on expression fold changes, from invasive (UM-UC-
3; MDA-MB231) to non-invasive (RT-4, MCF-7) cell lines of bladder and breast cancer,
to approximate the activation level of nodes having multiple regulators [166, 179, 180].
For example, in our bladder cancer model, CDH1 is inhibited by multiple molecules
including SNAI1, SNAI2, TWIST1, SRC, miR-25 and MDM2. Diﬀerential expression
analysis in bladder cancer showed that the expressions of SNAI2, SRC, miR-25 and
MDM2 were down-regulated in the invasive cell line, while SNAI1 and TWIST1 were
up-regulated. It is well established that CDH1 is down-regulated in most invasive cancer
phenotypes [144, 194, 196], therefore, I considered SNAI1 and TWIST1 more relevant for
the regulation of CDH1 than others. To encode the decisive role of SNAI1 and TWIST1
1https://www.yworks.com/products/yed
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Figure 3.3. Logic-based model of the core network regulating invasive
phenotype in bladder cancer. The black and red lines represent the type of
interactions (i.e., activation by black and inhibition by red) among the interacting
components. The microRNAs, receptors and proteins are represented by rectangular
boxes, while the EMT phenotype is represented by an ellipse in the output layer. The
model is divided into three layers, i.e., the input layer (green), the regulatory layer
(gray) and the output layer (pink). The ﬁgure is adopted from Khan et al., 2017 [124].
in the regulation of CDH1, I used an `AND' gate to connect them with the rest of the
factors, see Equation 3.3. For logical rules of both models, see Appendix D and E.
CDH1 = !(SRC ^ SNAI2 ^ miR 25 ^ MDM2) _ (! SNAI1) _ (! TWIST1) (3.3)
Further, I modeled the EMT phenotype by multi-valued logic functions, representing
its four ordinal levels (from 0, accounting for inactive EMT, to 3, accounting for full
activation) based on the sum of Boolean states of factor 1: [SMAD2/3/4, SNAI1,
ZEB1, TWIST1]; factor 2: CDH1; and factor 3: FGFR1, with the following structure:
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Figure 3.4. Logic-based model of the core networks regulating invasive
phenotype in breast cancer. The black and red lines represent the type of
interactions (i.e., activation by black and inhibition by red) among the interacting
components. The microRNAs, receptors and proteins are represented by rectangular
boxes, while the EMT phenotype is represented by an ellipse in the output layer. The
model is divided into three layers, i.e., the input layer (green), the regulatory layer
(gray) and the output layer (pink). The ﬁgure is adopted from Khan et al., 2017 [124].
EMT = [(SMAD2=3=4 ^ SNAI1) _ (ZEB1 ^ TWIST1)] ^ (! CDH1) ^ FGFR1
(3.4)
The motivation to select these factors as drivers of EMT was due to the fact that
CDH1 is a widely accepted driver of EMT together with SMAD2/3/4, SNAI1, ZEB1
and TWIST1 [144]. I also considered receptor proteins as decisive factors determining
the EMT phenotype, if they are present in the regulatory core, highly overexpressed in
the invasive phenotype and not connected to any of the EMT markers (e.g., FGFR1 in
bladder cancer) [197, 198].
46
3.2 Logic-based model of E2F1 in tumor invasion
3.2.3. Predictive model simulations
I determined the LSS of each variable in the model for diﬀerent initial values of the input
nodes using the software tool CellNetAnalyzer [199]. I consider two sets of scenarios for
simulations characterized by: (i) high expression of E2F1 (i.e., E2F1 = 1); and (ii) low
expression (i.e., E2F1 = 0) in all possible Boolean combinations of receptor molecules
in the input layer. For all possible Boolean combinations, I obtained 64 input vectors for
bladder cancer and 128 for breast cancer. For these inputs, I simulated the models to
evaluate their impact on the level of EMT (Table 3.2). The simulation results suggest
that when E2F1, TGFBR1 and FGFR1 are simultaneously active, bladder cancer cells
become highly invasive (i.e., EMT = 3). A similar eﬀect was observed in breast cancer
when E2F1, TGFBR2 and EGFR are simultaneously active.
Furthermore, I carried out in silico perturbation experiments to identify important
nodes that can be exploited for therapeutic interventions. Perturbation experiments were
performed for a highly invasive phenotype (EMT = 3) by changing the Boolean state
of each node in the `regulatory layer' to reduce the invasiveness. To identify potential
drug targets (i.e., single target or combinations with minimum number of targets), I used
single and double perturbations iteratively and observed the most prominent reduction of
EMT in the latter case (simulation results are provided in an Excel ﬁle at2). The results
of the perturbation experiments suggest that in bladder cancer: (i) double knockout of
ZEB1 in combination with either SNAI1, TWIST1 or NFKB1; (ii) knockout of ZEB1
and activation of CDH1; or (iii) knockout of SMAD2/3/4 in combination with TWIST1
or NFKB1 reduces EMT to 1. In case of breast cancer double perturbation by silencing
SRC, FN1, SNAI1, SNAI2 or activation of CDH1 in any of the combinations reduces
EMT to 1 (see Table 3.3).
3.2.4. Validation of in silico predictions in cancer cell lines
The in silico simulations revealed a common eﬀect of E2F1 and TGFB1 signaling on
tumor invasiveness in both cancer types. More speciﬁcally, TGFBR1 and FGFR1 in
combination with highly expressed E2F1 induce the most invasive phenotype in bladder
cancer, while in breast cancer TGFBR2, EGFR and E2F1 triggers high levels of
invasiveness. In order to validate the predicted inﬂuence of the receptors and E2F1 on
the invasive phenotype, our collaborators (from the Institute of Experimental Gene
Therapy and Cancer Research (IEGT)3, University Rostock Medical Center) used
chemical inhibitors and a shRNA-based approach to target these key players.
Although, receptors EGFR and FGFR1 are highly expressed in both cancer types (Fig.
5b on page 160), but in silico simulations suggest their distinctive role in each cancer
type, which was conﬁrmed by in vitro experiments, see Fig. 5a on page 160. It clearly
shows that inhibition of EGFR in UM-UC-3 (bladder cancer cells) and FGFR1 in
2https://sourceforge.net/projects/khan-phd/ﬁles/Boolean_in_Silico_perturbations.xlsx/download
3https://www.iegt-rostock.de/en/
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(a) Bladder cancer
E2F1 TGFBR1 FGFR1 EGFR CXCR1 RARA EMT
0 0 0 0/1 0/1 0/1 0
0 0 1 0/1 0/1 0/1 1
0 1 0 0/1 0/1 0/1 1
0 1 1 0/1 0/1 0/1 2
1 0 0 0/1 0/1 0/1 1
1 0 1 0/1 0/1 0/1 2
1 1 0 0/1 0/1 0/1 2
1 1 1 0/1 0/1 0/1 3
(b) Breast cancer
E2F1 TGFBR2 EGFR HMMR THRB IL1R1 RARA EMT
0 0 0 0/1 0/1 0/1 0/1 0
0 0 1 0/1 0/1 0/1 0/1 1
0 1 0 0/1 0/1 0/1 0/1 1
0 1 1 0/1 0/1 0/1 0/1 2
1 0 0 0/1 0/1 0/1 0/1 1
1 0 1 0/1 0/1 0/1 0/1 2
1 1 0 0/1 0/1 0/1 0/1 2
1 1 1 0/1 0/1 0/1 0/1 3
Table 3.2. The eﬀect of E2F1 and receptor molecules in diﬀerent combinations
on the EMT phenotype in (a) bladder and (b) breast cancer model. Table (a)
is the summary of 64 in silico simulations of bladder cancer. Each row represents the
result of eight simulations; where for the given Boolean state of E2F1, TGFBR1 and
FGFR1, all the eight combinations of EGFR, CXCR1 and RARA result in the same
phenotypical output. Table (b) is the summary of 128 in silico simulations of breast
cancer. Each row represents the result of 16 simulations; where for the given Boolean
state of E2F1, TGFBR2 and EGFR, all the 16 combinations of HMMR, THRB, IL1R1
and RARA results in the same phenotypical output. The results are published in Khan
et al., 2017 [124].
MDA-MB231 (breast cancer cells) had a minor inﬂuence on invasiveness. Furthermore,
the in silico predictive signatures for invasion were conﬁrmed by inhibiting E2F1,
TGFBR1/2 and FGFR1 in UM-UC-3 cells and E2F1, TGFBR1/2 and EGFR in
MDA-MB231 cells, which exhibit a profound impact on the invasive behavior in the
respective cancer type with the highest eﬀect upon combined inhibition, see Fig. 5c on
page 160. Moreover, our experimental partners examined the overexpression of E2F1
and receptor molecules EGFR, FGFR, TGFBR1/2 by stimulated their lingand to
induce invasion in RT-4 (bladder) and MCF-7 (breast) epithelial cells. Figures 5d on
page 160, show that overexpression of E2F1 or FGFR1 or TGFB1 (alone or in
combinations) enhance the invasiveness in RT-4, and overexpression of E2F1 or EGFR
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(a) Bladder cancer
Signature Double in silico perturbations in regulatory layer Output
E2F1 TGFBR1 FGFR1 ZEB1 TWIST1 SNAI1 NFKB1 SMAD2,3,4 CDH1 EMT
1 1 1 1 1 1 1 1 0 3
1 1 1 0 0 1 1 0 1 1
1 1 1 0 1 0 1 0 1 1
1 1 1 0 0 1 0 0 1 1
1 1 1 0 1 1 1 0 1 1
1 1 1 1 0 1 1 0 1 1
1 1 1 1 0 1 0 0 1 1
(b) Breast cancer
Signature Double in silico perturbations in regulatory layer Output
E2F1 TGFBR2 EGFR SRC FN1 SNAI1 SNAI2 CDH1 EMT
1 1 1 1 1 1 1 0 3
1 1 1 0 1 1 1 1 1
1 1 1 0 0 1 1 0 1
1 1 1 0 1 0 1 1 1
1 1 1 0 1 1 0 1 1
1 1 1 1 0 1 1 1 1
1 1 1 1 1 0 1 1 1
1 1 1 1 1 1 0 1 1
1 1 1 1 0 0 1 0 1
1 1 1 1 0 1 0 0 1
Table 3.3. In silico simulations of tandem perturbations of highly invasive
(EMT = 3) phenotype in (a) bladder and (b) breast cancer models. The ﬁrst
rows in both cancer models represent the predicted molecular signatures for highest
EMT level. The brown boxes represent the perturbed state of genes and their eﬀect
on the EMT phenotype is shown in the last column. The table is adopted from Khan
et al., 2017 [124].
or TGFB1 (alone or in combinations) raise the invasive potential of MCF-7. It also
conﬁrmed that EGFR and FGFR1 have less impact on RT-4 and MCF-7 invasive
potential respectively.
To validate the predictions of my in silico perturbation simulations (Table 3.3), our
experimental partners decided to knockdown NFKB1 and SMAD3 in UM-UC-3 cells
and SRC and FN1 in MDA-MB231 cells, instead of modulating the other well known
EMT markers, such as SNAI1/2, TWIST1, ZEB1 or CDH1. They performed single and
double knockdown of these genes and measured both, the transcriptional and
EMT/MET response. Whereas removal of single genes resulted in a clear reversal of
the EMT phenotype (reduced invasion) in both cell lines. The strongest eﬀect was
observed after double knockdown, as shown by their lowest invasive capacity, see Fig. 6
on page 161.
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3.2.5. Validation of model predictions with patient data
To further validate the molecular signatures that were predicted, by in silico
simulations, to regulate invasiveness in bladder cancer, we used data from a patient
cohort (n = 165) [191], in which a correlation between E2F1 expression and superﬁcial
to invasive progression was observed (GEO id: GSE13507). We grouped the patients
into high and low expression proﬁles of E2F1, TGFBR1 and FGFR1 from their
respective median expression values. For each group, the progression-free survival
probability was calculated and found that the survival probability was higher in the
patient group with low expression of each molecule individually. Furthermore, we
identiﬁed the subgroups of patients with high vs low expression of: (i) E2F1-FGFR1;
(ii) E2F1-TGFBR1; and (iii) E2F1-FGFR1-TGFBR1. The progression-free survival
probability of each subgroup revealed that patients with high expression of
E2F1-FGFR1 have the lowest mean survival time (33.79 months), while those with low
expression of E2F1-FGFR1-TGFBR1 have the best prognosis (93.35 months) among all
the subgroups analyzed (see Kaplan-Meier plots in Figure 3.5a-c). Our analyses
indicate that patients with a low expression of the molecular signatures survive more
than twice as long as the patient subgroup with high expression.
To validate the molecular signature from the regulatory core in breast cancer, we
used data from the TRANSBIG network (GEO id: GSE7390; n = 198) generated by
Desmedt and colleagues (2007) [200]. Similar to bladder cancer patients, we observed
that the progression-free survival probability of breast cancer patients was low for high
expression levels of E2F1, EGFR and TGFBR2 in diﬀerent combinations (Figure 3.5d-
f). Interestingly, we observed the highest mean survival time (97.29 months) in the
patient subgroup with low expression of E2F1-EGFR-TGFBR2. Similar to the bladder
cancer analyses, the patient subgroup with high expression of all three components had
nearly half the mean survival time (50.11 months) compared to the subgroup with low
expression.
We further validated molecular signatures in large patient cohorts of TCGA bladder
cancer (BLCA; n = 426) and TCGA breast cancer (BRCA; n = 1218) accessible through
UCSC Xena http://xena.ucsc.edu. Based on the molecular signatures identiﬁed through
model simulations, we successfully stratiﬁed bladder and breast cancer patients into early
and advance stages of disease (p-value < 0:005) (Figure 3.6a,b). In order to assess the
capability of our workﬂow to predict signiﬁcant molecular signatures associated with
invasive phenotypes, we generated 30 random signatures of three nodes from each of the
regulatory cores and arbitrarily assigned high or low expression values. We observed that
the molecular signature predicted for bladder cancer is the only one that distinguishes
between the early and advanced stage of cancer (Figure 3.6c). In case of breast cancer,
in addition to the predicted signature, some of the random signatures were also able
to distinguish between aggressive and less-aggressive cancer types (Figure 3.6d). This
might be due to the highly heterogeneous nature of breast cancers. Overall, our analysis
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reveals that an invasive tumor phenotype in bladder cancer is driven by E2F1, TGFBR1
and FGFR1, while in case of breast cancer it is driven by E2F1, TGFBR2 and EGFR.
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Figure 3.5. Kaplan-Meier plots of progression-free survival of patients with
bladder and breast cancer. Plots a-c show the survival curves for patients with
high and low expression of combined signatures (E2F1-FGFR1; E2F1-TGFBR1;
and E2F1-FGFR1-TGFBR1) in bladder cancer patients, while plots d-f are for the
combined signatures of E2F1-EGFR; E2F1-TGFBR2; and E2F1-EGFR-TGFBR2 in
breast cancer patients. In both cases, patients with low expression of the in silico
predicted signatures have high mean survival times and vice versa. High expression
of molecular signature(s) is represented as `_H' (black curve) and low expression as
`_L' (red curve). `N' is the number of patients observed with high/low expression of
molecular signatures and `MSM' is the mean survival month from the patient group.
p-values shown in the ﬁgures are from a log rank test. The ﬁgure is taken from Khan
et al., 2017 [124].
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Figure 3.6. Validation of molecular signatures in (a) TCGA bladder and (b)
TCGA breast cancer cohorts. In the bladder cancer cohort, ﬁrst the patients
are ﬁltered who are diagnosed with early (stage II) and advanced (stage IV) stages.
Further in both stages, we identiﬁed subsets of patients where expression of genes of the
molecular signature (i.e., E2F1, TGFBR1 and FGFR1) was above (signature) or below
(signature*) the respective mean expression value. In case of the breast cancer cohort,
we classiﬁed patients into aggressive (basal and Her2) vs. less-aggressive (luminal A
and B) molecular subtypes based on PAM50 stages provided. Afterwards, we identiﬁed
those subsets of patients where expression of genes of the molecular signature (i.e.,
E2F1, TGFBR2 and EGFR) was above (signature) or below (signature*) the respective
mean expression value. The distribution diﬀerence (%) of patients was calculated
within pathological stages in both cancer types. Similarly, distribution diﬀerences for
30 random signatures vs. signatures* derived from (c) bladder and (d) breast cancer
regulatory cores are shown as scatter plots. Signatures in the upper right or lower
left corners nicely distinguish patient phenotypes. The molecular signatures predicted
from my proposed workﬂow are shown in red. p-values are calculated using Pearson's
2 test. The ﬁgure is taken from Khan et al., 2017 [124].
3.2.6. Summary of results
Mathematical models, in combination with experimental data, are powerful tools to
predict and understand the eﬀect that diﬀerent stimuli have on the behavior of a system.
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Such systems biology approach further supports the formulation of new hypotheses about
the eﬀect of speciﬁc internal or external perturbations [156, 158]. To understand the
molecular sources of EMT regulation in bladder and breast cancer, I developed logic-
based models of the core-regulatory networks identiﬁed in Chapter 2. I divided each of
the core-networks into three layers: (i) input layer, (ii) regulatory layer, and (iii) output
layer. The input layer contains E2F1 and the receptor molecules. The regulatory layers
consist of all components of the core networks except E2F1 and receptor molecules. The
output layer comprises one node that represents the EMT process as the driver of the
invasive phenotype. The input layer and regulatory layers were encoded with Boolean
logic, while the phenotypical output of the network was modeled with multi-valued logics.
Multi-valued logic allows us to model several activity levels of the phenotype, which helps
in assessing the aggregated eﬀect of various network components on the phenotype [155].
However, the use of multi-valued logic increases the complexity of the model, therefore,
I applied it only to the phenotypical output. In logic-based models, when a molecule has
multiple regulator, the choice for `OR' and `AND' gate is challenging. Towards this, I
used qualitative information based on fold-change expression data to derive the Boolean
functions.
I simulated the model for diﬀerent combinations of input components, and their
analysis revealed that high levels of the E2F1-TGFBR1-FGFR1 in bladder cancer and
the E2F1-TGFBR2-EGFR in breast cancer constitute the molecular signatures that
represent the most aggressive phenotype in the respective cancer type. Surprisingly, the
other receptors that are part of the input layers in the models had no eﬀect on the
EMT process. The simulation results are in agreement with previous experimental
ﬁndings in bladder cancer studies where high levels of E2F1 [201], TGFBR1 [202] and
FGFR1 [197] were independently associated with tumor invasion. Similarly, in breast
cancer studies, high expression of E2F1 [203], TGFBR2 [204] and EGFR [205] was
separately observed to regulate invasive tumor phenotypes. Further, we validated the
role of predicted signatures using bladder and breast cancer patient survival data from
independent studies, see in Figure 3.5 and 3.6. For all our predicted signatures, high
expression of the constituent molecules mapped to low patient survival and vice versa.
These correlations prove that my approach successfully identiﬁed tumor-speciﬁc
molecular signatures regulating EMT and driving invasive phenotypes.
Further, the in silico predicted signatures were validated by in vitro experiments.
Inhibition of the predicted signatures in invasive bladder (UM-UC-3) and breast (MDA-
MB231) cancer cell lines shows profound impact on the invasive behavior of the respective
cell line and the highest eﬀect observed upon combined inhibition Fig. 5c on page 160.
Moreover, model simulations reveal that receptor molecules EGFR, CXCR1 and RAEA
had no eﬀect on the EMT in bladder cancer, and similarly in case of breast cancer
the receptors molecules FGFR, HMMR, THRB, IL1R1 and RARA had no eﬀect. The
minimal eﬀect of EGFR in bladder cancer and that of FGFR in breast cancer were
conﬁrmed experimentally (Fig. 5a on page 160).
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Furthermore, I performed in silico perturbations to identify potential therapeutic
candidates in cells, which have overexpression of the model-based identiﬁed molecular
signatures (i.e., E2F1-TGFBR1-FGFR1 in bladder and E2F1-TGFBR2-EGFR in
breast cancer). From the list of identiﬁed candidates, our experimental partners,
validated SMAD3-NFKB1 in UM-UC-3 bladder cancer and SRC-FN1 in MDA-MB231
in breast cancer by knock down using shRNA-based experiments. The experimental
results are in consensus with the model predictions, which shows a signiﬁcant reduction
in cell invasion by inhibiting the therapeutic targets alone or in combination (Fig. 6 on
page 161).
Overall, model-based treatment recommendations of E2F1-driven tumor, such as
advanced bladder or breast cancer, have the potential to support cohort-speciﬁc
treatment of patients in order to avoid therapy resistance and cope with aggressive
cancers. Finally, the workﬂow that I proposed (combining network structure analysis,
high-throughput data analysis and a dynamical model) and our comprehensive E2F1
interaction map can be applied to other cancer types in which E2F1 plays a similar
role, as well as to characterize mechanisms leading to other phenotypes, like
chemoresistance or angiogenesis, related to this transcription factor.
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Chapter4
Hybrid modeling of large-scale
biochemical networks
The models, the methodology for hybrid modeling and their subsequent analyses are
published in the following publications:
 Vera J, Schmitz U, Lai X, Engelmann D, Khan FM, Wolkenhauer O, Pützer BM. Kinetic
modeling-based detection of genetic signatures that provide chemoresistance via the E2F1-
p73/DNp73-miR-205 network. Cancer research. 2013 Feb 27. https://doi.org/10.1158/
0008-5472.CAN-12-4095.
 Khan FM, Schmitz U, Nikolov S, Engelmann D, Pützer BM, Wolkenhauer O, Vera J.
Hybrid modeling of the crosstalk between signaling and transcriptional networks using
ordinary diﬀerential equations and multi-valued logic. Biochimica et Biophysica Acta
(BBA)-Proteins and Proteomics. 2014 Jan 1;1844(1):289-98. https://doi.org/10.1016/j.
bbapap.2013.05.007.
Synopsis
Mathematical models can be created at diﬀerent levels of abstraction, ranging from
coarse-grained qualitative (e.g., logic-based) models of (large) sub-cellular processes to
detailed quantitative (e.g., ODEs based) models of (small) highly nonlinear processes. In
systems biology, it is an emerging dilemma to conciliate models of massive networks and
the adequate description of nonlinear dynamics with a single modeling framework. In
this chapter I present a hybrid modeling framework that combines ODEs and logic-based
models as a tool to dynamically analyze large-scale, nonlinear biochemical networks. As
a proof of concept, I illustrate the construction and analysis of a hybrid model for
regulatory network centered around the E2F1, a transcription factor involve in cancer.
The network is organized and divided into diﬀerent parts with distinctive regulatory
features and each part is modeled with the suitable modeling formalism. A hybrid model
provides a good compromise between quantitative/qualitative accuracy and scalability
when considering large networks.
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4.1. Background and motivation for hybrid modeling
In cells, biological processes are driven by complex networks integrating genes,
transcripts, like mRNAs and microRNAs (miRNAs), proteins and small molecules.
Concentrations and activity of these biomolecules are continuously changing in a
concerted manner in response to internal and external cell signals. Those changes are
regulated by multiple nested biological circuits that may contain feedback and
feedforward loops. These nonlinear biological circuits give rise to important cell
features like robustness against noise, adaptation despite environmental changes or
hysteretic responses with multistability [206]. In the last decade it has been found that
some biochemical networks are extremely large and complex [58, 59, 108110]: they are
commonly composed of hundreds of compounds and are enriched in nonlinear motifs
like feedback and feedforward loops [2, 134]. Under these conditions, the analysis of
biochemical networks evades human intuition. However, mathematical modeling is an
appropriate tool to help in understanding those networks [158, 207, 208]. Depending on
the features of the biochemical network under consideration and the available
experimental data, a variety of frameworks for mathematical modeling is available.
These range from simple and abstract approaches to biologically detailed ones, from
deterministic to probabilistic or from spatio-temporal continuous to discrete ones [209].
Models in ordinary diﬀerential equations (ODEs), accounting for the time dependent
variation of variables representing the concentration or activation state of biochemical
molecules, have been used to describe biological networks for decades [210]. These ODE
models allow the quantitative simulation of the concentration changes or activity
proﬁles of proteins, genes, RNAs and other molecules over time. These features allow
comparisons of model predictions with most of the standard experimental
measurements. When biological compartments are considered, they can also account for
a qualitative description of spatial features [211]. Finally, ODE models are the most
widely used modeling framework when investigating the features of biochemical
networks containing regulatory circuits like feedback- and/or feedforward loops [4].
However, a complete characterization of the model requires to specify the values of
several kinds of model parameters (for example, initial protein concentration and rate
constants), which in biochemical mid-size networks becomes a computationally
intensive task and requires large amounts of quantitative experimental data and
sophisticated optimization algorithms. For larger networks parameter estimation
becomes cumbersome and diﬃculties to identify unique values for model parameters
emerge [212214].
An alternative to the ODE models is the discrete modeling approach. It is a
qualitative approach that depends only on the network structure (i.e., parameter free)
with the simplifying assumption that network nodes, accounting for the expression level
or activation state of biological molecules, exist only in a well-deﬁned set of possible
discrete numerical values [213]. Discrete models allow the dynamical analysis of large
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biological systems of interactions among proteins, genes and other biomolecules to
understand their behavior upon diﬀerent input-stimuli and perturbations, and make
predictions on biologically relevant scenarios [164, 199, 215]. Boolean models are the
simplest discrete models, in which each element of the network can have one of two
possible states (1: ON, expressed or active; 0: OFF, non-expressed or inactive) at any
time point. This assumption is supported by biological evidences, e.g., when
genes/proteins exhibit ON/OFF switch like behavior. This can be adopted by assuming
a reduced set of biologically meaningful values for the model variables [175, 213, 216].
A number of recent papers illustrates how discrete logic models can capture the
behavior of large systems where the interactions are modeled with simple Boolean
assumptions [90, 91, 217]. However, discrete logic models do not reproduce some of the
time-dependent features associated to nonlinear circuits, like those containing nested
feedback/feedforward loops where small changes in the variable produce entirely
diﬀerent dynamics [2, 134].
A single modeling formalism is not suﬃcient to accommodate the inherent
complexity of biochemical networks (i.e., large number of components and nonlinear
network structure) [218]. Therefore, it is necessary to develop suitable modeling
strategies that realize a compromise between the ability to simulate the behavior of
large biochemical networks, the complexity associated to the existence of multiple
regulatory loops in them and the diversity of sources of experimental data. Towards
this, I propose a hybrid modeling framework, composed of ODE and logic sub-modules,
as a strategy to handle large-scale, nonlinear biochemical networks associated to cancer
and other complex diseases. I illustrate the construction of this kind of model using a
toy model of the regulation of the anti-apoptotic molecule BCL-w in Section 4.4 on
Page 70. Further, as a proof of concept I applied the hybrid modeling strategy to a
regulatory network centered around E2F1, to characterize its role along with other
receptor molecules in drug resistance. The model reproduced known features of the
network regulated the drug resistance phenotype and hypothesized that for high
expression of the E2F1 the tumor cell become independent of growth factors, which is
one of the hallmark of cancer [190, 219].
Hybrid models are mathematical and computational constructs that combine
interdependent variables that distributed over discrete/continuous or
deterministic/stochastic domains [220]. They account in an integrative manner for
diﬀerent spatio-temporal scales of the same biological phenomenon, which are described
using diﬀerent interconnected modeling frameworks [96, 221]. Further, hybrid modeling
i.e., combination of diﬀerent modeling formalisms, can be used to simulate large
systems of interacting molecules involving signaling, transcription and metabolic
layers [218, 222, 223]. The hybrid modeling approach seems especially valuable when
dealing with the multifactorial and multi-level nature of biological phenomena like
cancer emergence and progression [224, 225].
In the following text, I will ﬁrst describe ODE-based models, diﬀerent laws of mass
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action kinetics, and type of dynamical analysis one can perform with ODEs. Second, I
will present an ODE-based model of the E2F1-mediated drug resistance. Then, I will
present in detail the hybrid model of the drug resistance, its construction, implementation
and analysis.
4.2. ODE-based kinetic models
Kinetic-based models have successfully established their role in explaining the
non-intuitive behavior of complex cellular processes [6, 83, 226], and providing an
understanding of the molecular basis of cell functions in healthy and disease
conditions [227, 228]. In a recent review Magi et al. (2017) evaluate the current status
of mathematical models in the pursuit of a mechanistic understanding of complex
cancer phenotypes [228]. They provide a good overview of how mathematical models
unravel the non-intuitive dynamics of sub-/networks regulating the hallmarks of cancer:
cell cycle regulation abnormalities, resistance to cell death, angiogenesis, invasion and
metastasis, dysregulation of immune responses, and metabolism. Kinetic-based models
are more suitable for the investigation of nonlinear biological systems where the number
of interactions is small and suﬃcient quantitative data is available for parameter
characterization. In systems biology, mathematical models are developed in the
following steps: (i) construction of the model structure, (ii) derivation of mathematical
equations, (iii) identiﬁcation of parameters and initial conditions, and (iv) performing
model simulations that can explain the nonlinear behavior and unravel mechanisms,
which lead to testable hypotheses.
In kinetic models, the biological species are represented by variables (such as,
metabolite concentration or amount of mRNA), which are characterized by rate laws
that are modulated by various parameters. A general ODE system of equations is
written as:
dXi
dt
= vi(X1; : : : ; XN ; k1; : : : ; kN ) i=1,. . . ,N (4.1)
where dXi=dt represents the rate of change of species Xi at time t. X1; : : : ; XN is a
set of N number of variables representing the concentration of species. The temporal
behavior of the system is evaluated by functions vi (kinetic laws) depending on variables
X1; : : : ; XN and parameters k1; : : : ; kN . Variables are the quantities of interest in model
analysis, which typically change over time. Parameters are quantities, which are ﬁxed
for a given computational experiment to characterize speciﬁc quantitative behavior of
a model. Parameter values are typically derived from either literature, or databases,
such as BioModels [20], Brenda [160] and SABIO-RK [19], and can be estimated from
experimental data by calibrating the model to recapitulate the biological process as good
as possible [17, 18]. The parameterization of the model presented in this chapter is based
on: (i) published information, (ii) estimation by terning them to ﬁt published quantitative
and qualitative data, and (iii) ﬁxing some parameter values to normalize variables to the
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basal, non-stressed level of mRNA and protein (more details are provided in Appendix F
Section F.2). In the following sub-sections, I will brieﬂy describe diﬀerent laws of rate
kinetics, their general representation and applications.
4.2.1. Mass action kinetics
To evaluate the dynamics of a system, one needs to determine what the function vi (i.e.,
reaction rates) actually is. In systems biology practice, it can be described by appropriate
rate kinetics such as `mass action kinetics'. Mass action kinetics state that the rate of
a reaction is proportional to the probability of a collision of the reactants [229]. This
probability is in turn proportional to the product of concentrations of the reacting species
to the power of molecularity, which is the number in which the molecular species enter
the reaction [229]. The general representation of reaction rate in mass action kinetics
can be written as:
vi = ki 
lY
j=1
x
gij
j ; 8gij = mij 2 f0; 1; 2g (4.2)
where vi (i = 1; : : : ; N) is reaction rate of i
th reaction. Every reaction rate vi is described
as a product of a rate constant (ki) and biochemical species (xj ; j = 1; : : : ; l) participating
in the reaction. gij denotes the kinetic orders which is equal to the number of molecules
of xj involved in a reaction. When gij is zero the specie is not involve in a reaction, when
it is 1 the species participates, and for a value of 2 it represents the dimerization.
For example, using law of mass action the rate of a reaction,
S1 + S2
k1  *)  
k 2
2P (4.3)
where one molecule of substrate S1 and S2 are converted into two molecules of product
P and vice versa in a reversible reaction, can be written as:
v1 = k1S1  S2; v2 = k 2P 2
v = v1   v2 = k1S1  S2   k 2P 2 (4.4)
where v1 (the product of kinetic constant k1 with substrates S1 and S2) and v2
(product of kinetic constant K 2 with power of 2 (molecularity of P in the reaction) of
product P ) are the rates of forward and backward reactions respectively. The net rate
v, here represents the rate of formation of product P , is equal to the production rate
(v1) minus depletion rate (v2). Law of mass action is the precise and detailed
mathematical description for chemical reaction kinetics using ordinary diﬀerential
equations for which detailed structure of the system must be known, but this is diﬃcult
to achieve when many interacting components are involved. However, assuming some
conditions (e.g., steady state), more simpliﬁed rate kinetics (such as Michaelis-Menten
and Hill functions) can be derived to model a system of chemical reactions.
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4.2.2. Michaelis-Menten kinetics
For a quasi-steady state assumption, for example when a reaction is much faster than
other reactions, Michaelis-Menten (MM) is the algebraic substitution of diﬀerential
equations in mass action kinetics [229]. The general structure of MM reactions contains
an enzyme E, which binds to a substrate S to form an enzyme-substrate complex ES
which in turn releases product P and the original enzyme E, represented by the
following reaction:
E + S
k1  *)  
k 1
ES
k2  ! P + E (4.5)
The Michaelis-Menten approximation for the reaction rate is:
v =
vmaxS
kM + S
(4.6)
where vmax is the maximal rate, and kM is the Michaelis-Menten constant, which is
half of the maximum rate Figure 4.1. The Michaelis-Menten approximation holds, if the
concentration of the substrate in large excess of the enzyme and the quasi-steady state
assumption is fulﬁlled [229]. This means the elementary reaction produces short-lived
intermediates (such as the enzyme-substrate (ES) complex) and the reversible conversion
of an intermediate complex back into to the substrate is much faster than its conversion
into product. For detailed derivation and discussion of MM rate law, I would refer the
reader to the books written by Edda Klipp [229] and Brian Ingalls [157].
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Figure 4.1. Michaelis-Menten. The reaction rate approaches to maximum rate vmax
as the concentration of the substrate increases. The Michaelis-Menten constant is the
substrate concentration at which the reaction rate equal to half of the maximum rate
vmax.
4.2.3. Hill function
Besides MM kinetics, the Hill function is also used to replace the diﬀerential term in mass
action kinetics by an algebraic function. It is used to describe the level of cooperativity
of a ligand binding to an enzyme or receptor [157, 229]. This can be generalized for
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example to model biological processes involving cooperative interactions, which can result
in switch-like behavior. The general form of Hill function is the following:
v =
Sn
(Sn +Kn)
(4.7)
where K is Hill constant which is equal to half-saturation concentration of ligand and
n is the Hill coeﬃcient, describing the cooperative eﬀect on process (i.e., the steepness
of curve to reach from minimum to maximum rate and vice versa) see Figure 4.2. For
n = 1, there is no cooperative eﬀect and the shape of the curve is hyperbolic, while bigger
values (n > 1) induce a cooperative eﬀect, which produce a sigmoidal (S-shaped) curve.
For detailed derivation and discussion of the Hill function, the reader is referred to the
book written by Brian Ingalls [157].
substrate concentration (S)
re
ac
tio
n 
ra
te
 (v
)
n = 1
n = 4
n = 2
Figure 4.2. Hill function. For Hill coeﬃcient n = 1, the curve is hyperbolic.
When n increases, the signoidal cure becomes more switch-like. The ﬁgure is adopted
from [157].
4.2.4. Power-law models
The power-law model is another convenient representation for mass action
kinetics [210, 230]. It describes the reaction rate as a product of a rate constant and all
the reactants raised to power of non-integer values. Compared to mass action kinetics
shown in Equation (4.2), in which the kinetic orders gij are positive integers, power-law
models allow non-integer values (i.e., gij 2 R) Figure 4.3. The general form of the
power-law model is:
vi = ci  ki 
lY
j=1
x
gij
j ; 8gij 2 R (4.8)
Using a power-law model, the reaction rates v1 and v2 for Reaction 4.3 can be written
in the following form:
v1 = k1[S1  S2]g; v2 = 2k 2([P ]g)2 (4.9)
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where g is the power-law exponent, which can be any non-integer value. Based on
available knowledge about the cellular environment in which the reaction takes place,
two type of formulations exist for power-law models: simpliﬁed and detailed power-law
models [207, 231]. When little knowledge about the structure is available, the simpliﬁed
power-law model is well suited with the assumption of a homogeneous and well mixed
environment, in which both positive and negative (representing inhibition) real values
are applied for kinetic order [232]. When suﬃcient knowledge is available, the detailed
power-law model is used, which takes only positive real values for kinetic orders and
provides a more realistic characterization of inhomogeneity and molecular crowding of
the cellular environment [231].
We used power-law models for the construction of the E2F1-mediated chemoresistance
model, described in this chapter, due to the following remarkable features: (i) a power-law
model can represent the dynamics of inhibitory, activating and cooperative processes by
keeping the mathematical structure of the system intact and just modifying the value of
kinetic order [207, 232]; (ii) it allows to model diﬀerent strengths of activation/inhibition
of reactants in certain biological processes; and (iii) it makes detailed mathematical
models possible with little prior knowledge of the structure of the network.
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Figure 4.3. Power-law model. Power-laws can model diﬀerent dynamics by choosing
appropriate values of kinetic orders g [207]. Power-law model with negative rate
constant (i.e., g < 0) represent inhibition. A zero value for g indicates the substrate
has no eﬀect on the reaction rate. The value of rate constant in the range greater
than zero and less than 1 (i.e., 0 < g > 1) describes the saturation-like behavior.
When the value of g is equal to 1 (g = 1), it represent the linear dynamics; and ﬁnally
rate constant greater than 1 (g > 1) reproducing the cooperative processes.
4.2.5. ODE-based model analysis
After constructing the model structure, derivation of mathematical equations and
identiﬁcation of parameter values, model simulation and analysis begin. Model
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simulations are performed to study the dynamic behavior, the temporal evaluation of
components, of a system for a given condition (i.e., for given initial values and a set of
parameters). In case of ODEs, model simulations are carried out by numerical
integration using ODE solvers (e.g., ode23 from MATLAB). Model simulations
facilitate a temporal evaluation of states, and thus the behavior of a systems. If small
variations in the conditions produce large changes in the solution, we call the system
unstable. If small variations in the conditions produced inﬁnitesimal small changes in
the solution, then the systems is stable. Such type of simulations are called the
stability analysis, which can be used to study the behavior of the systems for
diﬀerent input stimuli and perturbations. For input stimuli one can study, for example,
how a system responds to signals from external environment. For perturbations one can
evaluate, for example, how a system behaves when variations are made in the
dependent variables, which can mimic mutations in the biological entities; or transient
input signal (e.g., some sort of stress) is apply to the system, which can be drug
intervention. Depending on the network structure (i.e., feedback or feedforward loops)
of the system, these changes in initial conditions and perturbations in parameters
induce interesting dynamical features on the state variables [2, 134]. In the following
text, I will describe the basic concept of stability (steady state and transient) analysis
of feedforward loops, which we later use to elucidate the mechanisms of
E2F1-p73/Dnp73-miR-205 in chemoresistance.
Stability analysis
In dynamical systems theory, the time dependent behavior of a system is characterized
by its states, which is the state of its components at a given point in time [229]. In
stability analysis, model simulations usually start from an initial condition and evolve
over time until eventually reaching a steady state or oscillation. The time-course from
initial state of a system to the long-time (or asymptotic) steady state is called transient
behavior Figure 4.4 [157]. On the other hand, in a steady state, variables remain
constant in time, i.e., the concentration of the species reach a steady level and exhibit
no variation over time [135, 157, 229]. Steady state of a system reﬂects its long term
behavior. To study the steady state, those states in which, the rate of change reaches to
zero are considered:
dXi
dt
= 0; i = 1; : : : ; N (4.10)
If a system is at steady state, it should remain there until an external perturbation
occurs. Depending on the system structure, perturbations can have the following eﬀects:
(i) stable: the systems returns to steady state; (ii) unstable: the system leaves the steady
state; and (iii) the system behavior is indiﬀerent [229]. If the system remains in any of
the states for suﬃciently long time (t!1) that behavior is called asymptotic stable.
Stability analysis is highly inﬂuenced by the structure of a system, for example,
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Figure 4.4. Transient and steady-state behavior. The transient behavior is the
time course from initial value X(0) till the system settles into a steady state at point
Xss.
feedback and feedforward loops [2, 134], which induce nonlinear dynamics in the
system's behavior. A feedback loop induces a switch like behavior and provides a
mechanism for a memory eﬀect to a transient input signal. On the other hand,
feedforward loops speed up or delay the system response to transient input signal.
There are eight types of feedforward loops, which are subdivided into two categories:
(i) coherent feedforward loop (cFFL) (see Figure 2.3c); and (ii) in-coherent feedforward
loop (iFFL) (see Figure 2.3d). The coherent type-1 and incoherent type-1 feedforward
loop are the most abundant [229, 233]. Coherent type-1 FFLs act as a ﬁlter for weak
pulses and cause a delayed response see Figure 4.5a, while incoherent type-1 FFLs can
act as a pulse generator with ﬁxed maximal length and can accelerate the system's
response to an input signal (see Figure 4.5b). Futher, incoherent FFLs induce
non-monototic behavior in system dynamics [234]. In a non-monotonic response, the
output of the systems ﬁrst increase with the input signal, but later decrease when the
input signal is high (see Figure F.3). Transient analysis of network motifs can help to
understand the dynamics of biochemical networks in response to time varying
stimuli/perturbations, which can provide valuable insights into mechanisms underlying
disease [235].
Figure 4.5 shows the dynamical behavior induced by coherent/incoherent feedforward
loop. In the loops, `X' regulates `Y' and then `X' and `Y' regulate `Z'. The two
regulators of `Z' can be processed by logical AND or OR functions.
4.3. ODE model-based detection of molecular signatures in
chemoresistance
Resistance to drugs is a major cause of cancer therapy failure. E2F1 is a transcription
factor that is involved in cell cycle progression, apoptosis, metastasis and drug
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Figure 4.5. Dynamical behavior of (a) coherent FFL and (b) incoherent FFL.
In the loops, `X' regulates `Y' and then `X' and `Y' regulate `Z'. The two regulators
of `Z' can be processed by logical AND or OR functions. (a) Coherent FFL type 1
with AND logic. The structure of the coherent type 1 FFL (ﬁrst row), and the curves
show the transient input X (second row), intermediate node Y (third row) and output
Z (fourth row). The curve of Z shows that short pulses are ﬁltered out, the response
to the longer pulse is delayed, but the response to the end of pulse is immediate. (b)
Incoherent FFL type 1 with AND logic. Each onset pulse in the input leads to a
pulse in Z with a ﬁxed maximal length. I reproduced the plots by model simulations
from the book written by Edda Klipp [229] for FFL with parameter values ay = 1:7,
by = 1:7, az = 10, and bz = 5.
resistance through an intricate signaling and gene regulatory network, which includes
other transcription factors like p73 [236], and cancer-related microRNAs like
miR-205 [119]. To investigate mechanistically the emergence of drug resistance, we
carried out dynamical system analyses of the regulatory network summarizing
knowledge of E2F1 and its interplay with p73/DNp73 and miR-205 in cancer drug
responses (see Figure 4.6a).
The structure of the E2F1-centered network that mediates the potential resistance
against anticancer therapies is a complex system, i.e., it is enriched with multiple
network motifs, including feedback and feedforward loops. Furthermore, these motifs
are well interconnected, overlapping, and cross-talk with other cancer-related signaling
pathways [120, 237]. Networks containing several of these motifs often induce
non-intuitive regulatory patterns, which require the use of mathematical modeling to
understand their function and regulation [238, 239].
We developed an ODE-based kinetic model of the E2F1-p73/DNp73-miRNA-205
network to get insights into the mechanisms underlying drug resistance. The model
represents the network response to certain genotoxic (DNA damage causing agents can
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lead to cell death) and cytostatic (agents toxic to cells may stop active growth and
induce cell death) drugs. The prototypical simulations (see Figure 4.6b) show that our
model is able to describe the cascade of regulatory events after drug administration
including stress signals (top), downstream intracellular responses including
E2F1-p73/DNp73-miR205, the regulation of pro- and antiapoptotic signals (for
genotoxic drugs) or proliferative signals (for cytostatic drugs) (middle), and ﬁnally the
global eﬀect on tumor cell population at the bottom. In Appendix F, I provided the
detailed description of the ODE-based model construction, parameterization and model
simulations.
Taken together, our in silico simulations suggest a relevant role for E2F1, DNp73,
and miR-205 in the regulation of resistance to several anticancer drugs. To this end, we
conducted simulations in which we iteratively perturbed the values of the parameters
accounting for E2F1 and miR-205 induction and computed the percentage of surviving
cells 48 hours after genotoxic drug administration. As shown in Figure 4.7a, in silico
cell lines with high levels of E2F1 display a high survival rate in response to
chemotherapy. The simulation results are in agreement with the experimental data
produced by our collaborators from the Institute of Experimental Gene Therapy and
Cancer Research (IEGT)1, University Rostock Medical Center, on melanoma
SK-Mel-147 cells (Figure 4.7b) [119]. SK-Mel-147 cells were treated with cisplatin and
a high percentage of cells underwent apoptosis (Scenario 1 in Figure 4.7b). Inhibition
of miR-205 with antagomir-205 reduces the percentage of apoptotic cells after
treatment (Scenario 2), whereas selective knockdown of endogenously high E2F1 leads
to a pronounced increase in apoptosis (Scenario 3). Finally, repression of both E2F1
and miR-205 reduces the apoptotic eﬀect of cisplatin (Scenario 4). These experimental
results conﬁrm the model predictions displayed in Figure 4.7a for the scenarios named
with the same numbers.
In addition, we found that a genetic signature composed of high E2F1, low miR-205,
and high ERBB3 can render tumor cells insensitive to both cytostatic and genotoxic
drugs (see Appendix F Figure F.2). Our model simulations also suggest that
conventional genotoxic drug treatment favors selection of chemoresistant cells in
genetically heterogeneous tumors, in a manner requiring dysregulation of incoherent
feedforward loops that involve E2F1, p73/DNp73, and miR-205 (see Appendix F
Figure F.3).
4.4. Hybrid modeling: combining ODE- and logic-based
models
Here, I address the problem of modeling large biochemical networks involving dozens to
hundreds of receptors, kinase proteins, transcription factors, mRNAs and microRNAs.
1http://www.iegt-rostock.de/en/
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Figure 4.6. Kinetic model for the E2F1-p73/DNp73-miR205 network. (a)
The model is composed of four modules: The core regulatory module (blue) describes
the dynamics of E2F1, p73, DNp73, and miR-205. The transcriptional targets module
accounts for representative apoptosis and proliferation-associated targets of E2F1, p73,
and miR-205, which may play a role in drug response. The tumor cell population
module connects the biochemical network to the fate of a population of tumor cells.
GxD accounts for genotoxic and CyD for cytostatic drug; red-colored symbols for
oncogenes and green for tumor suppressors. (b) Prototypical simulation of the model
showing the cascade of regulatory events after drug administration. The ﬁgures are
adopted from Vera et al., [121].
Their expression and activity are typically regulated by multiple, cross-talking
pathways that may even contain overlapping regulatory loops. The strategy is to
organize and divide the network into three parts with distinctive regulatory features
(Figure 4.8a): (i) The core regulatory module, a highly interconnected subnetwork
that contains the signaling and transcriptional pathways enriched in feedback and
feedforward loops, and therefore is expected to display a highly nonlinear behavior; (ii)
The target gene module, which accounts for dozens to hundreds of genes whose
expression is directly regulated by the proteins and transcription factors included in the
core regulatory module and can be experimentally quantiﬁed using high-throughput
transcriptomics and proteomics techniques; and (iii) A set of phenotypical
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Figure 4.7. The interplay between E2F1 and miR-205 promotes resistance to
genotoxic drugs. (a) Model simulations for diﬀerent values of the synthesis rates for
E2F1 and miR-205 (kE2F1, kmir 205 2 [10 1,101]) [121]. We determined the percentage
of surviving cells 48 hours after genotoxic stress. (b) Validation experiments with SK-
Mel-147 cells. The percentage of surviving cells was measured 48 hours after cisplatin
treatment for: (1) control; (2) after miR-205 knockdown; (3) after E2F1 knockdown;
and (4) after miR-205 and E2F1 knockdown. The scenarios named with the same
numbers. Data were extracted and processed from Alla and colleagues [119].
read-outs, phenomenological variables accounting for relevant phenotypes triggered
upon activation of groups of genes in the target gene module. Input signals external to
the networks are assumed to regulate or interact with key compounds of the core
regulatory module; although in some cases they could also be direct regulators of the
target genes.
In this approach, I modeled the core regulatory network using ODEs while the target
gene module and the phenotypical read-outs are encoded using discrete logic modeling
(Boolean or multi-valued logic). Both parts of the model are connected using a
discretization interface. Given the set of continuous time-dependent variables of the
core regulatory module (Xi;C , where i = 1; 2; : : : ; k), I deﬁned a set of auxiliary discrete
variables (Xi;D, where i = 1; 2; : : : ; k) for the discretization interface. Furthermore, I
discretized the time by considering a discrete and ﬁnite set of p time points within the
duration of the simulation (tj , where j = 1; 2; : : : ; p). For every time point considered,
the interface assigns values to the auxiliary discrete variables, Xi;D(tj), following a set
of discretization rules that depend on the current values of the continuous variables,
Xi;C(tj), and ni threshold values THi;m, where m = 1; 2; : : : ; ni. The number of
thresholds for each continuous variable deﬁnes the number of ordinal states for the
auxiliary discrete variables. The structure of the discretization rules is displayed in
Table 4.1.
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for i = 1; 2; : : : ; k
if Xi;C(tj) < THi;1 ! Xi;D(tj) = 0
if THi;1  Xi;C(tj)  THi;2 ! Xi;D(tj) = 1
if THi;2  Xi;C(tj)  THi;3 ! Xi;D(tj) = 2
...
if THi;n 1  Xi;C(tj)  THi;n ! Xi;D(tj) = ni   1
Table 4.1. Deﬁnition of the discretization rules. For the each of the k variables of the
core regulatory module (Xi;C , where i = 1; 2; : : : ; k) at the considered time point tj , I
assign a value Xi;C(tj) using these discretization rules.
To simulate the whole model, ﬁrst the core module is initialized and simulated with
a set of values deﬁned for the model inputs (Figure 4.8). At each of the p time points
deﬁned, the values of the auxiliary discrete variables, Xi;D(tj), are calculated following
the discretization rules. Those discrete values are passed as inputs to the logical module
accounting for the target genes and are used to update the values of its discrete variables
following a logical steady-state analysis. Subsequently, the updated values for the model
variables in the transcriptional circuitry module are used to update the phenotypical
read-outs. In this manner and for every discrete time point (tj), the model simulation
generates: (i) a set of continuous values for the variables of the regulatory core module,
Xi;C(tj); (ii) a set of discrete values for the auxiliary variables, Xi;D(tj); (iii) values for
the discrete variables accounting for the expression of the target genes, Tg(tj); and (vi)
Boolean values for the phenotypic read-outs (Figure 4.8c).
This approach has the advantage that the complex and highly regulated part of the
network, which is enriched in regulatory loops is encoded with a modeling approach
that provides many computational and analytical tools to investigate its
properties [211, 240]. On the other hand, the use of logic modeling to describe the
associated target genes allows the simulation of massive transcriptional networks with
dozens to hundreds of biologically relevant genes with low computational
burden [84, 166]. In this line, the data produced in high-throughput transcriptomics
and proteomics experiments can be discretized in the described way to substantiate
these large-scale transcriptional networks.
4.4.1. Software implementation
For the implementation of the hybrid modeling approach, I used built-in ODE solvers
from MATLAB to simulate the dynamics of the core regulatory module (MathWorks,
MA) and CellNetAnalyzer (CNA) [199] to simulate the logical part of the target genes
and phenotypical read-outs see Figure 4.8b. To connect both subparts, I developed a
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Figure 4.8. Hybrid modeling methodology. (a) Structure of the model. (b)
Data workﬂow in the hybrid model during simulations. (c) Sketch of a simulation,
with continuous and discrete variable sets, where X1C and X1D are continuous and
discrete variables respectively, Tg represents target gene sets and Pht stands for the
phenotype. The ﬁgures are adopted from Khan et al., [9].
MATLAB script that discretize the values of critical transcription factors and miRNAs in
the core regulatory module; and used these values as an input vector for the simulations
in CNA. Discretization is carried out using predeﬁned thresholds.
Using the input vector, I applied the following CNA command to perform logical steady
state (LSS) analysis:
[spec_lss] = CNAcomputeLSS (cnap; [input_vector]);
In this command, the vector [spec_lss] contains LSS values of the species in the target
gene module `cnap' which are based on the input_vector calculated in the core module.
The output of the model simulations (continuous and discrete variable values) can be
stored in a matrix, whose content is visualized using color coded surface plots.
4.4.2. Toy model demonstration of hybrid modeling
To illustrate the functioning of the proposed hybrid modeling approach, I derived a small
model describing the regulation of the tumor suppressor miRNA-205 by the transcription
factor p73, its isoform DNp73, and the subsequent regulation of the anti-apoptotic targets
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like BCL-w (Figure 4.9a) [119, 121]. I have simulated this regulatory module using a
model in ordinary diﬀerential equations (Figure 4.9c) and the hybrid modeling approach
(Figure 4.9d). The ODE model was extracted from our previous publication [121]. To
construct the hybrid version of the model, I preserved the ODEs describing the miR-
205 regulation and generated a multi-valued logic model to describe the regulation of
BCL-w by miR-205 (Figure 4.9b). Furthermore, the continuous ODE values of miR-
205 (miR205con) were discretized (miR205disc) into three possible values using the rule
described in Figure 4.9b. The two surface plots generated in the model simulations clearly
show that the hybrid model preserves the nonlinear nature of the BCL-w regulation for
diﬀerent expression values of p73 and DNp73 as displayed by the ODE model [121].
However, BCL-w expression is now represented by three ordinal states (0: no expression,
1: low expression and 2: high expression). MATLAB code for the toy model is given in
Appendix I.
4.5. Case study: hybrid model of chemoresistance
4.5.1. Background
The protein E2F1 is a transcription factor. Upon stimulation with diﬀerent signals
E2F1 can promote the activation and subsequent expression of diﬀerent sets of genes
involved in DNA replication and repair, cell cycle progression, proliferation and/or
apoptosis [241, 242]. Activation of E2F1 by growth factor associated signals induces
expression of target genes promoting cell cycle progression and proliferation [119, 243].
In addition, after genotoxic stress E2F1 regulates the expression and transcriptional
activity of the tumor suppressors p53 and p73, promoting the expression of multiple
genes related to the regulation of apoptosis and cell cycle arrest [120, 237, 244]. Having
the ability to regulate cell proliferation and apoptosis, it is not surprising that E2F1
has been found to be deeply involved in tumor progression and the resistance against
anti-cancer drugs [119, 121, 245].
Rather than isolated, E2F1 is part of a vast and complex biochemical network
involving regulation events and a transcriptional circuitry (Figure 2.2 on page 23). The
network is enriched in nonlinear network motifs, including feedback and feedforward
loops. This makes the use of mathematical modeling for the investigation of E2F1
deregulation in cancer mandatory. Several mathematical models have been developed
to investigate the regulation of E2F1 in diﬀerent biological contexts. For example, a
number of papers elucidation the role of E2F1 in the regulation of the mammalian G1-S
cell cycle transition by means of ODE modeling and bifurcation analysis [246, 247].
Others have investigated the mechanisms by which cellular stress (e.g., DNA damage)
shifts E2F1 activity to induce apoptosis, and how this mechanism is distorted in cancer
cells [248250]. The role of miRNAs in the regulation of E2F1 has also recently been
investigated via mathematical modeling [251]. Previously, we developed a mathematical
model to investigate the E2F1-p73/DNp73-miR-205 regulatory circuit in the emergence
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(a) (b)
(c) (d)
Figure 4.9. Toy model of hybrid modeling methodology. (a) Graphical
representation of transcriptional regulation of the oncogene BCL-w by the transcription
factor p73 and its isoform DNp73. (b) ODE model [121] and hybrid model
representations. (c) ODE model simulations. (d) Hybrid model simulations. In
the simulations, diﬀerent expression levels for p73 and DNp73 were considered and the
steady-state expression levels of miR-205 and BCL-w were computed using the two
versions of the model. ODE model parameters were: kdmiR = 0:029; ksmiR = 0:1010;
kimir = 10:2672; ksbclw = 0:1; kdbclw = 0:1; kiblc = 0:18; p73; DNp73 [10
 1; 102]. The
ﬁgures are adopted from Khan et al., [9].
of resistance to anti-cancer drugs [121]. Taken together, these studies investigate the
regulation of E2F1 in diﬀerent biological contexts, but none of them has addressed the
question of how these events are modulating E2F1 expression and activity aﬀecting the
expression of large transcriptional networks downstream of E2F1. The model described
here is the ﬁrst approach to answer this question with a focus on the role of E2F1 in
chemoresistance.
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4.5.2. Model structure
The derived model accounts for the critical elements of the signaling and
transcriptional network regulating the activity of E2F1 in tumor and normal cells
(Figure 4.10). The network can be divided into three parts: (i) the core regulatory
module, a signaling/transcriptional subnetwork accounting for the regulation of the
expression and activity of E2F1 by proliferative and genotoxic stress signals, (ii) the
target genes, a network accounting for the E2F1 modulated expression of critical genes
involved in the regulation of cell proliferation, genotoxic drug response and apoptosis;
and (iii) the phenotypical read-outs, a set of phenomenological variables accounting for
the activation of relevant phenotypes (e.g., proliferation, apoptosis, chemoresistance)
upon the expression of given genes in the target genes module.
The core regulatory module has been extended to account for the regulation of p73,
DNp73 and miR-205, which form together with E2F1 a regulatory circuit in the context
of the genotoxic stress response and apoptosis initiation [119, 121]. Furthermore, I
included a sub-module accounting for the activation of E2F1 via EGFR mediated
proliferative signals and the E2F1 mediated transcriptional regulation of EGFR [252].
Both sub-modules constitute experimentally conﬁrmed cases of feedback loops, a
negative one in the case of E2F1-p73/DNp73-miR-205 [119] and a positive one in the
case of E2F1/EGFR [121, 252]. In addition, input variables regulating the dynamics of
the core module account for: (a) the concentration of growth factors activating EGF
receptor (GF), (b) the cancer-related changes in the expression rate of E2F1 (FS), (c)
the expression level for the oncogene TGF-1 (TGFB1), and (d) the dose of a
genotoxic agent administered as anti-cancer drug (GxS). TGF-1 exempliﬁes a set of
proteins whose dynamics is external to the core module, but regulate the expression
and activation of the core regulatory module compounds.
On the other hand, genes considered in the target gene module account for: (i)
E2F1-regulated genes involved in cancer-related abnormal cell proliferation (e.g.,
GAB2, CCND1, ANCCA); (ii) E2F1-modulated genes involved in DNA-damage
response and apoptosis initiation (e.g., BIM, DUSP1-3, HRK, NOXA); (iii)
p73-regulated genes involved in apoptosis initiation (e.g., BAX, PUMA); and (iv)
miR-205-repressed genes involved in apoptosis repression and chemoresistance (e.g.,
BCL2, ABCA2). These genes are used here as an example and represent a wider set of
genes which undergo similar regulation.
Following the approach proposed, I derived an ODE model to describe the dynamics
of the core regulatory module, which was extracted and adapted from our previous
publication [121] described in Section 4.3. For the target genes, I constructed a discrete
multi-valued logic model, which was connected to phenotypical read-outs using also
multi-valued logic. The core regulatory module and the target gene module were
connected using a computational interface that discretizes the values of the model
variables in the regulatory module that control the expression of the genes in the target
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genes, namely, active E2F1 (E2F1p), p73, DNp73, and miR-205. The discretization
rules were established using manual training [121], where minimum expression level is
discretized to 0 and maximum to 1 or 2 in case of multi-valued logic 4.5.3. Taken
together, the model is composed by nine ODEs (see Equations (4.11) to (4.19) on
page 75) and 35 multi-valued logic functions (Table 4.3 on page 78).
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Figure 4.10. Structure of the hybrid model of E2F1 for chemoresistance.
The ﬁgure displays a CellDesigner map of the system and consists of three parts:
(i) the core regulatory module, a transcriptional subnetwork accounting for the
regulation of the expression and activity of E2F1 by proliferative and genotoxic stress
signals, (ii) the target gene module, a network accounting for the E2F1 modulated
expression of critical genes involved in the regulation of cell proliferation, genotoxic
drug response and apoptosis, and (iii) the phenotypical read-outs (purple hexagons),
a set of phenomenological variables that connect the transcriptional circuitry with
phenotypic responses. The ﬁgure is adopted from Khan et al., [9].
4.5.3. Model construction
In order to illustrate the hybrid modeling approach, I adopted a kinetic model of the
E2F1-p73/DNp73-miR-205 circuitry [121] using ordinary diﬀerential equations (ODEs)
as a core module and extended with a feedback loop analysis of E2F1-EGFR. The kinetic
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model accounts for the temporal evolution of system variables over time under basal
and genotoxic stress conditions. The interactive components of the core module are:
EGF, EGFR, ERK, E2F1, p73/DNp73 and miR205. The target gene module contains
E2F1, p73/DNp73 and miR205 targets that account for diﬀerent cellular functions like
proliferation, apoptosis, and chemoresistance. The target gene module is modeled using
a logical approach, which depends on the input vector [E2F1 p73 DNp73 miR-205]. For
calculating the input vector, I used thresholds representing a drug-induced genotoxic
stress level that is suﬃcient to induce high expression of E2F1, so that the inhibitory
role of DNp73 dominates the activator role of p73 in miR-205 synthesis and the expression
level of miR-205 reaches less than value of 1 [121].
(i) Core module: The core module is composed of nine ODEs accounting for the
evolution in time of: inactive and active epidermal growth factor receptor (represented
by EGFR and EGFR* respectively) (4.11), (4.12); extracellular-signal-regulated kinase
(ERK) (4.13); transcription factor E2F1-mRNA (4.14); un-phosphorylated E2F1
(E2F1i) (4.15); phosphorylated E2F1 (E2F1p) (4.16); both isoforms of p73
(respectively, p73 and DNp73) (4.17), (4.18); and miR-205 (4.19).
dEGFR
dt
=  k1  (GF + k2  EGFR)  EGFR 

k3  E2F1
kx + E2F1

  k4  EGFR (4.11)
dEGFR
dt
= k1  (GF + k2  EGFR)  EGFR  kxx  EGFR (4.12)
dpERK
dt
= k5  EGFR  (ERKt  ERK)  k6  pERK (4.13)
dmE2F1
dt
= GxS  k7 + FS  k8   k9  (1 + k10 miR205) mE2F1 (4.14)
dE2F1i
dt
= k11 mE2F1  k12  E2F1i  pERK + k13  E2F1p  k14  E2F1i (4.15)
dE2F1p
dt
= k15  E2F1i  pERK   k16  E2F1p (4.16)
dp73
dt
= k17  E2F1p  k18  p73 (4.17)
dDNp73
dt
= k19  E2F1p  k20 DNp73 (4.18)
dmiR205
dt
= k21  TGFB 1  p73 

1 +
DNp73
k22

  k23 miR205 (4.19)
The MM-type equation (4.11) accounts for the E2F1 mediated synthesis of EGFR
(k3) and its degradation (k4) [121, 252, 253]. Equation (4.12) accounts for the external
ligand EGF and auto regulation (k1; k2) of active EGFR (i.e., EGFR
) and its
degradation (kxx) [121, 254]. Equation (4.13) accounts for the EGFR-mediated
phosphorylation (k5) of ERK to represent mitogenic signaling pathways and its
degradation (k6) [255]. Equation (4.14) accounts for basal and genotoxic
stress-mediated synthesis of E2F1 mRNA, characterized by parameter k8 and k7,
respectively [121]. GxS is an input variable accounting for genotoxic stress.
Furthermore, the core module contains a term for the miR-205 mediated E2F1
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degradation (k10) [256] and its basal degradation (k9) [257]. Equation (4.15) accounts
for the E2F1 mRNA-mediated synthesis (k11) of un-phosphorylated E2F1 (here
represented by E2F1i) [121, 258]. It also contains an expression for mitogenesis
signal-mediated and basal degradation (k12; k14) of E2F1i [259]. Equation (4.16)
accounts for the mitosis-mediated phosphorylation (k15) of E2F1 protein (represented
by E2F1p) and for its basal degradation (k16) [259]. Equations (4.17) and (4.18)
account for the E2F1-mediated synthesis of p73 and DNp73 (k17 and k19
respectively) [260], and basal degradation (k16 and k18). In addition, equation (4.19)
accounts for miR-205 synthesis and degradation (k21; k23) in which p73 acts as activator
of miR-205, while DNp73 plays an inhibitory role [261, 262]. Here, we use a reduced
power law term [207]. According to the observation reported for several tumor types,
we assumed that when both isoforms of p73 are overexpressed the inhibitory eﬀect of
DNp73 dominates and cancels out p73 activation of miR-205 [263]. Besides, we
included a term for the repression of miR-205 by the oncogenic signal from the TGF-1
pathway (TGFB1) [121, 264].
(ii) Discretization rules: Here I have chosen threshold values for discretization using
manual training of the model variables E2F1, p73, DNp73 and miR205 [121]. If the
continuous values of these variables lie below or above a certain limit, it is assigned a
discrete value of `0', `1' or `2'. These discrete values represent diﬀerent activity levels of
those variables depending on Boolean or multi-valued logic. In case of Boolean logic,
discrete value `0' represents low expression, which is not suﬃcient to activate the
downstream target, while `1' represents high expression, which is suﬃcient to activate
the downstream target. In multi-valued logic `0' represents low expression, `1'
represents a medium level, and `2' represents a high level of expression. Using the
system, I discretized E2F1 for multi-valued logic i.e., `0', `1' and `2' representing low,
medium and high expression respectively. p73, DNp73 and miR205 are discretized as
`0' and `1' representing low and high expression.
(iii) Target gene and phenotypical module: In the proposed hybrid methodology,
I modeled the target gene module in a multi-valued logic and phenotypical module in
simple Boolean logic. The set of rules, listed in Table 4.3, describes how E2F1, p73,
DNp73 and miR-205 activate or inhibit the target genes involved in proliferation,
apoptosis, and chemoresistance. All reactions are supported by the literature (PubMed
references are provided). The rules are written in CellNetAnayzer (CNA) notation for
performing logical steady state analysis [199]:
hcoecientireactant = hcoecientiproduct. The activity levels of reactants and
products are denoted by coeﬃcient in front of them.
4.5.4. Hybrid model simulations of E2F1 network in drug resistance
I simulated cancer and non-cancer like cells with diﬀerent input vectors (i.e., initial
values) by modulating the values of the model inputs GF, FS, TGFB1, and GxS Table 4.4.
I considered two sets of scenarios, characterized by: (i) the presence of a suﬃcient amount
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if E2F1pc < 1:15! E2F1pD = 0
if 1:15  E2F1pc(tj) < 12! E2F1pD = 1
if E2F1pc  12! E2F1pD = 2
if miR205c < 5! miR205D = 0
if miR205c  5! miR205D = 1
if p73c < 1! p73D = 0
if p73c  1! p73D = 1
if DNp73c < 10! DNp73D = 0
if DNp73c  10! DNp73D = 1
Table 4.2. Deﬁnition of the discretization rules for E2F1, miR205, p73 and DNp73.
E2F1pc, miR205c, p73c, DNp73c represent continuous value of expression and
E2F1pd, miR205d, p73d, DNp73d represent their discrete state.
of growth factor (GF = 1) to trigger proliferation, and (ii) the lack of growth factor
stimulation (GF = 0). Next, I modiﬁed sequentially and systematically the values
of the other input variables, obtaining all possible biological scenarios accounting for
the eﬀect of genotoxic drug administration on cancer and non-cancer cells with/without
overexpression of E2F1 and TGF-1. The hybrid model was used to compute the steady-
state values of the model variables. The eﬀect of genotoxic drug administration (GxS)
in these diﬀerent biological scenarios is substantiated in the model by the emerging
gene expression pattern and triggering one of the phenotypes considered in the model.
The computation of the complete set of simulations took approximately 1 second on a
conventional workstation.
The results obtained are in accordance with those previously derived from an ODE
model and with other experimental evidence in the literature [119, 121, 252]. However,
our hybrid model delivered additional interesting results. For example, our model
simulations for conditions of non-growth factor stimulation (GF = 0) indicate that in
the case of suﬃcient overexpression of E2F1 tumor cells may become self-suﬃcient in
growth signals [190, 219]. We link this simulation result to the existence of a positive
feedback loop between E2F1 and EGFR [252]. Furthermore, suﬃcient overexpression of
either E2F1 (E2F1 = 10) or TGF-1 (TGFB1 = 10) can promote resistance to
anti-cancer drugs by the repression of miR-205. This conclusion is in agreement to the
results of our previous publication [121]. On the other hand, another version of the
model, completely constructed using multi-valued logic, fails to reproduce the features
associated to the existence of the indicated feedback loops. I provided the details of the
exclusive logical representation of the model in Appendix K.
Furthermore, I modiﬁed the E2F1 synthesis parameter (FS) and TGF-1 expression
level (TGFB1) to investigate their combined eﬀect on the emergence of a resistant
phenotype [121]. To this end, the values of the input variables FS and TGFB1 were
iteratively modiﬁed and simulations were performed to observe whether resistance to
apoptosis initiation (chemoresistance) after stimulation with a genotoxic drug emerged
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No. Reactions Functionality Type of Rec. References (PubMed) 
1a E2F1p = Gab2 Proliferation, Metastasis Monotone 15574337, 17310989, 
19342374
1b 2 E2F1p = 2 Gab2 Proliferation, Metastasis Monotone 15574337, 17310989, 
19342374
2a E2F1p = CCND1 Proliferation, Metastasis Monotone 17637753, 23278726
2b 2 E2F1p = 2 CCND1 Proliferation, Metastasis Monotone 17637753, 23278726
3a E2F1p = ANCCA Proliferation, Metastasis Monotone 19843847
3b 2 E2F1p = 2 ANCCA Proliferation, Metastasis Monotone 19843847
4a E2F1p = MAP3Ks Proliferation, Metastasis Monotone 20026813
4b 2 E2F1p = 2 MAP3Ks Proliferation, Metastasis Monotone 20026813
5a E2F1p = ACTR2 Proliferation, Metastasis Monotone 20124470, 16648476
5b 2 E2F1p = 2 ACTR2 Proliferation, Metastasis Monotone 20124470, 16648476
6a E2F1p + GxD = EZH2 Proliferation, Metastasis Monotone 19893569, 20675184
6b E2F1p + 2 GxD = 2 EZH2 Proliferation, Metastasis Monotone 19893569, 20675184
7 E2F1p + 2 !EZH2 = BIM Apoptosis Non-monotone 19893569, 20675184
8 E2F1p + GxD = FOXO3 Apoptosis Non-monotone 20013022, 17482685
9 E2F1p + GxD = DUSPx Apoptosis Non-monotone 20013022
10 E2F1p + GxD = NOXA Apoptosis Non-monotone 17146434, 14684737
11 E2F1p + GxD = HRK Apoptosis Non-monotone 14684737, 9130713
12 P73 + !DNp73 = BAX Apoptosis Non-monotone 14634023
13 P73 + !DNp73 = PUMA Apoptosis Non-monotone 14684737, 14634023
14 !miR-205 + E2F1p = Bcl-2 Chemoresistance, 
Aggressiveness
Monotone 22871739, 21159167, 
11559537
15 !miR-205 + E2F1p = ABCA2 Chemoresistance, 
Aggressiveness
Monotone 22871739, 21159167
16 !miR-205 + E2F1p = ABCA5 Chemoresistance, 
Aggressiveness
Monotone 22871739, 21159167
17 Proliferative_complex + !DUSPx + !FOXO3 = Proliferation Monotone 20806045, 22107151
18 E2F1_Drug_apoptotic_comp + p73_apop_genes + 2 !EZH2 + 
!miR-205_reg_genes = Apoptosis
Monotone 19893569, 14634023, 
22871739, 21159167
19 miR-205_reg_genes = Chemoresistance Monotone 22871739
Table 4.3. Multi-valued logic-based rules of target gene and phenotypical
module. This set of rules encodes how the E2F1-p73/DNp73-miR-205 circuitry
regulates target genes involved in proliferation, apoptosis, and chemoresistance [9].
The orange color rows in table contain equations for target gene module and violet
color rows for phenotypical module. The + symbol represents a logical `AND' and
the ! symbol represents a logical `NOT'. In CellNetAnalyzer the monotone type of
reaction represent that the logical level of the product is activated by an equal or
greater logical level of the reactant, while in non-monotone reactions the product level
strictly dependents on the given logical level of reactant [199]. Here I modeled EZH2
as non-monotone which means it will inhibit apoptosis only when it is highly expressed
(i.e., logical level 2).
(Table 4.4). Our model simulations suggest that drug resistance emerges with lower
combined expression level of E2F1 and TGF-1 compared to their individual expression
levels. In contrast to Boolean models, the use of a hybrid model is suﬃcient to
determine precise expression levels of E2F1 and TGF-1 shifting the phenotype from
chemosensitive (blue area) to chemoresistant (red area) (Figure 4.11).
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InputsCore moduleTarget genesPhenotype
 GF
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
FS
0
0
0
0
0
0
1
1
1
1
1
1
10
10
10
10
10
10
0
0
0
0
0
0
1
1
1
1
1
1
10
10
10
10
10
10
TGFB1
1
1
1
10
10
10
1
1
1
10
10
10
1
1
1
10
10
10
1
1
1
10
10
10
1
1
1
10
10
10
1
1
1
10
10
10
GxS
0
0.5
1
0
0.5
1
0
0.5
1
0
0.5
1
0
0.5
1
0
0.5
1
0
0.5
1
0
0.5
1
0
0.5
1
0
0.5
1
0
0.5
1
0
0.5
1
E2F1
0,00
0,04
0,08
0,00
0,04
0,08
0,41
0,41
0,41
0,42
0,42
0,42
98,08
100,48
102,88
99,70
102,11
104,53
0,00
0,46
2,49
0,00
0,46
2,52
10,25
12,82
15,40
10,69
13,37
16,05
110,48
113,17
115,86
112,12
114,83
117,53
p73
0,00
0,03
0,05
0,00
0,03
0,05
0,28
0,28
0,28
0,28
0,28
0,28
63,76
65,30
66,90
64,81
66,37
67,97
0,00
0,27
1,50
0,00
0,27
1,52
6,67
8,33
10,01
6,95
8,69
10,43
71,84
73,58
75,33
72,90
74,66
76,42
DNp73
0,00
0,03
0,06
0,00
0,03
0,06
0,33
0,33
0,33
0,34
0,34
0,34
74,62
76,43
78,29
75,85
77,68
79,54
0,00
0,31
1,71
0,00
0,31
1,73
7,80
9,76
11,72
8,14
10,17
12,21
84,11
86,15
88,20
85,36
87,41
89,47
m
iR-205
0,00
0,05
0,10
0,00
0,00
0,01
0,76
0,76
0,76
0,08
0,08
0,08
1,99
1,99
1,99
0,20
0,20
0,20
0,00
0,38
1,70
0,00
0,04
0,17
4,56
4,61
4,62
0,46
0,46
0,46
1,71
1,71
1,71
0,17
0,17
0,17
Gab2
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
2
2
2
0
0
1
0
0
1
1
2
2
1
2
2
2
2
2
2
2
2
CCND1
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
2
2
2
0
0
1
0
0
1
1
2
2
1
2
2
2
2
2
2
2
2
M
AP3Ks
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
2
2
2
0
0
1
0
0
1
1
2
2
1
2
2
2
2
2
2
2
2
ANCCA
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
2
2
2
0
0
1
0
0
1
1
2
2
1
2
2
2
2
2
2
2
2
ACTR2
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
2
2
2
0
0
1
0
0
1
1
2
2
1
2
2
2
2
2
2
2
2
EZH2
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
2
2
2
0
0
1
0
0
1
1
2
2
1
2
2
2
2
2
2
2
2
BIM
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
FOXO3
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
1
1
0
0
1
0
0
1
0
1
1
0
1
1
0
1
1
0
1
1
DUSPx
0
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0
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0
1
1
0
0
0
0
0
0
0
0
0
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1
0
1
1
0
1
1
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0
0
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0
0
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0
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0
0
0
0
0
0
0
0
0
0
1
1
0
1
1
0
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1
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0
0
0
0
0
0
0
0
0
0
0
1
0
0
1
0
0
0
0
0
0
0
0
1
0
0
1
0
0
1
0
0
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0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
1
0
0
0
0
0
0
0
0
0
0
0
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0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
1
1
0
0
0
0
0
0
0
0
0
0
1
1
0
1
1
0
1
1
Table 4.4. Model simulations for the eﬀect of genotoxic drug administration on
cancer and non-cancer cells with/without overexpression of E2F1 and TGF-1, and
with/without growth factor stimulations [9].
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Figure 4.11. E2F1-TGFB1-Chemoresistance relation. Emergence of
chemoresistance upon deregulation of E2F1 and TGF-1 expressions [9]. The values
of the input variables accounting for E2F1 synthesis rate (FS) and TGF-1 expression
(TGFB1) were iteratively modiﬁed in an interval of physiologically feasible values
(values were normalized to the ones in the wild-type chemosensitive cell line described
in [119, 121]). I simulated the system under genotoxic drug administration and
analyzed for each pair of values for FS and TGFB1, respectively, whether apoptosis
initiation was triggered (blue area) or the cell displays chemoresistance (red area).
MATLAB code for the hybrid model is given in Appendix J. Logic-based model (in
CNA representation) of the target gene and phenotypical module can be access at2.
4.6. Summary of results and discussion
In the present chapter, I proposed and illustrated the construction of hybrid models,
composed of ODEs and logic sub-modules, as a strategy to handle large-scale, nonlinear
biochemical networks. In this methodogy, I organized the network into three parts: (i)
the core regulatory module, a subnetwork of signaling and transcriptional processes that
displays high interconnectivity and is enriched in nonlinear regulatory loops, (ii) the
target gene module, accounting for genes whose expression is directly regulated by the
signaling proteins and transcription factors included in the core module, and (iii) the
phenotypical read-outs. The core module is modeled using ODEs, while the target genes
and the phenotypical read-outs are encoded using discrete logic modeling. Furthermore,
an interface is designed that links both parts by discretizing the values of variables in
the core module. Although the approach proposed seems simple, a number of questions
emerge when trying to generalize the method and make it more accurate.
In this case study, the network construction relied on the manual retrieval of
biomedical information and integration into a regulatory map. Real case study
networks can be much more complex and large, especially in terms of the target genes,
2https://sourceforge.net/projects/khan-phd/ﬁles/Target_Gene_Phenotype_CNA.rar/download
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which makes it hard to manually retrieve the information. One approach to construct
these networks could be the systematic use of existing databases of protein-protein
interactions and transcriptional regulation [121, 124, 265, 266]. Further, the
determination of a core regulatory module is typically not straightforward. It is
required, to determine in a systematic manner, which parts of the network display
structural complexity and are enriched in nonlinear regulatory loops. Towards this, I
developed a network-based integrative workﬂow (Chapter 2 Section 2.2 on Page 28)
that combines network analysis, with expression data and biomedical information to
identify disease-speciﬁc core-regulatory networks [124].
In addition, in some cases there may be feedback between the core regulatory module
and the target gene module. In our case study, for example, EGFR is a transcriptional
target of E2F1, in turn EGFR regulates E2F1 activity in a system that constitutes a
positive feedback loop [252]. Given that this motif aﬀects the regulation of the system,
the dynamics of the transcriptional target EGFR were included in the nonlinear core
regulatory module. This idea could be used to account for this kind of motifs in other
models. In a more advanced setup of the methodology, network biology methods would
be used to detect feedback loops between diﬀerent parts of the network. These motifs
would then be included in the nonlinear core regulatory module. In addition, the use of
logical modeling would be reserved for linear transcriptional regulation.
When modeling the core regulatory module with ODEs, two fundamental tasks have
to be addressed: ﬁrst, the derivation of the model equations and second, the estimation
of model parameters. The construction of model equations may beneﬁt from using
canonical modeling frameworks like classical kinetic or power-law modeling to obtain
more consistent, homogeneous and easy to derive equations [207, 210, 232]. Secondly,
the characterization of the ODE model will require adequate quantitative experimental
data (dose-response experiments, quantitative time series, etc; see [207, 211] for further
details), but also adequate methodologies for parameter estimation [214, 267].
A critical element of the proposed approach is to determine the discretization rules for
the core regulatory variables that control the target genes. These rules are the basis of the
interface between the ODE and logic modules. In this case study, the discretization rules
were derived by manual training [211], but in a real case with a larger set of genes involved
in the target gene module a more systematic approach will be necessary. This approach
will require transcriptomics and proteomics data from experiments, in which expression
and activity of the proteins and transcription factors controlling transcriptional programs
are modulated in a dose-response fashion. Furthermore, computational methodologies
will be required to determine precise discretization rules and gene-dependent activation
thresholds for the transcriptional factors [268, 269].
In Table 4.5 we compared the performance of ODE, discrete logic and hybrid models
with respect to a number of biological and computational features, which are important
when choosing a strategy to construct a mathematical model for a biochemical system.
The table indicates that among them there is not a perfect modeling framework, able
81
4 Hybrid modeling of large-scale biochemical networks
to deal better than the others in all the features considered. This is a conclusion that
can be extended to a wider pool of modeling frameworks and emerges after inspecting
decades of scientiﬁc publications on modeling of biochemical models [5, 6, 270, 271].
Some modeling frameworks are clearly better in some features but have a poor
performance for other features. When choosing the right modeling framework one has
to think which of those features that are more important in the biochemical system
investigated. I think that hybrid models like the ones proposed are a good compromise
between quantitative/qualitative accuracy and scalability when considering large
biochemical networks with a small core of highly interconnected processes and a large
set of transcriptionally and post-transcriptionally regulated genes.
ODE
models
Logic models Hybrid
models
Encoding of non-
Legend Good Acceptable Poor
Table 4.5. Comparison of ODE, discrete logic and hybrid models for the analysis of
biochemical networks [9].
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Unraveling mechanisms underlying diseases for the prediction of diagnostic and
therapeutic markers has motivated the development of various systems biology and
bioinformatics approaches to process data. For example, (i) methods to identify
expression patterns for normal and diseased states; (ii) graph theoretical analyses of
biochemical networks to identify important hub nodes and small recurring regulatory
motifs; and (iii) dynamical systems theory to simulate the dynamics of biological
systems. Individually these approaches cannot capture the entire biological complexity
associated with regulatory processes involved in diseases. For example, the expression
patterns identiﬁed by data analysis tools, like machine learning, cannot explain the
underlying mechanisms and causes that induce such patterns; the utility of graph
theory is conﬁned only to static analysis; and each modeling formalism oﬀered by
dynamical systems theory has its own limitations due to the fact that biological systems
are enormous in size and complexity (i.e., large number of components interacting in
nonlinear fashion). The integration of multiple systems biology and bioinformatics
methods, here named as integrative workﬂows, is a promising approach to analyze
large-scale, complex biochemical networks to provide insights into diseases. Further,
these integrative workﬂows in systems biology are scarce but highly demanded [75].
Towards this, I developed an integrative workﬂow that combines heterogeneous
sources of information to analyze large-scale biochemical networks in complex diseases
(Figure 2.4). More speciﬁcally, the workﬂow integrates network structural properties
with omics data, biomedical information and dynamical analysis to understand
mechanisms underlying diseases. Using the proposed workﬂow, I analyzed a large-scale
molecular interaction map of E2F1, a transcription factor involved in cancer, to
understand its role in the regulation of epithelial-mesenchymal transition (EMT). First,
we constructed a molecular interaction map from the literature and databases
around E2F1 in cancer. The network is presented in standard SBGN format containing
annotation for nodes and interactions. I performed network structural analysis using
Cytoscape plugins to determine the centrality measures and identifying network motifs.
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Centrality measures including degree centrality and betweenness centrality provide
useful information e.g., these measurements can be used to detect hub nodes (nodes
with large degree) and gate keeper nodes (nodes with high betweenness centrality),
which play an essential role in network organization. Network motifs are repeated small
structural patterns and are considered to be the reservoir for network dynamics [2]. In
biology, sets of genes/proteins/miRNAs involved in certain processes/phenotypes are
highly interconnected and regulate each other through regulatory loops (motifs)
including feedback and feedforward loops [2, 134]. Very often, these network motifs are
disrupted or abnormally regulated in cancer, and the analysis of their diﬀerential
regulation can provide important information on the emergence of disease
phenotypes [134]. However, the identiﬁcation of important feedback loops in a highly
connected network is a methodological challenge [103, 154].
I here introduced a new motif ranking scheme using a weighted multi-objective
function that combines the topological properties (e.g., node degree and betweenness
centrality) with non-topological properties (e.g., gene expression), which enables to
identify core-regulatory networks in bladder and breast cancer. We consider
core-regulatory networks the important driver for the epithelial-mesenchymal transition
(EMT). Topological properties account for the structural importance of the nodes, and
non-topological properties for their disease-type and context-speciﬁc relevance. The
core networks are amenable for dynamical modeling using a suitable mathematical
formalism. Using logic-based models, the in silico analysis of core-networks identiﬁed
molecular signatures and therapeutic targets for each cancer type. Model-based
predictions were validated experimentally and through patient data. The workﬂow
presented in this dissertation realizes a complete cycle of the system biology approach
(presented in Figure 1.1).
I used a multi-objective function FM =
Pl=4
l=1wlk  fl; where wl is weight assigned
to sub-function fl which is normalized by ) with multiple weighting scenarios (wk; k =
1; : : : ; n) to provide motif ranking as unbiased as possible regarding the assessed objective
functions. Here, I refer to (ND + BC ), GP , DP , and FC as four objective functions,
where ND is the node degree, BC is betweenness centrality, GP is gene prioritization, DP
is disease pathway association, and FC is expression fold change. Since we do not have
any reference criteria for ranking, I manually chose 13 weighting scenarios, each giving
weight (i.e., importance) to one or another objective function. In this way I obtained
the Pareto sets of ranking scores for each feedback loop. Pareto sets contain solutions
where none of the optimized solution (F ) can be improve in value for a given objective
function without degrading some of the other objective functions. Top-ranked loops from
each scenarios were selected and merged using Cytoscape to a obtain core-regulatory
network.
I used the linear summation of multi-objective function that can highlight the solutions
where sub-functions have uneven values i.e., some sub-functions have minimal and other
has maximal values. In this case the optimized solution is better for some sub-functions
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and worse for others. The alternatives to linear summation can be, for example, the
nonlinear product or power law function (i.e., F =
Q
j(fj)
wj ), which will highlight only
those solutions where sub-functions has non-zero even values (i.e., the solution is better
for all sub-functions), which is practically hard if not impossible to achieve.
A major bottleneck to our workﬂow is the preparation of a directed regulatory network.
This requires huge manual eﬀorts as many state-of-art interaction databases either do
not provide directions for interactions or they contain false positive/negative interactions
complied by text-mining algorithms from published literature. I believe that new methods
are needed for deﬁning regulatory directions to interacting molecules. This may be
possible by extracting regulatory information from databases (e.g., BioModels database),
literature and/or already published molecular interaction maps. Towards this, some
eﬀorts are already initiated, for example, the SIGNOR database [272] containing directed
interactions; and the INDRA tool [273], which extracts molecular mechanisms in term
of activation, inactivation and complex formation from the literature via text mining.
Using logic-based modeling, I analyzed the core-networks for: their
stimulus-response behavior to identify molecular signatures relevant for disease
progression; and perturbations to determine possible therapeutic targets. I divided the
model into three layers: (i) input, (ii) regulatory, and (iii) output layer. The input layer
contains E2F1 and the receptor molecules, and the regulatory layer contains all
components of core network except E2F1 and receptor molecules. The output layer
comprises only one node that represents the EMT process as the driver of invasive
phenotype. The input layer and regulatory layers are encoded with Boolean logic. The
phenotypical output is modeled with multi-valued logics, which accepts four ordinal
levels ranging from 0 (no EMT) to 3 (high EMT). Here, multi-valued logic is used to
assess the aggregated eﬀect of various network components on the phenotype [155].
However, the use of multi-valued logic increases the complexity of model, therefore, I
applied it only to the phenotypical output. Further, I used qualitative information
based on fold-change expression data to derive the Boolean functions to approximate
the activation level of molecules having multiple regulators.
For diﬀerent combinations of receptor molecules and E2F1, the model simulations
revealed molecular signatures, E2F1-TGFBR1-FGFR1 in bladder cancer and
E2F1-TGFBR2-EGFR in breast cancer, that render cells from non-invasive to invasive
cancer when highly expressed. Surprisingly, the other receptors that are part of the
input layers in the models had no eﬀect on the EMT process. Model predictions are in
agreement with previous experimental ﬁndings in bladder and breast cancer studies,
where high expression of these molecules were separately observed to regulate tumor
invasion [203205]. Further, to conﬁrm the role of predicted signatures on the
regulation of tumor invasion, we used bladder and breast cancer patient survival data
from independent studies. For all our predicted signatures, high expression of the
constituent molecules mapped to low patient survival and vice versa (Figure 3.5).
Further, compare to random signatures, the model predicted signatures more distinctly
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classify patients into early and advanced stages of cancer (Figure 3.6). Furthermore,
the model predictions were validated by shRNA-based in vitro experiments (Fig. 5
on page 160). Inhibition of the predicted signatures in invasive bladder (UM-UC-3) and
breast (MDA-MB231) cancer cell lines shows profound impact on the invasive behavior
of the respective cell line and the highest eﬀect (drastic reduction in invasion) observed
upon combined inhibition (Fig. 5c on page 160). The role of other receptors, for
example, EGFR in bladder cancer not constituting molecular signatures had no eﬀect
on tumor invasion, were also experimentally validated. Based on these results, one can
propose that EGFR targeted therapies might be ineﬀective in invasive bladder cancer
exhibiting elevated levels of E2F1. Moreover, the in silico perturbation experiments
identiﬁed potential therapeutic targets for invasive cancer cells. From the list of
identiﬁed candidates, provided in Table 3.3, our experimental partner validated
SMAD3-NFKB1 in UM-UC-3 bladder cancer and SRC-FN1 in MDA-MB231 in breast
cancer. The experimental results are in consensus with model prediction, which show
signiﬁcant reduction in cell invasion by inhibiting the therapeutic targets alone or in
combination (more profound eﬀect) (Fig. 6 on page 161).
Integrative workﬂow-based treatment recommendations for diseases, such as advanced
bladder or breast cancer, have the potential to support cohort-speciﬁc patient treatment
in order to avoid therapy resistance and cope with aggressive cancers. Further, I think
the method proposed can be used to investigate other disease networks besides those
focused on the E2F family discussed here.
Dynamical analysis of large-scale biochemical networks suﬀer from the scarcity of
detailed quantitative data to characterize model parameters. Typically, such type of
data is available for a small number of molecules, which allows the construction of a
detailed quantitative model (i.e., ODE-based models) for small networks. On the other
hand, high throughput omics data can be used for coarse grained dynamical analysis
(e.g., using logic-based models) of large-scale networks. It is an emerging dilemma to
consolidate models of large-scale biochemical networks and adequate description of
nonlinear dynamics. To address this challenge, I developed a hybrid modeling
method, which combines ODE-based models with logic-based models as a strategy to
simulate large-scale, nonlinear biochemical networks as a dynamical system.
I illustrated the methodology by constructing a hybrid model of a biochemical
network around the transcription factor E2F1 in drug resistance (Figure 4.10). The
network is organized and divided into three modules with distinctive regulatory
features: (i) Regulatory module, highly interconnected subnetwork containing feedback
and feedforward loops, which induces nonlinearity in systems dynamics, (ii)
Transcription activation of gene module, containing diﬀerent sets of genes involved in
certain phenotypes, which are directly regulated by molecular factors in the regulatory
module, and (iii) Phenotypical read-outs module. The regulatory module was encoded
by an ODE-based formalism, which is widely used to capture the nonlinear dynamics
induced by regulatory motifs. The transcription gene module was modeled with
86
logic-based formalism, which showed how genes are activated/inactivated based on the
expression level of variables in the regulatory module. I also encoded the phenotypical
read-outs by logical formalism, which indicates how cell switch from one phenotype to
other. The simulations of hybrid model are in consensus with those we previously
derived from an ODE-based models, especially the eﬀect of incoherent feedforward
loops between E2F1-p73/DNp73-miR205 on drug resistance. Further, the hybrid model
simulations derived additional interesting results, for example, in case of suﬃcient
overexpression of E2F1 the tumor cell may become independent of growth signals
(Table 4.4). We attribute this nonlinear behavior due to the feedback loop exist
between E2F1 and EGFR (Figure 4.10).
A critical issue for hybrid models relates to the timing in the model simulations. ODE
models are continuous-time models, in which time is, at least theoretically, a continuous
variable, while in discrete logic-models the time is discrete per se. A more advanced
version of the computational interface between the ODE and logic submodules will require
rules for time discretization. Therefore, a criterion has to be established to re-compute
iteratively in deﬁned time-intervals, the discrete values for the regulators of the target
genes (Table G.1 in Appendix G). This strategy could even be enhanced by integrating
time-dependent gene expression and phenotypic data in the analysis.
An interesting option, when using a modular representation of regulatory networks
connected to phenotypical readouts, is the investigation of phenotype probability
distributions in heterogeneous cell populations. This kind of approach can be used to
connect single-cell and cell-population models. Toward this alternative to our method,
other approaches based on continuous variables may be considered (e.g., partial
diﬀerential equations) [274]. In the current study, our approach was used to investigate
the behavior of the signaling and transcriptional machinery of single cells belonging to
homogenous populations, and their connection to the emergence of given phenotypes.
Thus, the discrete representation of the phenotypical readouts remains valid.
Furthermore, the hybrid approach proposed could be integrated in more advanced
methodologies accounting for the dynamics of cell populations, like for example
agent-based models of cell populations [275]. In this case, our hybrid model approach
would account for the regulatory machinery of each individual cell, which would be
connected to the phenotypic parameters controlling, in the agent-based model, the
dynamics of the modeled cell. For models of mid-size cell populations, the use of our
hybrid approach for describing the internal regulatory machinery of each cell reduces
the computational eﬀort necessary for simulations of the agent-based model.
Exploring large-scale nonlinear dynamical networks will remain an art form. What I
am aiming for here is a rational approach to what is eﬀectively guesswork, forced upon
us by the wonderful complexity found in living systems. The computational analyses of
such networks can improve our understanding of disease processes in a mechanistic way.
Ultimately, this shall provide the ability to manipulate and optimize processes towards
treatment.
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AppendixA
Topological properties of the E2F1 map
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Figure A.1. Node degree distribution of E2F1 interaction map. The red line
indicates that node degree distribution follows a power law, which indicates a scale-free
topology of the network. The ﬁgure is adopted from Khan et al., 2017 [124].
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Figure A.2. Clustering coeﬃcient distribution of E2F1 interaction map.
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A Topological properties of the E2F1 map
Figure A.3. Cytoscape view of E2F1 interaction map. The size of the nodes
represents the value of the node degree. The node color ranges from green (low
betweenness centrality) to red (high betweenness centrality). The ﬁgure is adopted
from Khan et al., 2017 [124].
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AppendixB
Algorithm for multi-objective function
Below is the MATLAB code for multi-objection optimization function used to calculate
scores for network motifs.
Matlab code for motifs ranking
1 %Read average node degree (ND), avereage Betweenness Centrality (BC), average Disease
Pathway (DP), average Gene Prioritization (GP) and absolute average expression
Fold Change (FG) of each feedback loop from Excel file
2 ND = xlsread(’Path to Excel file\Excel file.xls’,Sheet_number,’A2:A445’);% read average
Node Degree (ND)
3 BC = xlsread(’Path to Excel file\Excel file.xls’,Sheet_number,’B2:B445’);% read average
Betweenness Centrality (BC)
4 DP = xlsread(’Path to Excel file\Excel file.xls’,Sheet_number,’C2:C445’);% read average
Disease Pathway (DP)
5 GP = xlsread(’Path to Excel file\Excel file.xls’,Sheet_number,’D2:D445’);% read average
Gene Prioritization (GP)
6 FC = xlsread(’Path to Excel file\Excel file.xls’,Sheet_number,’E2:E445’);% read
absolute average expression Fold Change (FG) for breast cancer
7 ND_max = max(ND);
8 BC_max = max(BC);
9 DP_max = max(DP);
10 GP_max = max(GP);
11 FC_max = max(FC);
12 clear F_obj;
13
14 % assigning different weights to ND, BC, DP, GP and FC which represent 13 scenarios for
multi - objective function
15 w = [1 0 0 0;0 0 1 0;0 0 0 1;0 0 1/4 3/4;0 1/4 0 3/4;1/4 0 0 3/4;1/16 1/16 1/8 3/4;1/16
1/8 1/16 3/4;1/8 1/16 1/16 3/4;1/4 1/4 1/4 1/4;0 1/8 1/8 3/4;1/8 1/8 0 3/4;1/8 0
1/8 3/4];
16
17 for i = 1:length(w) % For loop for 13 weighting scenario
18 for j = 1:length(ND) % For loop for all 444 feedback loops
19 F_obj(j,i) = w(i,1) /2 * ND(j,1)/ ND_max + w(i,1) /2 * BC(j,1)/ BC_max + w(i,2) * DP(j
,1)/ DP_max + w(i,3) * GP(j,1)/ GP_max + w(i,4) * FC(j,1)/ FC_max; %Multi-
objective function
20 end
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21 end
22 % Writing ranking score of all 444 feedback loops for 13 scenarios
23 SUCCESS = XLSWRITE(’Path where to save the ranking score for feedback loops\
FBLs_ranking_score_in_xyy_type_cancer.xls’,F_obj)
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AppendixC
Asynchronous states update of
logic-based models
Figure C.1. Asynchronous update of the positive feedback loops. Network
shown in the upper left corner is a positive feedback loop, where x1 activates x2 and
x2 activates x1 which is represented by Boolean functions. State transition graph
represents the asynchronous state update of the systems where the binary digits from
left represent the state of nodes x1 and x2, respectively. In asynchronous update,
starting from initial condition, a state can have more than one successor which means
only one node changes in a state transition form x(t) to x(t+1), therefore, it is possible
for a state to leave the cycle. In the state transition graph the gray circles represent
steady states 00 and 11. The states 01 and 10 are unstable state which can be followed
by either 00 or 11 depending on weather x or y changes ﬁrst.
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AppendixD
Logic-based rules for bladder cancer
regulatory core
The reactions are represented in CellNetAnalyzer (CNA) format: (Coeff:) Reactants =
(Coeff:) Products, where `Coeﬀ.' stands for coeﬃcient which indicates the level of
expreesion of reactants and products.
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(Coeff.) Reactants = (Coeff.) Products References (Pubmed IDs)
1 !nfkb1 = 1 e2f1 19088195
1 !e2f1 + akt1 = 1 nfkb1 9368006; 10485711; Calibrated the equation with bladder cancer cell 
lines RT-4 (less-invasive) to UM-UC-3 (invasive) from ArrayExpress 
database (accession no.:E-MTAB-2706, PMID: 25485619 )
1 e2f1 = 1 axin2 15572025, 15766563
1 e2f1 = 1 zeb1 25466554
1 cdh1 = 1 egfr 10969083
1 egfr = 1 src 21303975;23066441
1 !src + 1 !snai2 + 1 !mir_25_3p + 1 !mdm2 = 1 cdh1 23906494;22450326,25189528; Calibrated the equation with bladder 
cancer cell lines RT-4 (less-invasive) to  UM-UC-3 (invasive) from 
ArrayExpress database (accession no.:E-MTAB-2706, PMID: 5485619)
1 fgfr1 = 1 ppp2r2c 17255109
1 fgfr1 = 1 ppp2r1a 17255109
1 fgfr1 = 1 ppp2r1b 17255109
1 fgfr1 = 1 ppp2r2b 17255109
1 !kiaa1524 = 1 ppp2r2b 17632056
1 !e2f1 = 1 mdm2 20812030
1 !mdm2 = 1 tp53 18485870
1 akt1 = 1 mdm2 15140942;15574337
1 !sirt1 = 1 tp53 16354677
1 !bcl2 = 1 tp53 12670866
1 !mir_25_3p = 1 tp53 20935678
1 tp53 = 1 e2f1 24076372
1 tp53 = 1 mir_205_5p 22578566
1 tp53 = 1 sfn 17546054;21625211
1 e2f2 = 1 myc 11564866
1 !rara = 1 foxa1 25303530
1 e2f1 = 1 cdkn2a 15175242;11034215
1 e2f2 = 1 cdkn2a 11883935
1 sp1 = 1 cdkn2a 21555589
1 tp53 = 1 mdm2 19106616
1 !rb1 = 1 tp53 17080083
1 foxo3 = 1 tp53 25241761
1 !sfn = 1 e2f1 20196847
1 !mir_205_5p = 1 e2f1 21454583;22578566
1 myc = 1 e2f1 18345030
1 !ppp2r2b = 1 e2f1 25483052; 24204027
1 !ppp2r1b = 1 e2f1 25483052; 24204027
1 !ppp2r1a = 1 e2f1 25483052; 24204027
1 !ppp2r2c = 1 e2f1 25483052; 24204027
1 e2f3 = 1 e2f1 10766737;14576826
1 foxa1 = 1 e2f1 21900400
1 !cdkn2a = 1 e2f1 21478909
1 !tp53 = 1 cdkn2a 25241761;22480684;20676136
1 !cdkn2a = 1 mdm2 17909018
1 e2f1 = 1 tp53 11739724
1 sp1 = 1 tp53 16740634
1 mdm2 = 1 e2f1 16170383
1 ctnnb1 + 1 lef1 = 1 snai2 25189528;14623871
1 ctnnb1 + 1 lef1 = 1 snai1 25189528;14623871
1 ctnnb1 = 1 twist1 25189528
1 !snai1 = 1 cdh1 21317430; Calibrated the equation with bladder cancer cell lines RT-4 
(non-invasive) to  UM-UC-3 (invasive) from ArrayExpress database 
(accession no.:E-MTAB-2706, PMID: 25485619 )
1 !twist1 = 1 cdh1 22581441;20519943; Calibrated the equation with bladder cancer cell 
lines RT-4 (non-invasive) to UM-UC-3 (invasive) from ArrayExpress 
database (accession no.:E-MTAB-2706, PMID: 25485619 )
1 ctnnb1 = 1 lef1 17980157
1 lef1 = 1 axin2 11809808
1 !cdh1 + 1 !axin2 = 1 ctnnb1 22007144;22935447
1 smad4 + 1 smad3 + 1 smad2 = 1 snai1 20519943
Logic-based rules for bladder cancer regulatory core simulations
1 smad3 = 1 mir_200b_3p 22020340 
1 !mir_200b_3p = 1 zeb1 21049046;18829540;18376396;19854497;19839049;18411277
1 !nfkbia + 1 akt1 = 1 chuk 9346485;10485710
1 chuk = 1 nfkb1 22833419
1 nfkb1 = 1 nfkbia 14743216
1 e2f1 = 1 rb1 15362224
1 e2f1 = 1 foxo3 17482685
1 e2f1 = 1 fgfr1 12543798
1 e2f1 = 1 kiaa1524 12766778
1 e2f1 = 1 sp1 8657142
1 e2f1 = 1 e2f2 15014447
1 !e2f1 = 1 rara 24608861
1 e2f1 = 1 mir_25_3p 19034270 
1 e2f1 = 1 akt1 15574337
1 e2f1 = 1 sirt1 19188449
1 e2f1 = 1 bcl2 11559537;11704823
1 !rb1 = 1 e2f1 19401190
1 !rb1 = 1 e2f3 19249677
1 snai1 = 1 zeb1 18411277
1 lef1 = 1 e2f1 17980157
1 fgfr1 = 1 src 20154139
1 !mdm2 = 1 snai2 19448627
1 !mir_200b_3p = 1 e2f3 22144583;22139708
1 nfkb1 = 1 twist1 17332324
1 !zeb1 = 1 cdkn2a 24371144
1 lef1 = 1 myc 17466981
1 !mir_200b_3p = 1 bcl2 21993663
1 tp53 = 1 mir_200b_3p 21518799 
1 smad4 + 1 smad3 + 1 smad2 = 1 sp1 15242331;16714330;10878024
1 lef1 + 1 e2f3 = 1 axin2 25189528;Calibrated the equation with bladder cancer cell lines RT-4 
(non-invasive) to  UM-UC-3 (invasive) from ArrayExpress database 
(accession no.:E-MTAB-2706, PMID: 25485619 )
1 !twist1 = 1 tp53 18504427
1 ctnnb1 = 1 myc 9727977
1 !tp53 = 1 snai2 16207734
1 !mir_205_5p = 1 zeb1 19502803;18376396
1 e2f2 = 1 axin2 15572025, 15766563
1 !twist1 = 1 cdkn2a 25368021
1 !smad4 + 1 !smad3 + 1 !smad2 = 1 myc 19022773;12150994
1 nfkb1 = 1 bcl2 12170775
1 nfkb1 = 1 myc 11114727
1 !chuk = 1 foxo3 16887827
1 tgfbr + 1 zeb1 = 1 smad2 25189528; 21593157;21717360
1 tgfbr + 1 zeb1 = 1 smad3 25189528; 21593157;21717360
1 tgfbr + 1 zeb1 = 1 smad4 25189528; 21593157;21717360
1 tgfbr = 1 snai1 25189528
1 tgfbr = 1 snai2 25189528
1 e2f1 + 1 cxcr1 = 1 zeb1 25466554;http://www.fedoa.unina.it/id/eprint/9883; Calibrated the 
equation with bladder cancer cell lines RT-4 (non-invasive) to  UM-UC-3 
(invasive) from ArrayExpress database (accession no.:E-MTAB-2706, 
PMID: 25485619 )
1 cxcr1 + 1 smad4 + 1 smad3 + 1 smad2 = 1 snai1 25189528;20519943; Calibrated the equation with bladder cancer cell 
lines RT-4 (non-invasive) to UM-UC-3 (invasive) from ArrayExpress 
database (accession no.:E-MTAB-2706, PMID: 25485619 )
Multi-valued logic based rules for EMT phenotype
1 !cdh1 = 1 emt 23461975;24556840
1 fgfr1 = 1 emt 22701738
(1 smad4 + 1 smad3 + 1 smad2 + snai1) OR (1 zeb1 
+ 1 twist1) = 1 emt 
22945800; 20713713;21317430; Calibrated the equation with bladder 
cancer cell lines RT-4 (non-invasive) to  UM-UC-3 (invasive) from 
ArrayExpress database (accession no.:E-MTAB-2706, PMID: 25485619)
(1 smad4 + 1 smad3 + 1 smad2 + snai1) OR (1 zeb1 
+ 1 twist1)+ 1 !cdh1 = 2 emt 
Calibrated the equation with bladder cancer cell lines RT-4 (non-
invasive) to  UM-UC-3 (invasive) from ArrayExpress database (accession 
no.:E-MTAB-2706, PMID: 25485619 )
1 fgfr1 + 1 !cdh1 = 2 emt Calibrated the equation with bladder cancer cell lines RT-4 (non-
invasive) to  UM-UC-3 (invasive) from ArrayExpress database (accession 
no.:E-MTAB-2706, PMID: 25485619 )
1 fgfr1 + (1 smad4 + 1 smad3 + 1 smad2 + snai1) OR (1 
zeb1 + 1 twist1) = 2 emt 
Calibrated the equation with bladder cancer cell lines RT-4 (non-
invasive) to  UM-UC-3 (invasive) from ArrayExpress database (accession 
no.:E-MTAB-2706, PMID: 25485619 )
1 fgfr1 + (1 smad4 + 1 smad3 + 1 smad2 + snai1) OR (1 
zeb1 + 1 twist1) + 1 !cdh1 = 3 emt 
Calibrated the equation with bladder cancer cell lines RT-4 (non-
invasive) to  UM-UC-3 (invasive) from ArrayExpress database (accession 
no.:E-MTAB-2706, PMID: 25485619 )
AppendixE
Logic-based rules for breast cancer
regulatory core
The reactions are represented in CellNetAnalyzer (CNA) format: (Coeff:) Reactants =
(Coeff:) Products, where `Coeﬀ.' stands for coeﬃcient which indicates the level of
expreesion of reactants and products.
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(Coeff.) Reactants = (Coeff.) Products References (Pubmed IDs)
1 !akt1 = 1 gsk3b 10385618, 12459251
1 !axin2 + 1 ctnnb1 = 1 gsk3b 22935447
1 !bcl2 = 1 tp53 12670866
1 !birc2 = 1 birc3 11084335;22274400;19153467
1 !birc3 = 1 e2f1 15674331
1 !cdh1 + 1 !axin2 = 1 ctnnb1 15662113;22935447
1 !cdkn2a = 1 e2f1 21478909
1 !cdkn2a = 1 mdm2 17909018
1 !e2f1 = 1 mdm2 20812030
1 !e2f1 = 1 rara 24608861
1 !gsk3b = 1 e2f1 18367454
1 lef1 = 1 e2f1 17980157
1 !mdm2 = 1 myc 10541552
1 !mdm2 = 1 snai2 19448627
1 !mdm2 = 1 tp53 18485870
1 !mir_17_5p = 1 ncoa3 16940181
1 !mir_205_5p = 1 e2f1 21454583;22578566
1 !mir_25_3p = 1 tp53 20935678
1 !rara = 1 foxa1 25303530
1 !rb1 = 1 e2f1 19401190
1 !rb1 = 1 e2f3 19249677
1 !rb1 = 1 tp53 17080083
1 !sirt1 = 1 tp53 16354677
1 !src + 1 !snai1 = 1 cdh1 21317430; Calibrated the equation with breast cancer cell lines MCF-7 
(non-invasive) to  MDA-MB231 (invasive) from ArrayExpress database 
(accession no.:E-MTAB-2706, PMID: 25485619 )
1 !src + 1 !snai2 = 1 cdh1 21317430; Calibrated the equation with breast cancer cell lines MCF-7 
(non-invasive) to  MDA-MB231 (invasive) from ArrayExpress database 
(accession no.:E-MTAB-2706, PMID: 25485619 )
1 !tp53 = 1 cdkn2a 25241761;22480684;20676136
1 !tp53 = 1 snai2 16207734
1 !twist1 + 1 !mdm2 + 1 !mir_25_3p = 1 cdh1 22581441;20519943; Calibrated the equation with breast cancer cell 
lines MCF-7 (non-invasive) to  MDA-MB231 (invasive) from 
ArrayExpress database (accession no.:E-MTAB-2706, PMID: 
25485619 )
1 !twist1 = 1 cdkn2a 25368021
1 !twist1 = 1 tp53 18504427
1 akt1 = 1 mdm2 15140942;15574337
1 birc2 = 1 e2f1 21653699
1 cdh1 = 1 egfr 10969083
1 ctnnb1 + 1 !gsk3b = 1 snai1 25189528;14623871
1 ctnnb1 + 1 lef1 = 1 twist1 25189528
1 ctnnb1 = 1 lef1 17980157
1 ctnnb1 = 1 myc 9727977
1 e2f1 + 1 hmmr = 1 fn1 Calibrated the equation with breast cancer cell lines MCF-7 (non-
invasive) to  MDA-MB231 (invasive) from ArrayExpress database 
(accession no.:E-MTAB-2706, PMID: 25485619 ); 25042645
1 e2f1 + 1 snai1 = 1 fn1 Calibrated the equation with breast cancer cell lines MCF-7 (non-
invasive) to  MDA-MB231 (invasive) from ArrayExpress database 
(accession no.:E-MTAB-2706, PMID: 25485619 ); 25042645; 
24360956
1 e2f1 = 1 akt1 15574337
1 e2f1 = 1 axin2 15572025, 15766563
1 e2f1 = 1 bcl2 11559537;11704823
1 e2f1 = 1 cdkn2a 15175242;11034215
1 e2f1 = 1 e2f2 15014447
1 e2f1 = 1 fn1 25042645
1 e2f1 = 1 foxo3 17482685
1 e2f1 = 1 mir_17_5p 19034270;19066217 
1 e2f1 = 1 mir_25_3p 19034270 
1 e2f1 = 1 rb1 15362224
1 e2f1 = 1 sirt1 19188449
1 e2f1 = 1 sp1 8657142
1 e2f1 = 1 tp53 11739724
Logic-based rules for breast cancer regulatory core simulations
1 e2f2 = 1 cdkn2a 11883935
1 e2f2 = 1 myc 11564866;90001421
1 e2f3 = 1 axin2 15572025, 15766563
1 e2f3 = 1 e2f1 10766737;14576826
1 egfr = 1 src 21303975;23066441
1 flt4 = 1 e2f1 24014887
1 fn1 = 1 flt4 
1 fn1 = 1 kpna2 21988832
1 foxa1 = 1 e2f1 21900400
1 foxo3 = 1 tp53 25241761
1 gsk3b = 1 axin2 12023307;23602568
1 gsk3b = 1 ctnnb1 22935447
1 il1r1 + 1 !birc3 = 1 traf1 9384571
1 kpna2 = 1 e2f1 22843992; 25109899
1 lef1 = 1 axin2 11809808
1 lef1 = 1 myc 17466981
1 mdm2 = 1 axin2 
1 mdm2 = 1 e2f1 16170383
1 myc = 1 cdkn2a 11494151
1 myc = 1 e2f1 18345030
1 ncoa3 = 1 e2f1 15169882
1 rara = 1 ncoa3 25303530
1 sp1 = 1 cdkn2a 21555589
1 sp1 = 1 tp53 16740634
1 ctnnb1 + 1 tgfbr = 1 snai1 25189528;14623871;Calibrated the equation with breast cancer cell 
lines MCF-7 (non-invasive) to  MDA-MB231 (invasive) from 
ArrayExpress database (accession no.:E-MTAB-2706, PMID: 
25485619 )
1 ctnnb1 + 1 tgfbr = 1 snai2 25189528;14623871;Calibrated the equation with breast cancer cell 
lines MCF-7 (non-invasive) to  MDA-MB231 (invasive) from 
ArrayExpress database (accession no.:E-MTAB-2706, PMID: 
25485619 )
1 tgfbr = 1 snai1 25189528
1 tgfbr = 1 snai2 25189528
1 thrb = 1 myc 
1 tp53 = 1 e2f1 24076372
1 tp53 = 1 mdm2 17875722;9724636
1 tp53 = 1 mir_205_5p 21518799 
1 traf1 = 1 birc2 
1 vegfc = 1 flt4 24014887
Multi-valued logic based rules for EMT phenotype
1 fn1 = 1 emt 25042645;12730682
1 !cdh1 = 1 emt 23461975;24556840
1 src + 1 snai1 + 1 snai2 = 1 emt 22945800;23913825;20713713;21317430
1 src + 1 fn1 + 1 snai1 + 1 snai2 = 2 emt Calibrated the equation with breast cancer cell lines MCF-7 (non-
invasive) to  MDA-MB231 (invasive) from ArrayExpress database 
(accession no.:E-MTAB-2706, PMID: 25485619 )
1 src + 1 !cdh1 + 1 snai1 + 1 snai2 = 2 emt Calibrated the equation with breast cancer cell lines MCF-7 (non-
invasive) to  MDA-MB231 (invasive) from ArrayExpress database 
(accession no.:E-MTAB-2706, PMID: 25485619 )
1 !cdh1 + 1 fn1 = 2 emt Calibrated the equation with breast cancer cell lines MCF-7 (non-
invasive) to  MDA-MB231 (invasive) from ArrayExpress database 
(accession no.:E-MTAB-2706, PMID: 25485619 )
1 src + 1 !cdh1 + 1 fn1 + 1 snai1 + 1 snai2 = 3 emt Calibrated the equation with breast cancer cell lines MCF-7 (non-
invasive) to  MDA-MB231 (invasive) from ArrayExpress database 
(accession no.:E-MTAB-2706, PMID: 25485619 )
AppendixF
Construction and simulation of the drug
resistance model
F.1. Model construction of E2F1 network in drug resistance
We set up and analyzed a kinetic model using ordinary diﬀerential equations of the
regulatory map (shown in Figure 4.6) representing the network response to diﬀerent
anticancer drugs. The kinetic model is composed of twelve ordinary diﬀerential
equations accounting for the evolution in time of: E2F1 mRNA (in the model
represented with the variable mE2F1) and protein (E2F1), both isoforms of p73
(respectively, p73 and DNp73), miR-205 (miR205), E2F1 regulated pro-apoptotic genes
(represented by Harakiri, Hrk), p73 regulated pro-apoptotic genes (Bax), miR-205
repressed anti-apoptotic genes (BCL2), E2F1 regulated and active EGFR (EGFR*),
cytostatic drug inhibited EGFR (EGFR I), and ERBB3 (ERBB3). In addition, we
considered another diﬀerential equation that accounts for the population size of tumor
cells with the genetic background deﬁned by our model (TC). The kinetic model is
organized in four interconnected modules: (i) The core regulatory module, (ii & iii) two
transcriptional target modules and; (iv) one for tumor cell population. A detailed
description of the model structure and ODE equations is:
(i) The core regulatory module: The core regulatory module of the kinetic model
is composed of E2F1, both isoforms of p73 (respectively, p73 and DNp73) and miR-205
and accounts for their temporal evolution under drug administration [119]. We include
here the transcriptional regulation of miR-205 expression by the known oncogene TGF-
1 (TGFB1), which exempliﬁes the set of regulators of miR-205 expression external to
the core module. The inclusion of this variable allows for the investigation of cross-
talk, via miR-205, between E2F1 signaling and other oncogenic signals involved in the
epithelial-mesenchymal transition (EMT). EMT has been associated with the emergence
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of chemoresistance [276].
dmE2F1
dt
= GxD  k1 + FS  k2   k3  (1 + k4 miR205) mE2F1 (F.1)
dE2F1
dt
= k5 mE2F1  k6  E2F1 (F.2)
dp73
dt
= k7  E2F1  k8  p73 (F.3)
dDNp73
dt
= k9  E2F1  k10 DNp73 (F.4)
dmiR205
dt
= k11  TGFB1 1  p73 

1 +
DNp73
k13
 2
  k12 miR205 (F.5)
In case of E2F1 mRNA, Eq. F.1, the model contains mass-action kinetic rates accounting
for its basal and genotoxic-stress mediated synthesis (characterized respectively by the
parameters k2 and FS, and k1 ; GxD is an input variable accounting for genotoxic drug),
as well as for its basal degradation (k3). In addition, the model includes a term accounting
for the miR-205 mediated E2F1 repression (k4, [256]). We notice that in our qualitative
kinetic model, mE2F1 represents the fraction of transcriptionally active messenger RNA
in a similar manner that our previous publications [266].
In case of E2F1 protein expression, Eq. F.2, the model describes its mRNA-mediated
synthesis (k5) and basal degradation (k3). In case of p73 and DNp73, Eq. F.3 and Eq. F.4,
the model includes the E2F1-mediated synthesis (k7 and k9, respectively [236]) and basal
degradation (k8 and k10) for both isoforms.
In case of miR-205, Eq. F.5, the model describes the regulation of its synthesis and
degradation (k11, k12). In this equation, we assumed that p73 acts as activator of miR-
205 synthesis, while DNp73 plays an inhibitory role [119, 261, 262]. According to the
observations reported for several tumor types, we assumed that when both isoforms are
overexpressed the inhibitory eﬀect of DNp73 dominates and cancels out p73 activation
of miR-205 [263]. Besides, we included the repression of miR-205 by the oncogenic signal
from the TGF-1 pathway (TGFB1). This is to exemplify the set of regulators of miR-205
expression, which are external to the E2F1-p73/DNp73-miR-205 network [264, 277, 278].
To represent these features, we used reduced power-law terms [207, 279].
(ii) Apoptosis related module: This module includes pro- and antiapoptotic
transcriptional targets, which are regulated by the network components in response to
genotoxic stress. Precisely in this module the ODEs account: (i) for representing the
dynamics of proapoptotic proteins whose expression is promoted by E2F1, we included
a variable accounting for Harakiri (Hrk) expression [244]; (ii) similarly, for
proapoptotic proteins whose expression is positively regulated by p73 and negatively
regulated by DNp73, a variable accounting for Bax (Bax) expression is deﬁned [280];
and ﬁnally (iii) for antiapoptotic proteins whose expression is repressed by miR-205, we
chose BCL-2 (BCL2) as a representative and deﬁned a corresponding variable [119].
These pro- and antiapoptotic proteins are used here as an example and represent a
wider set of proteins which undergo similar regulation. This kind of simpliﬁcation has
been successfully applied to reduce the complexity of models of biochemical networks,
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for example, in the study conducted by Aguda and colleagues [251].
dBax
dt
= k14 DS  p73
g
kg16 + p73
g


1 +
DNp73
k13
 2
  k15 Bax (F.6)
dHrk
dt
= k17 DS  E2F1
g
kg16 + E2F1
g
  k18 Hrk (F.7)
dBCL2
dt
= k19 

1 +
miR205
k20
 1
  k21 BCL2 (F.8)
In order to model Bax protein expression, Eq. F.6, we introduced a rate equation that
accounts for Bax synthesis and degradation (k14 and k15 respectively). For Bax synthesis
and based on experimental results [281], we assumed that DNA damage signals trigger
acetylation and activation of p73 which is required to promote Bax expression. Drug
induced DNA damage signals are here encoded in the binary variable DS (genotoxic
drug treatment: DS = 1; no treatment DS = 0). P73 mediated synthesis of Bax is
represented by a Hill equation (k16; g). This is to ensure that relevant levels of pro-
apoptotic genes (here Bax) occur only in presence of suﬃcient p73 levels. We have used
this strategy previously to model the transcriptional regulation of other DNA-damage
dependent genes [265]. To account for the inhibitory eﬀect of DNp73 on the expression
of Bax, we adopted the same modeling strategy as for miR-205.
In case of Harakiri (Hrk) Eq. F.7, the model contains rates equations accounting for its
synthesis and degradation (k17 and k18 respectively). Based on experimental results [282],
we assumed that DNA damage signals are required for the acetylation and activation of
E2F1, which triggers the Hrk expression. Therefore we made the synthesis dependent
on a binary variable DS which accounts for genotoxic drug treatment (DS = 1) or
no treatment (DS = 0). Like in the case of p73-regulated pro-apoptotic genes, a Hill
equation describes the E2F1-regulated synthesis of Hrk.
In case of BCL-2 (BCL2), Eq. F.8, the model contains rates equations accounting
for the synthesis and degradation (k19 and k21 respectively). We have previously shown
that BCL-2 expression is post-transcriptionally regulated by miR-205 [119]. This is
represented in our model by a reduced power-law term [207, 279] (k20).
(iii) Proliferative related target module: Furthermore, the model includes a
module for receptors whose activity is regulated in response to cytostatic drugs. This
module includes variables accounting for the dynamics of EGFR, whose expression is
promoted by E2F1 [252]; and ERBB3, which is repressed by miR-205 [261, 283]. In
several tumors the heterodimerization of these receptors has been linked to abnormal
cell proliferation and changes in the sensitivity of tumor cells to cytostatic drugs [284].
Additional input variables account for the eﬀect of genotoxic (GxD) and cytostatic
(CyD) drugs triggering DNA damage-E2F1-mediated apoptosis and abolishment of
tumor cell proliferation, respectively [285].
The module contains ODEs for the de novo EGFR (EGFR), growth factor-activated
EGFR (EGFR), cytostatic drug inhibited EGFR (EGFRi), and miR-205 repressed
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ERBB3 (ERBB3). The following three equations describe the EGFR dynamics:
dEGFR
dt
= k36  E2F1
g2
kg235 + E2F1
g2
  k28 GF  EGFR  k30  CyD  EGFR  k40  EGFR
dEGFR
dt
= k28 GF  EGFR  k29  EGFR
dEGFRi
dt
= k30  CyD  EGFR 

1 +
ERBB3
ERTH
 1
  k31  EGFRi
We deﬁned a variable accounting for the total amount of EGFR, EGFRTotal:
EGFRTotal = EGFR+ EGFR + EGFRi
Thus, we can estimate the amount of de novo inactive EGFR as:
EGFR = EGFRTotal   EGFR   EGFRi
According to previous results from our collaborators [117], we assume that the total
amount of EGFR (EGFRT ) is regulated by E2F1. We modeled this with dependency
with a Hill equation and therefore we can change the previous equation to:
EGFR = k36  E2F1
g2
kg235 + E2F1
g2
  EGFR   EGFRi
When we apply this to the previous equations, the model reduces to:
dEGFR
dt
= k28 GF 

k36  E2F1
g2
kg235 + E2F1
g2
  EGFR   EGFRi

  k29  EGFR (F.9)
dEGFRi
dt
= k30  CyD 

k36  E2F1
g2
kg235 + E2F1
g2
  EGFR   EGFRi

  k31  EGFRi (F.10)
dERBB3
dt
= k33 

1 +
miR205
k33
 1
  k34  ERBB3 (F.11)
In case of EGFR, Eq. F.9, the model contains equations accounting for its growth
factor (GF) mediated activation and its degradation (k28 and k29, respectively). We
notice that GF here is a binary input variable (stimulation with growth factor: GF = 1;
no stimulation: GF = 0). In case of EGFRi, Eq. F.10, the model contains an equation
that accounts its cytostatic drug (CyD) mediated inhibition and its degradation (k30
and k31, respectively). Given that interactions between EGFR and ERBB3 promote
tumor resistance to certain cytostatic drugs [284], we included a reduced power-law
term accounting for the eﬀect of ERBB3 as inhibitor of cytostatic drugs regulating
EGFR activity (ERTH). For ERBB3, Eq. F.11, the model contains equations
accounting for its synthesis and degradation (k32 and k34, respectively). According to
previous experimental results [261, 283], we assumed that ERBB3 expression is
post-transcriptionally regulated by miR-205 and therefore used a reduced power-law
term [207, 279] to account for the miR-205-mediated inhibition of ERBB3 (k33).
(iv) Tumor cell population: Finally, the last module includes a phenomenological
kinetic equation, which connects the components of the network to the dynamics of
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tumor cell population. In this equation, the representatives for pro- and antiapoptotic
proteins regulate the cell death rate after genotoxic stress, whereas EGFR and ERBB3
control the tumor cell proliferation rate. This module composed of a unique ordinary
diﬀerential equation accounting for the size of a population of tumor cells (TC).
dTC
dt
= k24  EGFR  TC   k22 Hrk Bax 

1 +
BCL2
k23
 1
 TC (F.12)
In this equation, Eq. F.12, active EGFR connects the proliferation of the tumor cell
population to proliferative signals [252] (k24), while the representatives for pro- and anti-
apoptotic proteins (Hrk, Bax, and BCL2, respectively) regulate the cell death rate after
genotoxic stress (k22, k23). We notice that in some of the simulations we considered
tumors to be composed of three subpopulations of tumor cells with diﬀerent genetic
signatures. Towards this end, we constructed three instances of the model, which diﬀer
in their genetic signature as explained below in subsection F.3.
F.2. Model parameterization of E2F1 in drug resistance
Values of the model parameters characterizing the reaction rates were assigned
following a hybrid strategy [211, 286], which is composed of: (i) Extracting parameter
values from published information (e.g. protein, mRNA and miRNA half-lives); (ii)
Estimating a subset of parameter values by tuning them to ﬁt published quantitative
and qualitative data; (iii) ﬁxing some parameter values to normalize variables to the
basal, non-stressed levels of mRNA and protein. Finally, we assigned values within the
region of feasible values to few parameters in a way our model reproduces the
phenotype shown by chemosensitive tumor cells, according to published
knowledge [119] . The parameters and their assigned values are listed in Table F.1. The
plots in ﬁgure SM3 compare our model predictions with the available (own and
published) data after estimating some of the model parameters.
F.3. Model simulations to detect genetic signatures for drug
resistance
In model simulations, we considered two families of drugs: genotoxic drugs, like
doxorubicin and cisplatin, inducing apoptosis; and cytostatic drugs, like erlotinib and
lapatinib, repressing tumor cell proliferation. In some scenarios, it has been observed
that these drugs loose eﬃcacy when some of the network components are
dysregulated [119, 294]. With the help of the kinetic model, we analyzed whether
speciﬁc genetic signatures of the core module can be linked to a phenotype response of
resistance to these anti-cancer drugs. We deﬁne a genetic signature as a group of genes
in a tumor cell whose combined expression pattern is linked to a speciﬁc phenotype
(i.e., chemoresistant or chemosensitive). In line with this, we designed a nominal in
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Figure F.1. Fitting of the model to the experimental data: The model
parameters k4, k7, k9, k11, k13 were estimated by manual tuning to minimize the
distance between model simulations (black bar) and experimental data (white bar).
We show the comparison between both quantities for a chosen set of parameter values
from Table F.1. Data displayed in A, B and D were produced and quantiﬁed by
our collaborators and published in [117], while data in C was extracted from 1 (a.u.:
arbitrary units; wt: wild-type E2F1; ox: overexpressed E2F1; p73(+): cells transfected
with 1g pcDNAp73; DNp73(+): 1g pcDNAp73 + 0:1g DNp73; DNp73(++): 1g
pcDNAp73 + 0:5g DNp73; DNp73(+++): 1g pcDNAp73 + 1g DNp73). The
ﬁgures are taken from Vera et al., [121].
silico chemosensitive genetic signature, inspired on that of SK-Mel-147 [119]. This
signature accounts for the expression of the network components for which an in silico
cell line holds the phenotype of a chemosensitive tumor cell; that is, abnormal
proliferation but responsiveness to genotoxic drugs (via triggering of apoptosis) and
cytostatic drugs (via inhibition of proliferation, see Figure F.2B).
To detect genetic signatures providing chemoresistance, we generated a population of
104 model conﬁgurations obtained by random perturbation of the model parameter values
of the nominal chemosensitive genetic signature. In the following, we deﬁne these distinct
conﬁgurations as in silico cell lines. For each one of them, we simulate the model and
obtained the expression levels of the network components and the tumor cell population
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Parameters Description of associated process Value Comments
k1
genotoxic-stress mediated synthesis of E2F1
mRNA
1.237 hr 1 represents eﬀective drug dosey
k2 basal synthesis of E2F1 mRNA 2.085 hr
 1 assumed for normalization
k3 basal degradation of E2F1 mRNA 0.139 hr
 1 ref. [257]
k4 miR-205 mediated repression of E2F1 0.01 a.u. estimated, ﬁgure F.1
k5 mRNA-mediated synthesis of E2F1 0.231 hr
 1 assumed for normalization
k6 basal degradation of E2F1 0.231 hr
 1 ref. [259]
k7 E2F1 mediated synthesis of p73 0.150 hr
 1 estimated, ﬁgure F.1
k8 basal degradation of p73 1.386 hr
 1 ref. [287]
k9 E2F1 mediated synthesis of DNp73 0.1317 hr
 1 estimated, ﬁgure F.1
k10 basal degradation of DNp73 0.173 hr
 1 ref. [288]
k11 p73 mediated synthesis of miR-205 0.101 hr
 1 estimated, ﬁgure F.1
k12 basal degradation of miR-205 0.029 hr
 1 ref. [289]
k13 threshold eﬀective DNp73 repression of miR-205 10.2672 estimated, ﬁgure F.1
k14 p73 mediated synthesis of Bax 1 a.u. assumed for normalization
k15 degradation of Bax 0.1 hr
 1 ref. [290]
k16
E2F2 level producing 1/2 of maximum
expression level for Hrk
16.89 a.u. estimated
g Hill-constant 5.61 a.u. estimated
k17 E2F1 mediated synthesis of Hrk 0.1 a.u. assumed for normalization
k18 degradation of Hrk 0.1 hr
 1 ref. [291]
k19 synthesis of BCL-2 0.03 a.u. assumed for normalization
k20 threshold miR-205 repression of BCL2 5.56 a.u. assumed
k21 degradation of BCL2  0.1 hr 1 ref. [292]
k22 rate of apoptotic cells increase 1.0 a.u. assumed
k23
threshold for eﬀective anti-apoptotic gene
expression
0.028 a.u. assumed for normalization
k24 tumor size duplication time 0.0021 hr
 1 estimatedU [252]
FS factor for E2F1 expression modulation 1 a.u. tunable
k28 growth factor mediated EGFR activation 2.7726 a.u. assumed
k29 EGFR
deactivation/degradation 0.6931 hr 1 ref. [254]
k30
cytostastic drug mediated inhibition of
EGFR activation
0.6931 a.u. assumed
k31 EGFR
i deactivation/degradation 0.06931 hr 1 ref. [253]
k32 ERBB3 synthesis 0.2773 a.u. assumed for normalization
k33 threshold miR-205 repression of ERBB3 1 a.u. assumed for normalization
k34 ERBB3 degradation 0.2773 hr
 1 ref. [293]
k35
E2F2 level producing 1/2 of maximum
expression level for EGFR
7.0711 a.u. estimated¿
g2 Hill-constant 1.5053 estimated
¿
ERTH
threshold for eﬀective ERBB3-mediated
inhibition of cytostatic drug
0.1 hr 1 assumed for normalization
GF growth factor [0,1] a.u. tunable, binary
DS
genotoxic-drug mediated induction of
pro-apoptotic genes
[0,1] a.u. tunable, binary
Table F.1. Model deﬁnition and parameters: y In the current model
parameterization, this parameter represents a drug-induced genotoxic stress level
suﬃcient to induce high levels (60%) of apoptotic cells 48 hr after stress induction in a
population of normal tumor cells, as described in the main text. * Those parameters
were estimated to reproduce a sigmoid curve in the transcription of the pro-apoptotic
genes, in which the normalized transcription function gets 0.05 for E2F1 = 10 (a.u.)
and 0.9 for E2F1 = 25. The same applies to p73-promoted pro-apoptotic genes.
UThis value is equivalent to the duplication time for the tumor size (measured as total
amount of tumor cells) of two weeks. ¿ Those parameters were estimated to reproduce
a sigmoid curve in the transcription of the pro-apoptotic genes, in which the normalized
transcription function gets 0.05 for E2F1 = 1 (a.u.) and 0.95 for E2F1 = 50.
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in three cancer-relevant scenarios: (i) under nonstress conditions, at time zero, and after
120 hours; (ii) after genotoxic drug administration, at 48 hours; and (iii) after cytostatic
drug administration, at 120 hours. The in silico cell lines were classiﬁed into the following
groups: (i) cell lines that show abnormal proliferation in nonstress conditions, named as
tumor cells; (ii) those resistant to genotoxic drugs; (iii) those resistant to cytostatic drugs;
and (iv) those resistant to both genotoxic and cytostatic drugs. For each group, the data
describing the expression levels of the network components at time zero were normalized
with respect to the nominal chemosensitive values (Figure F.2C)..
Our results indicate that 30% of the in silico cell lines are resistant to genotoxic
drugs (Figure F.2C). These cells display high basal levels (at time zero, nonstress
conditions) of E2F1 and DNp73, whereas miR-205 is downregulated compared with the
nominal chemosensitive tumor cell and the group of in silico tumor cells (Figure F.2A).
In addition, approximately 1% of the cell lines display resistance to cytostatic drugs.
These cells have a genetic signature composed of much higher basal E2F1, DNp73, and
ERBB3 levels, whereas miR-205 appears strongly downregulated and TGF-1 is
moderately upregulated. In both cases, EGFR is expressed at its maximum level, but
our analysis indicates that this is a property already acquired by the group of tumor
cells as a consequence of high levels of E2F1. Finally, a small fraction of the cell lines
display a phenotype of double resistance and their genetic signature is very similar to
that of cytostatic drug-resistant cells.
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Figure F.2. (A) Genetic signatures of the E2F1-p73/DNp73-miR-205 network that
confer drug resistance. Box-and-whisker plots of simulated non-stress levels for E2F1,
p73, DNp73, miR-205, BCL2, TGF-1, ERBB3 and EGFR for the diﬀerent subsets
of in silico cells generated: (i) entire set of randomly generated solutions (grey); (ii)
tumor cells (orange); (iii) genotoxic drug resistant (blue); (iv) cytostatic drug resistant
(green); (v) double drug resistant (red). In each bar the central mark is the median,
the edges of the box are the 25th and 75th percentiles, the whiskers extend to the
most extreme data points. The dashed horizontal line in the plot accounts for the
values in the nominal chemosensitive genetic signature. (B) Phenotype of the in silico
chemosensitive tumor cell line. Percentage of cells with respect to initial population.
Legend: control(0): population size at 0hr, no drug injection; control(120): population
at 120hr, no drug injection; CyD(120): 120 hr after cytostatic drug; GxD(48): 48 hr
after genotoxic drug. (C) Distribution of the initial set of randomly generated 104 in
silico cell lines in the diﬀerent subpopulations. Percentage over the total is indicated.
The ﬁgures are adopted from Vera et al., [121].
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Figure F.3. Design principles underlying chemoresistance. E2F1-regulated shift
of the p73/DNp73 ratio can induce non-monotonic, nonlinear regulation of miR-205
expression. The peak of miR-205 expression is reached for intermediate E2F1 levels
and downregulation for very high E2F1 expression. This system is an incoherent
feedforward loop and, according to our hypothesis, nonlinear regulation of the branches
in the feedforward loop switches the status of the feedforward loop from one in which
the positive branch predominates (e.g., p73 N) and promotes target expression to
another in which the negative branch predominates (e.g., DNp73 N) and the target
expression is repressed. The ﬁgure is taken from Vera et al., [121].
136
AppendixG
Time series model simulation of hybrid
model
For one of the scenarios considered previously, I simulated the eﬀect of pulse-like drug
administration for diﬀerent time points. The simulation time was discretized
(t = 0; 60; 120; 180; 240; 270 h) and each target gene and phenotype were updated at
those time points.
t=0 t=60 t=120 t=180 t=240 t=270
GF 1 1 1 1 1 1
FS 1 1 1 1 1 1
TGFB1 1 1 1 1 1 1
GxS 0 0 1 1 1 0
E2F1 10.25 10.25 10.25 14.27 15.37 12.38
p73 6.66 6.66 6.66 8.97 9.98 8.55
DNp73 7.80 7.80 7.80 10.35 11.69 10.19
miR-205 4.56 4.56 4.56 4.61 4.61 4.53
Gab2 1 1 1 2 2 2
CCND1 1 1 1 2 2 2
EGFR 1 1 1 2 2 2
ANCCA 1 1 1 2 2 2
ACTR2 1 1 1 2 2 2
EZH2 1 1 1 2 2 2
BIM 0 0 0 0 0 0
FOXO3 0 0 0 1 1 0
DUSPx 0 0 0 1 1 0
HRK 0 0 0 1 1 0
NOXA 0 0 0 1 1 0
BAX 0 0 0 0 0 0
PUMA 0 0 0 0 0 0
BCL2 0 0 0 1 1 0
ABCA2 0 0 0 1 1 0
ABCA5 0 0 0 1 1 0
Proliferation 1 1 1 0 0 1
Apoptosis 0 0 0 0 0 0
Chemoresistance 0 0 0 1 1 0
Table G.1. Time series model simulation of hybrid model.
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Hybrid model parameters.
Parameters Description of associated process Value Comments/ref. (PubMed ID)
k1 EGF mediated synthesis of EGFR 0.6932 hr
 1 11597398, 23447575
k2 self activation of EGFR 1 hr
 1 assumed for normalization
k3 E2F1 mediated synthesis of EGFR 0.2012 hr
 1 23447575
kx Hill's constant 2 estimated
k4 basal degradation of EGFR 0.06931 23447575, 16473627
kxx basal degradation of EGFR
 1 23447575, 2335562
k5 EGFR mediated synthesis of ERK 0.1 hr
 1 19935650
k6 basal degradation of ERK 0.01 hr
 1 19935650
k7
genotoxic-stress mediated synthesis of
E2F1 mRNA
1.0 hr 1 23447575
k8 basal synthesis of E2F1 mRNA 2.085 hr
 1 23447575
k9 basal degradation of E2F1 mRNA 0.139 hr
 1 19001483, 23447575
k10 miR-205 mediated repression of E2F1 0.01 hr
 1 23447575
k11 mRNA-mediated synthesis of E2F1i 0.231 hr
 1 23447575
k12 E2F1 and Rb disassociation by pERK 1.5*0.16075 hr
 1 11965250
k13 E2F1 and Rb association 0.235 11965250
k14 basal degradation of E2F1i 0.231 a.u. 10077601, 23447575
k15 E2F1 phophorilation by mitogenic signal 1.5*0.16075 hr
 1 11965250
k16 basal degradation of E2F1p 0.235 a.u. 10077601, 23447575
k17 E2F1 mediated synthesis of p73 0.1502 23447575
k18 basal degradation of p73 0.231 hr
 1 10469568
k19 E2F1 mediated synthesis of DNp73 0.1317 23447575
k20 basal degradation of DNp73 0.173 23447575, 20185758
k21 p73 mediated synthesis of miR-205 0.101 23447575
k22
threshold eﬀective DNp73 repression
of miR-205
9.2672 23447575
k23 basal degradation of miR-205 0.029*1.5 23447575, 20051982
ERKt total ERK concentration 1 assumed
Table H.1. Model deﬁnition and parameters: Parameter values used in the core
module of this model along with their relevant references. Some of the parameters in
this model are not exactly the same as the values given in the citation but were scaled
to ﬁt to the performance of our current model.
138
Appendix I
Hybrid toy model code
Below is the MATLAB code for toy model simulation.
Matlab function to encode the ODEs
1 function dy = H_model2_13Feb13(t,y)
2 global p73 Dp73
3 dy = zeros(2,1);
4 miR = y(1); BCLW = y(2);
5 kx = 1.84; k11 = 0.3419 / kx^2;
6 k12 = 0.029; k13 = 5.58 * kx;
7 k25 = 0.1; k26 = 0.1; k27 = 0.18;
8 dy(1) = k11 * p73 * (1 + Dp73./k13).^ (-2) - k12 * miR; % miR205
9 dy(2) = k25./(1 + k27 * miR) - k26 * BCLW; % BCLW
Matlab Code for simulations
1 global p73 Dp73
2 tint = 0:0.1:50; % simulation time
3 p73log = -1:0.1 * 0.40:2;
4 Dp73log = -1:0.1 * 0.4:2;
5 p73vector = 10 .^ p73log; % input vector for model simulation
6 Dp73vector = 10 .^ Dp73log; % input vector for model simulation
7 count2 = 0;
8 numpoints = length(p73vector);
9 Xl = [0 1]; %initial values
10 for i = 1 : length(p73vector)
11 coun = 0;
12 for j = 1:length(Dp73vector)
13 Dp73 = Dp73vector(j);
14 Dp73matrix(i,j) = Dp73vector(j);
15 p73 = p73vector(i);
16 p73totalmatrix(i,j) = p73vector(i);
17 coun = coun+1;
18 Dp73_count=length(Dp73vector) - coun;
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19 [t,x] = ode23(@H_model2_13Feb13,tint,Xl);
20 miRc(i,j) = x(length(tint),1);
21 BCLWc(i,j) = x(length(tint),2);
22 mir_v(i) = x(length(tint),1);
23 % Now this will discritize p73 and DNp73 for hybrid simulation.
24 if miRc(i,j) < 5
25 miRd(i,j) = 0;
26 BCLWd(i,j) = 2;
27 elseif miRc(i,j) >= 5 && miRc(i,j) <= 20
28 miRd(i,j) = 1;
29 BCLWd(i,j) = 1;
30 else
31 miRd(i,j) = 2;
32 BCLWd(i,j) = 0;
33 end
34 count2 = count2+1;
35 iteration = numpoints^2 - count2;
36 if round(iteration./100)==iteration./100
37 clc
38 iteration
39 end
40 end
41 end
42 % drawing surface plot of ODE model
43 figure(’units’, ’centimeters’, ’position’, [2 2 7 5.5], ...
44 ’paperunits’, ’centimeters’, ’paperposition’, [2 2 7 5.5], ...
45 ’paperpositionmode’, ’auto’);
46 axes(’position’, [.20 .20 .80 .70], ’fontsize’, 8, ’box’, ’on’)
47 surf(p73totalmatrix,Dp73matrix,BCLWc,’Edgecolor’,’none’);
48 set(gca, ’FontName’, ’Times New Roman’)
49 colormap(jet)
50 axis([0.1 100 0.1 100 0 1]);
51 set(gca,’XScale’,’log’,’fontsize’,9.);
52 set(gca,’YScale’,’log’,’fontsize’,9.);
53 view([0 0 1])
54 colorbar
55 xlabel(’p73’,’fontsize’,10,’fontweight’,’b’);
56 ylabel(’DNp73’,’fontsize’,10,’fontweight’,’b’);
57 title(’BCL-w ODE model’,’fontsize’,10,’fontweight’,’b’);
58 % drawing surface plot of hybrid model
59 figure(’units’, ’centimeters’, ’position’, [2 2 7 5.5], ...
60 ’paperunits’, ’centimeters’, ’paperposition’, [2 2 7 5.5], ...
61 ’paperpositionmode’, ’auto’);
62 axes(’position’, [.20 .20 .80 .70], ’fontsize’, 8, ’box’, ’on’)
63 surf(p73totalmatrix,Dp73matrix,BCLWd,’Edgecolor’,’none’);
64 set(gca, ’FontName’, ’Times New Roman’)
65 colormap(jet)
66 axis([0.1 100 0.1 100 0 2]);
67 set(gca,’XScale’,’log’,’fontsize’,8.);
68 set(gca,’YScale’,’log’,’fontsize’,8.);
69 view([0 0 1])
70 colorbar
71 xlabel(’p73’,’fontsize’,10,’fontweight’,’b’);
72 ylabel(’DNp73’,’fontsize’,10,’fontweight’,’b’);
73 title(’BCL-w hybrid model’,’fontsize’,10,’fontweight’,’b’);
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Appendix J
Hybrid model code
Below is the MATLAB code for hybrid model simulation.
Matlab function to encode the ODEs
1 function dy = model_E_miR_12feb13(t,y)
2 global FS k1 k5 k6 k8 k9 k10 k11 k12 k13 k14 k15...
3 DrugInd GF TGFB1 timedd
4 dy = zeros(9,1);
5 % Variables
6 EGFR = y(1); EGFRstar = y(2); pERK = y(3); mE2F1 = y(4); E2F1i = y(5);
7 E2F1p = y(6); p73 = y(7); DNp73 = y(8); miR = y(9);
8 if t >= timedd
9 DrugInd = k1;
10 DS = 1;
11 else
12 DrugInd = 0;
13 DS = 0;
14 end
15 kegf = 1.5;
16 EGFRtotal = 10;
17 k28 = 0.6932; k36 = 2; g2 = 1; k35 = 0.2012; k29 = 0.6931; kxx = 1; k31 = 0.06931;
18 dy(1) = - k28 * (kegf * GF + kxx * EGFRstar) * EGFR +(k35 * E2F1p .^g2./ (k36 .^g2 +
E2F1p .^g2 )) - k31 * EGFR; % EGFR synthesis
19 dy(2) = k28 * (kegf * GF + kxx * EGFRstar) * EGFR - k29 * EGFRstar;% EGFR
Phosphorylation
20 % pERK
21 ERKt = 1; k5 = 0.1; k6 = 0.01;
22 dy(3) = k5 * EGFRstar * (ERKt - pERK) - k6 * pERK;
23 % mE2F1
24 k8 = 2.085; k9 = 0.139; k10 = 0.01;
25 dy(4) = DrugInd + FS * k8 - k9 * (1 + k10 * miR) * mE2F1;
26 % E2F1i
27 k11 = 0.231; k12 = 0.231;
28 kx = 1.5*0.16075; ky=0.235; % taken from pubmedID 11965250% multiply by 0.16075
29 dy(5) = k11 * mE2F1 - kx * E2F1i * pERK + ky * E2F1p - k12 * E2F1i;
30 % E2F1p
31 dy(6) = kx * E2F1i * pERK - ky * E2F1p;
32 % p73
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33 k13 = 0.15020; k14 = 0.2310;
34 dy(7) = k13 * E2F1p - k14 * p73;
35 % DNp73
36 k15 = 0.1317; k16 = 0.173;
37 dy(8) = k15 * E2F1p - k16 * DNp73;
38 % mir205
39 k11a = 0.101; k13a = 9.2672; k12a = 0.0435;
40 dy(9) = k11a * TGFB1 .^(-1) * p73 * (1 + DNp73 ./ k13a) .^(-2) - k12a * miR;
Matlab Code for simulations
1 global timedd FS k1 kdi kapo1 kapo2 kbaxo kbako DrugInd GF TGFB1
2 ti = 0; % initial time
3 tf = 300; % final time
4 timeint = ti:1:tf;
5 timedd = 200;
6 kdi = 15*0.139; kapo1 = 0.028; kapo2 = 1.0;
7 kbaxo = 0.0; kbako = 0.0;
8 % Initial condition
9 xo = [0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1];
10 clear aggressive TGFB1matrix FSmatrix chemoresistance
11 FSvector = 0.1:0.09*5:10; % Simulations for multiple values of FS
12 TGFB1vector = 0.1:0.09*5:10; % Simulations for multiple values of TGFB1
13 count2 = 0;
14 numpoints = length(FSvector);
15 for i = 1:length(FSvector)
16 coun = 0;
17 for j = 1:length(TGFB1vector)
18 FS = FSvector(i);
19 FSmatrix(i,j) = FSvector(i); % Matrix for surface plot
20 TGFB1 = TGFB1vector(j);
21 TGFB1matrix(i,j) = TGFB1vector(j); % Matrix for surface plot
22 GF = 1;
23 k1 = 1;
24 coun = coun + 1;
25 FS_count = length(FSvector) - coun;
26 [t,sol] = ode23(@model_E_miR_12feb13,timeint,xo);
27 % Input matric for H-model
28 % e2f1p discretization
29 if max(sol(150:300,6)) <= 1.150
30 e2f1p = 0 ;
31 else if max(sol(150:300,6)) <= 12
32 e2f1p = 1;
33 else
34 e2f1p = 2;
35 end
36 end
37 % p73 discretization
38 if max(sol(150:300,7)) > 1 && max(sol(150:250,7)) <= 10
39 p73 = 1 ; % very low and high p73 is not effective in non-monotonics
40 else
41 p73 = 0;
42 end
43 % dnp73 discretization
44 if max(sol(150:300,8)) <= 10
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45 dnp73 = 0 ;
46 else
47 dnp73 = 1;
48 end
49 %mir205 discretization
50 if DrugInd == 0
51 mir205 = 1; % drug administration induced high DNp73 and low mir205
52 else if max(sol(150:300,9)) < 2.5
53 mir205 = 0;
54 else if p73 <= dnp73
55 mir205 = 0;
56 else
57 mir205 = 1;
58 end
59 end
60 end
61 % GxS discretization
62 if DrugInd == 0
63 gxd = 0 ; % low drug administration
64 else
65 if DrugInd == 0.5
66 gxd = 1; % medium drug administration
67 else
68 gxd = 2; % high drug administration
69 end
70 end
71 % Commond for compuatation of logical steady state (LSS) of a model "e2f1_h_cna2" for
initial values of [gxd e2f1p p73 dnp73 mir205]
72 [spec_lss] = CNAcomputeLSS (e2f1_h_cna2,[gxd e2f1p p73 dnp73 mir205]);
73 [e2f1_h_cna2.specID num2str(spec_lss’)]; %shows LLS value of each species
74 proliferative(i,j) = spec_lss(23); % output of the model
75 apoptosis(i,j) = spec_lss(24); % output of the model
76 chemoresistance(i,j) = spec_lss(25); % output of the model
77 aggressive(i,j) = spec_lss(26); % output of the model
78 count2 = count2+1;
79 iteration = numpoints ^2 - count2;
80 if round(iteration ./ 250) == iteration ./250
81 iteration
82 end
83 end
84 end
85 %Surface plot of Chemoresistance for different expressions of E2F1 and TGFB
86 figure(’units’, ’centimeters’, ’position’, [2 2 6 6], ...
87 ’paperunits’, ’centimeters’, ’paperposition’, [2 2 6 6], ...
88 ’paperpositionmode’, ’auto’);
89 axes(’position’, [.20 .20 .70 .70], ’fontsize’, 8, ’box’, ’on’)
90 surf(FSmatrix, TGFB1matrix, chemoresistance, ’Edgecolor’, ’none’);
91 colormap(jet)
92 set(gca,’fontname’,’Times New Roman’)
93 set(gca,’XScale’,’log’,’fontsize’,10.);
94 set(gca,’YScale’,’log’,’fontsize’,10.);
95 view([0 0 1])
96 colorbar
97 xlabel(’FS (a.u.)’);
98 ylabel(’TGFB1 (a.u.)’);
99 title(’Chemoresistance’,’Fontsize’,10);
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AppendixK
Exclusively logical representation of the
chemoresistance model
Figure K.1 is a graphical representation of the logical model created in ProMoT [195].
The model was simulated for logical steady states (LSS) analysis using CellNetAnalyzer
(CNA). LSSs were calculated for the same combination of inputs as applied to the hybrid
model. Simulation results of the logical and the hybrid model are the same for scenarios
where growth factor is present. In absence of the growth factor the logical model cannot
reproduce the behavior of the system, where for high expression of the E2F1 the tumor cell
become independent of growth factors, which is one of the hallmark of cancer [190, 219]
(see Table K.2). The logic-based model in CNA representations can be access at1.
Table K.1. Logic-based reactions for core module of hybrid model. Logical
reactions of the core module of the E2F1 transcriptional factor hybrid model. The
target gene module and phenotypical modules has the same equations as in Table 4.3
in main text on page 78.
1https://sourceforge.net/projects/khan-phd/ﬁles/Exclusive_logical_model_CNA.rar/download
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Figure K.1. Logical representation of hybrid model. The Logical representation
of E2F1 hybrid model. The model is created using a process modeling tool
(ProMoT) [195] and simulations are carried out in CellNetAnalyzer [199].
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GF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
FS 0 0 0 0 0 0 1 1 1 1 1 1 2 2 2 2 2 2 0 0 0 0 0 0 1 1 1 1 1 1 2 2 2 2 2 2
TGFB1 0 0 0 1 1 1 0 0 0 1 1 1 0 0 0 1 1 1 0 0 0 1 1 1 0 0 0 1 1 1 0 0 0 1 1 1
GxS 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2 0 1 2
E2F1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 2 2 1 2 2 2 2 2 2 2 2
p73 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1
DNp73 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1
miR-205 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 1 0 0 1 0 0
Gab2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 2 2 1 2 2 2 2 2 2 2 2
CCND1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 2 2 1 2 2 2 2 2 2 2 2
MAP3Ks 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 2 2 1 2 2 2 2 1 2 2 2
ANCCA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 2 2 1 2 2 2 2 2 2 2 2
ACTR2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 2 2 1 2 2 2 2 2 2 2 2
EZH2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 2 2 1 2 2 2 2 2 2 2 2
BIM 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
FOXO3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 1 1 0 1 1 0 1 1 0 1 1
DUSPx 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 1 1 0 1 1 0 1 1 0 1 1
HRK 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 1 1 0 1 1 0 1 1 0 1 1
NOXA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 1 1 0 1 1 0 1 1 0 1 1
BAX 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
PUMA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
BCL2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 0 1 1 0 1 1
ABCA2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 0 1 1 0 1 1
ABCA5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 0 1 1 0 1 1
Proliferation 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 1 0 0 1 0 0
Apoptosis 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
Chemoresistance 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 0 1 1 0 1 1
Table K.2. Excusively logical simulation of E2F1 hybrid model. The logical
model nicely capture the role of E2F1 in chemoresistance in the presence of growth
factor (i.e., GF = 1). But it can not produce the system dynamics when external
growth factor is removed (i.e., GF = 0) due to ignoring feedback loops in steady state
analysis of logical model.
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Theses
Faiz M. Khan - An integrative workﬂow for large-scale networks
1. To understand mechanisms underlying drug resistance and tumor invasion, the
analysis of the E2F1-focused biochemical network can provide useful insights
(Section 2.1).
2. Biochemical networks tend to be large and complex, therefore, a single
computational method/approach cannot decode the mechanisms underlying
cellular processes in normal and disease conditions (Section 2.2).
3. Using an integrative workﬂow that combines network structure properties, with
high-throughput and biomedical data, one can identify cell type and disease
phenotype-speciﬁc sub-networks, which are amenable for dynamical systems
analysis (Section 2.2).
4. Logic-based modeling formalisms do not require detailed quantitative data which
make them suitable for modeling large biochemical networks. Their analysis can
identify disease signatures that can successfully stratify patients between early and
advanced stages of cancer (Chapter 3).
5. Ordinary diﬀerential equations (ODEs) quantitatively describe the dynamics of
small molecular networks to quantify expression levels of model variables over time
(Section 4.3).
6. A hybrid model can be a good compromise between the convenience of logical
models for scalability and the quantitative description of non-linear dynamics by
ODE models (Section 4.4).
7. The integrative workﬂow and hybrid modeling framework can be generalized to any
biochemical network underlying diseases (Chapter 5).
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ARTICLE
Unraveling a tumor type-speciﬁc regulatory core
underlying E2F1-mediated epithelial-mesenchymal
transition to predict receptor protein signatures
Faiz M. Khan1, Stephan Marquardt2, Shailendra K. Gupta1,3, Susanne Knoll2, Ulf Schmitz1,4,5, Alf Spitschak2,
David Engelmann2, Julio Vera 6, Olaf Wolkenhauer1,7 & Brigitte M. Pützer2
Cancer is a disease of subverted regulatory pathways. In this paper, we reconstruct the
regulatory network around E2F, a family of transcription factors whose deregulation has been
associated to cancer progression, chemoresistance, invasiveness, and metastasis. We
integrate gene expression proﬁles of cancer cell lines from two E2F1-driven highly aggressive
bladder and breast tumors, and use network analysis methods to identify the tumor type-
speciﬁc core of the network. By combining logic-based network modeling, in vitro
experimentation, and gene expression proﬁles from patient cohorts displaying tumor
aggressiveness, we identify and experimentally validate distinctive, tumor type-speciﬁc
signatures of receptor proteins associated to epithelial–mesenchymal transition in bladder
and breast cancer. Our integrative network-based methodology, exempliﬁed in the case of
E2F1-induced aggressive tumors, has the potential to support the design of cohort- as well as
tumor type-speciﬁc treatments and ultimately, to ﬁght metastasis and therapy resistance.
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Recent advances in sequencing and omics technologiesprovide us with data that can be used to identify andcharacterize cancer and tumor-speciﬁc molecular networks.
The analyses of these networks have given insights into various
aspects of carcinogenesis, tumor progression, and metastasis1, 2. The
set of mutated, deregulated, or epigenetically modiﬁed cancer genes
is highly patient and tumor-type variable, and more important,
these genes are integrated in a small set of regulatory pathways2.
Further, these pathways are not isolated: they crosstalk to shape and
ﬁne-tune basic cellular phenotypes that are subverted in cancer. In
recent years, several researchers have deployed methodologies based
on the reconstruction of cancer-associated networks and used them
to analyze high-throughput cancer data3–5. Interestingly, it has been
found that cancer networks are enriched in regulatory motifs, and
beyond, that cancer-related regulatory motifs do crosstalk. Network
hubs, feedback, and feedforward loops, the regulatory motifs often
encountered in cancer networks, are able to induce a complex
regulatory behavior that evades the use of conventional data
analysis tools for their understanding6, 7. Hence, the utilization
of advanced network-based methodologies and mathematical
modeling becomes necessary to get a deeper understanding of
cancer networks.
An outstanding example of a deregulated cancer network is
the one controlled by the E2F family of transcription factors.
The most prominent member of this family, E2F1, is involved
in a number of essential cancer-related cellular processes such
as proliferation, apoptosis, and differentiation8. E2F1 is a
remarkable example of a network hub as this protein interacts
with many genes, proteins, and other transcription factors
through a variety of regulatory mechanisms. In the context
of solid tumors, unbalanced E2F1 regulation can lead to the
emergence of aggressive tumor cells, which drive cancer
progression, resistance to anti-cancer drugs, and the rise of
metastatic lesions9–13.
Enforced E2F1 expression in advanced tumors and metastases
of different kinds of cancers correlates with pronounced resis-
tance towards therapy and poor patient prognosis14, 15. E2F1
drives epithelial–mesenchymal transition (EMT), similar to the
classical EMT inducer TGFB1, via signaling pathways that involve
non-coding RNAs16. As a direct target of E2F1, enforced
expression of miR-224/452 in melanoma cells stimulates a
mesenchymal phenotype by repressing the metastasis suppressor
TXNIP associated with changes in the actin cytoskeleton towards
an enhanced invasive cell behavior. TXNIP in turn controls E2F1
activity in a negative regulatory loop. This process is reversible
through ablation of endogenous E2F1 in highly aggressive skin
cancer cells, leading to increased TXNIP and E-Cadherin and loss
of mesenchymal markers SNAI2, ZEB1, and Vimentin9, 17.
Apoptosis Survival
EMT/Invasion/
angiogenesis
Post-translational
modification of E2F1
DNA repairQuiescence
Cell cycle
Metabolism
Regulators of E2F1
transcriptional activity
Extra-/intracellular receptor
signaling 
Active E2F1-3 Stress stimuli
Fig. 1 A modularized map of E2F1 in tumor progression and metastasis. The map contains three E2F1 regulatory compartments: (i) Extra-/intracellular
receptor signaling (n= 113); (ii) Post-translational modiﬁcations of E2F1 (n= 24); (iii) Regulators of E2F1 transcriptional activity (n= 66). Furthermore,
there are seven functional compartments: (i) Cell cycle (n= 145); (ii) Quiescence (n= 29); (iii) DNA repair (n= 33); (iv) Metabolism (n= 11);
(v) Apoptosis (n= 89); (vi) Survival (n= 52); (vii) EMT/invasion/angiogenesis (n= 69), where n stands for the number of factors in each compartment.
Biomolecules are visualized in standard CellDesigner format (gene: yellow rectangle; protein: light green round cornered box; receptor: light yellow hexagon;
ligand: green oval; phenotype: violet hexagon; drug/external stimulus: pink box). For better visualization, in the map transcription and translation are
condensed to one reaction directly leading from gene to protein. In red, we represent place holders for protein families (e.g., FGFR for FGFR1-4, FGF for
FGF1-23, ITGA, and ITGB for alpha and beta integrins) and unspeciﬁed genes responding to a given transcription factor. The microRNA layer is not included
in this CellDesigner diagram, but in the Cytoscape network provided as Supplementary Information. The interactive E2F1 interaction map can be accessed
at: https://navicell.curie.fr/pages/maps_e2f1.html
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Another mediator of E2F1-induced EMT is miR-20511, 13. Inhi-
bition of the E-Cadherin repressors ZEB1 and ZEB2 by this
microRNA results in stabilization of the epithelial cancer cell
phenotype18. The relevance of this transcription factor to tumor
progression was also shown in a genetic model by interbreeding
Neu transgenics with E2F1 knockout mice as well as in HER2+
breast cancer patients, in which the E2F activation status predicts
relapse and metastatic potential of MMTV-Neu-induced
tumors19. In fact, E2F-responsive genes deﬁne a novel mole-
cular subset of high-grade human tumors of the breast, ovary, and
prostate, termed ERGO (E2F-responsive gene overexpressing)
cancers20. Our studies also revealed that vascular endothelial
growth factor-C (VEGF-C) and its cognate receptor VEGFR-3,
both highly upregulated in cancer cells with abundant E2F1
expression, are direct targets of this transcription factor21.
Co-regulation of VEGF-C/VEGFR-3 by E2F1 stimulates
endothelial cells to form tubule-like structures and promotes
neovascularization in mice. E2F1 is activated by VEGFR-3
signaling in a positive feedback loop and both proteins
cooperate in the nucleus to co-regulate transactivation of the
proangiogenic cytokine PDGF-B. In addition, we identiﬁed the
epidermal growth factor receptor (EGFR) as a direct target of
E2F1 and demonstrated that inhibition of receptor signaling
abrogates E2F1-induced invasiveness9. These results provide
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Fig. 2 Invasive potential and EMT marker expression in less-invasive and invasive human bladder and breast cancer cell lines. a Boyden chamber assay
and western blot showing the invasive potential and the expression of E2F1 and EMT markers of various bladder and breast cancer lines. RT-4 was used
as reference. b Indicated cells were transduced with adenoviral vector expressing the 4-OHT responsive estrogen receptor (ER)-E2F1 fusion protein
(Ad.ER-E2F1) to conditionally activate E2F1 nuclear translocation. After 24 h they were applied to Boyden chamber assay and induced with 4-OHT or
ethanol as control (left panels) or harvested for protein isolation and western blotting (right panels). c Cells were transduced with adenoviral vector
expressing shE2F1 or shcontrol. After 72 h cell invasion was determined (left). Protein level and shE2F1 knockdown is indicated by immunoblots (right).
All ﬁgures are representatives of at least three independent experiments. Error bars indicate s.e.m., n.d. not detectable
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support for the outstanding, cell context-dependent unique role
of E2F1 in driving cancer aggressiveness.
Here, we use a network approach to identify the tumor type-
speciﬁc regulatory core and to predict receptor protein signatures
associated with E2F1-mediated EMT transitions in two types of
highly aggressive solid tumors, bladder, and breast cancer. To this
end, we construct a comprehensive map of the regulatory
network around the E2F family. By mapping gene expression
proﬁles from cancer cell lines displaying the features of EMT
transition onto the E2F1 interaction map, we identify a tumor
type-speciﬁc regulatory core. We then analyze the regulatory core
to predict tumor-speciﬁc receptor protein signatures linked to
aggressiveness. By conducting in vitro experiments, we could
verify the impact of these molecules on tumor cell invasiveness.
We also found a correlation between the molecular signatures
and clinical tumor aggressiveness in relevant patient data.
Results
A comprehensive E2F1 interaction map. To understand
how E2F1 interacts with different molecules and how it mediates
cancer-related processes, we constructed a functionally
modularized interaction map based on information retrieved
from published literature and databases (Fig. 1). The compre-
hensive map of E2F1 regulation and activity is based on manual
exploration of over 800 publications related to E2F1 and other
E2F family proteins, as well as connected pathways having a role
in cancer-related cellular processes. The map contains 879 nodes
including different types of factors (genes, proteins, microRNAs,
or complexes) and 2278 interactions. To improve visualization,
we modularized the map into several regulatory and functional
compartments (Fig. 1). The map comprises HUGO annotations
of all the factors, together with meta-information about isoform
expression (e.g., DNp73 or mutant TP53) and corresponding
PubMed references.
E2F1 drives EMT in bladder and breast cancer. Recent clinical
results indicate that E2F1 is upregulated in high-grade bladder and
breast cancers14, 22, 23. To further substantiate these ﬁndings, we
examined the effects of E2F1 activity on the invasive capacity of
patient-derived metastatic bladder and breast tumor cell lines using
functional invasion assays, western blotting, and PCR analysis. The
experiments revealed a clear correlation of E2F1 expression with the
invasive behavior and EMT marker expression in both cell models:
high levels of E2F1 and mesenchymal markers in invasive bladder
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(UM-UC-3, SW1710, J82, T24) and breast (MDA-MB231, BT549)
vs. low expression in non-invasive or less-invasive epithelial bladder
(RT-4, VM-CUB1, HT1197) and breast (MCF-7 and T47D) cell
lines (Fig. 2a). Our experimental data are supported by gene
expression data from the CCLE database (Supplementary Fig. 5).
Increased expression of E2F1 commonly observed in EMT-like cell
lines is also evident from several other aggressive tumor entities
such as pancreatic, lung, and prostate cancer (Supplementary Fig. 6)
as well as cutaneous melanoma9. Furthermore, overexpression of
E2F1 induces an invasive phenotype in RT-4 and MCF-7 cells by
upregulation of mesenchymal and downregulation of epithelial
markers (Fig. 2b). In contrast, knockdown of the transcription
factor in aggressive UM-UC-3 and MDA-MB231 cells results in
reduced invasiveness and decreased expression of mesenchymal
ZEB1 as well as upregulation of E-Cadherin in MDA-MB231
(Fig. 2c).
Network motif prioritization. From the E2F1 interaction map,
we identiﬁed a large set of feedback loops (n= 444; 213 positive,
228 negative, and 3 neutral) that are responsible for non-intuitive
behavior of the system (Supplementary Data 1). From such
a large set of feedback loops, our aim was to identify the
most important ones involved in the investigated phenotype.
Towards this end, we used a weighted multi-objective function
containing topological and non-topological network parameters
(see “Methods”). Further, we selected different weighting
scenarios for motif prioritization to avoid any bias induced by the
parameters used in the multi-objective function (for details
see Supplementary Methods).
We used KEGG’s cancer disease pathway (KEGG: hsa05200) to
estimate the number of nodes of a motif associated to a cancer
pathway. For calculating the gene prioritization parameter, we ﬁrst
selected all the known EMT markers in our map proposed in
Lanouille et al.24 and calculated the score for all the nodes using a
random walk with restart algorithm implemented in the Cytoscape
plugin GPEC25. A complete list of the selected motifs along with
structural and biomedical parameters as well as the motifs ranking
scores are provided in Supplementary Data 1. Further, we selected
the top ten motifs from each of the weighting scenarios
implemented in the multi-objective function. In this way, we
obtained 32 non-redundant motifs associated with an invasive
phenotype in bladder and 28 with breast cancer, respectively.
Derivation of tumor type-speciﬁc core regulatory network. To
obtain the core regulatory network, we merged all the unique
motifs using the Cytoscape plugin NetDS26 (v3.0). We retrieved
three disjoint sub-networks in both tumor entities, which we
connected by reviving interactions among the nodes from the
E2F1 regulatory network. Thereby, we obtained tumor-speciﬁc
(bladder and breast cancer) core regulatory networks (Fig. 3).
Both networks include the transcription factors E2F1-3 and the
cell cycle regulators RB1, MYC, CDKN2A, TP53/MDM2, SP1,
FOXA1, FOXO3, and AKT1. Furthermore, both contain the
enzyme SIRT1 that modiﬁes targets like E2F1, TP53, and histones
to silence their function. In addition, both core networks contain
the CDH1 regulators SNAI1/2 and TWIST1, and interaction
partners of CTNNB1 (AXIN2, LEF1).
In bladder cancer, we additionally found ﬁbroblast growth
factor receptor 1 (FGFR1) and its downstream regulatory
subunits of the protein phosphatase 2 (PP2; inhibitor of cell
growth and division), and the pro-proliferative inhibitor of PP2,
KIAA1524 (CIP2A). Also, we found the transforming growth
factor beta receptor (TGFBR) 1/2 downstream signaling mole-
cules SMAD2-4 and their regulator ZEB1. In the breast cancer
core network, we found Fibronectin 1 (FN1), which is related to
migration; FLT4 involved in angiogenesis; GSK3B, an anti-
proliferative enzyme; KPNA2, a nucleopore transporter and the
EP300-associated transcriptional activator NCOA3.
In addition, we observed feedback loops concerning nuclear
factor kappa B subunit 1 (NFKB1) activation (CHUK, NFKBIA;
related to cell survival) in bladder cancer, anti-apoptotic BIRC2/3,
and pro-apoptotic TRAF1 factors in breast cancer, respectively.
Interestingly, both loops are related to each other, as NFKB1 and
BIRC2/3 are survival molecules and NFKB1 activates BIRC
transcription. The regulatory cores, which we consider as
the drivers of the invasive phenotypes contain 41 nodes and
107 interactions in bladder cancer and 35 nodes and 86
interactions in breast cancer.
Logic-based models for EMT-driving molecular signatures. To
evaluate the input–output relationship of the obtained regulatory
core networks, we used logic-based modeling formalism. The
input layer of the logic-based models contains E2F1 and all
receptors present in the regulatory core (Fig. 4). In bladder and
breast cancer, two common receptors are part of the input layer:
(i) EGFR and (ii) the retinoic acid receptor alpha (RARA). In
addition, we found FGFR1 only in the regulatory core of bladder
cancer. In simulations of the model, we considered signal
propagation from input to output layer.
To capture all possible input signals to the regulatory network
cores, we expanded the input layers by including additional
receptors present in the comprehensive interaction network,
which are directly connected to nodes constituting the regulatory
cores. Thus, we included TGFBR, which is connected to SMADs,
and the chemokine (C-X-C motif) receptor 1 (CXCR1) connected
to ZEB1 and SNAI1 in the bladder cancer model. Similarly, we
expanded the breast cancer input layer with the hyaluronan-
mediated motility receptor (HMMR) connected to FN1; the
TGFBR connected to SNAI1 and SNAI2; the interLeukin 1
receptor type I (IL1R1) and the thyroid hormone receptor beta
(THRB) connected to TRAF1 and MYC, respectively. For bladder
cancer, we selected TGFBR1 and for breast TGFBR2 due to their
tissue-speciﬁc expression proﬁles. We derived Boolean functions
for the input signals and their propagation through the nodes
constituting the regulatory layer (Supplementary Data 2).
The output layer of the models comprises a unique node that
represents the EMT process as the driver of the invasive
phenotype, which is determined by a logic function involving
the EMT markers present in the regulatory core. The output,
determined through a multi-valued logic function, accepts four
ordinal levels, ranging from 0 (no EMT) to 3 (high EMT).
Predictive model simulations. We determined the steady states
of each variable in the model for different initial values of the
input nodes. We consider two sets of scenarios, characterized by:
(i) high expression of E2F1 (i.e., E2F1= 1); and (ii) low expression
(i.e., E2F1= 0) in all possible Boolean combinations of receptors
in the input layer. We obtained 64 input vectors for bladder cancer
and 128 for breast cancer. Next, we simulated the network to
determine the impact of the input vectors on the level of EMT
(Table 1). Our simulation results suggest that when E2F1,
TGFBR1, and FGFR1 are simultaneously active, bladder cancer
cells become highly invasive (EMT= 3). A similar effect was
observed in breast cancer when E2F1, TGFBR2, and EGFR are
simultaneously active. Furthermore, we carried out in silico
perturbation experiments to identify important nodes that can be
exploited for therapeutic interventions. Perturbation experiments
were performed for a highly invasive phenotype (EMT= 3) by
changing the Boolean state of each node in the regulatory layer to
reduce invasiveness. We used single and double perturbation
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iteratively and observed the most prominent reduction of EMT in
the latter case (simulation results are provided in Supplementary
Data 5). Our perturbation results suggest that in bladder cancer
(i) double knockout of ZEB1 in combination with either
SNAI1, TWIST1, NFKB1; (ii) knockout of ZEB1 and activation of
CDH1; or (iii) knockout of SMAD2/3/4 in combination with
TWIST1 or NFKB1 reduces EMT to 1. In case of breast cancer
double perturbation by silencing SRC, FN1, SNAI1, SNAI2, or
activation of CDH1 in any of the combinations reduces EMT to 1
(Supplementary Table 4).
Validation of in silico predictions with cell line models. Our
model predictions revealed a common impact of E2F1 and
TGFB1 signaling on tumor invasiveness in both cancer types.
More speciﬁcally, TGFBR1 and FGFR1 in combination with
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Fig. 5 Effects of the EGFR, FGFR1, and TGFBR pathways on bladder and breast cancer invasion. a Different effects of EGFR inhibitor and FGFR1 inhibitor on
invasive bladder (UM-UC-3) and breast cancer (MDA-MB231) cell lines. b Western blots and PCRs show the expression levels of the indicated receptors
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d Boyden assay indicating the invasive potential of epithelial cell lines after stimulation with growth factors and/or overexpression of E2F1 transcription
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overexpression of ER-E2F1, which was activated by adding 4-OHT. Fold-changes were calculated relative to control cells (set as 1). All ﬁgures are
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highly expressed E2F1 induce the most invasive phenotype in
bladder cancer, whereas in breast cancer, it is the combined
action of TGFBR2, EGFR, and E2F1 that triggers high levels of
invasiveness. To validate the predicted inﬂuence of the receptors
and E2F1 on the invasive phenotype, we used chemical inhibitors
and a shRNA-based approach to target these key players. In line
with the in silico simulations, inhibition of EGFR in UM-UC-3
(bladder) or FGFR1 in MDA-MB231 (breast) had a minor
inﬂuence on cell invasion (Fig. 5a). To conﬁrm that this is not due
to a lack of EGFR in UM-UC-3 or FGFR1 in MDA-MB231,
respectively, receptor expression was conﬁrmed by PCR and
immunoblot in all cell lines. As Fig. 5b shows, all receptors are
highly expressed in both invasive cell lines. Furthermore, as
predicted by the simulations, inhibition of E2F1, TGFBR1/2
and FGFR1 in UM-UC-3 and E2F1, TGFBR1/2, and EGFR in
MDA-MB231 had a tremendous impact on the invasive behavior
of the respective cell line with the highest effect upon combined
inhibition (Fig. 5c).
Referring to the initial data where we have shown induction of
an invasive phenotype in epithelial cell lines (RT-4, MCF-7) by
overexpressing E2F1, we now stimulate the signaling pathways by
applying their respective ligands (epidermal growth factor (EGF),
ﬁbroblast growth factor 2 (FGF2), transforming growth factor
beta-1 (TGFB1)) to induce invasion in those cell lines. Figure 5d
demonstrates that the in silico predicted selective response to the
different stimuli actually occurs: In RT-4 cells, overexpression
of E2F1 or stimulation with FGFR1 ligand or TGFBR2 ligand
(alone or in combination) raises the invasive potential, whereas
stimulation with EGFR ligand has no effect on cell invasion. In
contrast, EGFR stimulation of MCF-7 cells promotes cell invasion
in a manner comparable with the TGFBR1/2 stimulation or E2F1
overexpression. Here, activation of FGFR1 has no impact on the
invasive potential of the MCF-7 cell line. Taken together, by
combining the predictions from in silico simulations and the
in vitro experimental validation, we were able to ﬁnd molecular
signatures that regulate invasive phenotypes in E2F1-driven
bladder and breast cancer.
To validate ﬁndings of the in silico perturbation simulations,
we decided to knockdown NFKB1 and SMAD3 in UM-UC-3, and
SRC and FN1 in MDA-MB231, instead of modulating the other
well known EMT markers SNAI1/2, TWIST1, ZEB1, or CDH1.
We performed single and double knockdown of these genes and
measured both the transcriptional and EMT/MET response.
Although the removal of single genes resulted in a clear reversal
of the EMT phenotype (reduced invasion) in both cell lines,
the strongest effect was observed after double knockdown,
as demonstrated by their lowest invasive capacity, increased
E-Cadherin, and decreased Vimentin levels (Fig. 6).
Validation of model predictions with patient data. To further
validate the molecular signature that regulates invasiveness in
bladder cancer, we used data from a patient cohort (n= 165)14, in
which a correlation between E2F1 expression and superﬁcial to
invasive progression was observed (GEO id: GSE13507). We
grouped the patients into high and low expression proﬁles of
E2F1, TGFBR1, and FGFR1 from their respective median
expression values. For each group, we calculated the progression-
free survival probability and found that the survival probability
was higher in the patient group with low expression of each
molecule individually. Furthermore, we identiﬁed the subgroups
of patients with high vs. low expression of: (i) E2F1–FGFR1;
(ii) E2F1–TGFBR1; and (iii) E2F1–FGFR1–TGFBR1. The
progression-free survival probability of each subgroup reveals
that patients with high expression of E2F1–FGFR1 have lowest
mean survival time (33.79 months), whereas those with
low expression of E2F1–FGFR1–TGFBR1 have the best prognosis
(93.35 months) among all the subgroups analyzed
(see Kaplan–Meier plots in Fig. 7a–c). Our analyses indicate that
patients with low expression survive more than twice as long as
the patient subgroup with high expression of the molecular
signature.
To validate the molecular signature from the regulatory core in
breast cancer, we used data from the TRANSBIG network (GEO
id: GSE7390; n= 198) generated by Desmedt et al.22 Similar to
bladder cancer patients, we observed that the progression-free
survival probability of breast cancer patients was low for high
expression of E2F1, EGFR, and TGFBR2 in different combina-
tions (Fig. 7d–f). Interestingly, we observed the highest mean
survival time (97.29 months) in the patient subgroup with low
expression of E2F1–EGFR–TGFBR2. Similar to the bladder cancer
analyses, the patient subgroup with high expression of all three
components had nearly half the mean survival time
(50.11 months) compared with the subgroup with low expression.
We further validated molecular signatures in large patient
cohorts of TCGA bladder cancer (BLCA; n= 426) and TCGA
breast cancer (BRCA; n= 1218) accessible through UCSC Xena
(http://xena.ucsc.edu). We found that signatures predicted using
Boolean simulations were able to distribute patients into early
vs. advanced stages in bladder cancer and aggressive vs. less-
aggressive stages in breast cancer signiﬁcantly (P-value< 0.005)
(Fig. 8a, b; Supplementary Fig. 7). To assess the capability of our
workﬂow in predicting signiﬁcant molecular signatures associated
with invasive phenotypes, we generated 30 random signatures of
three nodes from each of the regulatory cores and arbitrarily
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Fig. 6 Validation of in silico knockout simulations by gene knockdown
experiments. By in silico simulations, we identiﬁed the most effective
combination of double knockouts regarding reversal of EMT. The invasive
potential of UM-UC-3 and MDA-MB231 was measured by Boyden chamber
assay upon treatment with lentiviral vector expressing SMAD3, NFKB1, SRC,
or FN1-speciﬁc shRNA, alone or in combination (left panels). Changes of
EMT markers E-Cadherin and Vimentin after gene knockdown are shown on
transcriptional level (right panels). Fold-changes were calculated relative to
control cells (treated with control LV.shC002; set as 1). All error bars
indicate s.e.m. For statistical signiﬁcance t-test was used (*P-value< 0.05;
**P-value< 0.01; ***P-value< 0.001). ShRNA efﬁciency was conﬁrmed by
western blot
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assigned high or low expression values (Supplementary Data 7
and 8). We observed that the molecular signature predicted for
bladder cancer is the only one that nicely distinguishes between
the early and advanced stage of disease (Fig. 8c). In case of breast
cancer, in addition to the predicted signature, some of the
random signatures were also able to distinguish between
aggressive and less-aggressive cancer types (Fig. 8d). This might
be due to the highly heterogeneous nature of breast cancers.
Overall, our analysis reveals that an invasive tumor phenotype in
bladder cancer is driven by E2F1, TGFBR, and FGFR1, whereas in
case of breast cancer it is driven by E2F1, TGFBR, and EGFR.
Discussion
To improve the treatment outcomes of patients who develop
metastases and drug resistance, a mechanistic understanding of
the determinants of these processes is indispensable. A large
number of clinical studies have recently been published which
identiﬁed E2F1 as a key transcription factor that switches duties
from a tumor suppressor to a driver of metastasis11, 14, 27.
To understand how E2F1 switches its duties, we derived a
comprehensive interaction map (Fig. 1) that includes state of the
art knowledge on transcriptional, post-transcriptional, and
protein–protein interactions around the E2F family. The map
contains 879 nodes and 2278 interactions of gene regulation and
signaling processes associated with the E2Fs, thereby providing
ways not only for the detailed elucidation of E2F regulation
but also for tracing their connections to other cancer-related
pathways. Recently, the idea of analyzing regulatory maps by
integrating multi-omics data for the detection of disease driving
molecules and the identiﬁcation of therapeutic targets has gained
momentum28–32. In the context of our work, Calzone et al.28
reconstructed a comprehensive map of the E2F transcription
factor family. Their work focused on the differing roles of
E2F family members in the cell cycle, reﬂecting the complex
interplay between the E2Fs, RB1, its homologs RBL1 and 2, the
cyclins/cyclin-dependent kinases, and cell cycle arresters.
In contrast, our map sets a main focus on the newly discovered
role of activating members of the E2F family (E2F1-3) in cancer
development and progression, with an emphasis on pro-apoptotic
and anti-apoptotic (survival), angiogenic as well as functions
relevant for EMT. We included additional key players connected
to E2F1 directly or through its neighbors along with a
post-transcriptional layer of microRNAs in the context of
cancer. Interestingly, the majority of the components in the
map by Calzone and coworkers are included in our map
(see Supplementary Fig. 8 for further details).
The underlying idea of our approach is that the structural and
data-driven analysis of this map allows the identiﬁcation of
key functional modules, here named core regulatory networks,
composed of regulatory motifs and critical molecular interactions
that drive given cancer phenotypes. To this end, we have
integrated coherent workﬂow tools coming from data analysis,
bioinformatics, and mathematical modeling. Precisely, and to the
best of our knowledge, we do not ﬁnd in the literature a precedent
of combining network-based high-throughput data analysis,
network reduction, and Boolean modeling. Existing work either
focuses on network-based analysis5, 33 or Boolean network
construction and simulation34, 35. Further, our methodology
includes an innovative element in terms of network reduction,
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Fig. 7 Kaplan–Meier plots of progression-free survival of patients with bladder and breast cancer. Plots a–c show the survival curves for patients with high
and low expression of combined signatures (E2F1–FGFR1; E2F1–TGFBR1; and E2F1–FGFR1–TGFBR1) in bladder cancer patients, whereas plots d–f are for the
combined signatures of E2F1–EGFR; E2F1–TGFBR2; and E2F1–EGFR–TGFBR2 in breast cancer patients. In both cases, patients with low expression of the
molecular signatures have high mean survival times and vice versa. High expression of molecular signature(s) is represented as ‘_H’ (black curve) and
low expression as ‘_L’ (red curve). ‘N’ is the number of patients observed with high/low expression of molecular signatures and ‘MSM’ is the mean survival
month from the patient group. P-values shown in the ﬁgures are for log rank test
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namely the use of an algorithm employing multi-objective
optimization concepts to rank and select key regulatory motifs,
based on network topology features and expression proﬁles.
As far as we know, this has not been explored before in the
context of cancer.
The analysis of topological properties can provide important
information about the cues that have a signiﬁcant impact on the
dynamics of the network7, 36. In our workﬂow, we analyzed the
network properties node degree and betweenness centrality.
Nodes with a high degree, often named hubs, are known for
their importance in network organization and very often are
transcription factors having a central role in orchestrating cell
differentiation programs37, 38. Nodes with high betweenness
centrality serve as gate keepers in the communication between
different components of a network39. As our network was
constructed with all possible regulatory processes around E2F1,
one can expect that values of the topological properties for some
of the nodes are relatively higher than for others, a potential bias
compensated by also considering non-topological properties.
Precisely, we assigned different weights to the genes in the
network according to their known relatedness to relevant cancer-
associated pathways. Furthermore, we used the gene expression
fold-change in cell lines reﬂecting the cancer phenotypes
investigated, thereby providing a data-driven approach to make
the core network cancer-type and context-speciﬁc.
As sets of genes involved in certain phenotypes are highly
interconnected and regulate each other through coherent and
incoherent regulatory loops (motifs) from different pathways,
analysis of these can provide key insights into the structure and
dynamics of the network40 followed by identiﬁcation of disease
biomarkers41, 42. In intracellular regulatory networks, feedback
loops provide stability and robustness against intrinsic and
extrinsic noise, homeostasis or even all-or-nothing patterns of
activation6, 40, 43. Very often, these network motifs are disrupted
or abnormally regulated in cancer and therefore, the analysis of
their differential regulation provides important information on
the emergence of cancer phenotypes. However, the identiﬁcation
of important feedback loops in a highly connected network is a
methodological challenge. From the E2F1 interaction map, we
identiﬁed a large set of three-nodes feedback loops responsible for
non-intuitive behavior of the system (Supplementary Data 1). We
considered three-node feedback loops due to the fact that larger
sized network loops are typically composed of one or more three-
node loops43.
Motif identiﬁcation-based methods have been previously used
to recognize key network regulators. For example, Zhang et al.41
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ranked network motifs using gene expression data to detect breast
cancer susceptible genes and Koschützki et al.44 used motifs with
various network topological parameters to identify important
nodes in a biochemical network. We here introduced a new motif
ranking scheme using a weighted multi-objective function that
integrates topological (e.g., node degree and betweenness
centrality) and non-topological (e.g., gene expression, gene
prioritization) properties. Topological properties account for
the structural importance of the nodes, and non-topological
properties for their cancer-type and context-speciﬁc relevance.
We used multiple weighting scenarios in the multi-objective
function to provide motif ranking as unbiased as possible
regarding the properties assessed in the function. Our proposed
multi-objective function and ranking scheme can easily be
extended to add new information layers in the workﬂow. Thus,
we think that the method proposed can be used for investigating
other cancer networks besides those focused on the E2F family
discussed here.
Using our proposed multi-objective function for motif
prioritization, we have ranked feedback loops identiﬁed in the
E2F1 interaction map (Supplementary Data 1). To understand
the combined effect of top-ranked feedback loops on the
regulation of EMT processes in bladder and breast cancer, we
interconnected them to generate tumor-speciﬁc regulatory core
networks (Fig. 3), which we believe are the main drivers of the
network dynamics. Furthermore, we analyzed the core regulatory
network for the identiﬁcation of molecular signatures driving the
invasive phenotype by using logic-based model simulations45. We
used Boolean logic for the input and regulatory layers, whereas
multi-valued logic representation for the phenotypical output
of the network. Multi-valued logic allows us to model several
activity levels of the phenotype, which helps assessing
the aggregated effect of various network components on the
phenotype29. However, the use of multi-valued logic increases the
complexity of the model, and therefore, we apply it only to the
phenotypical output.
The in silico simulation results indicated that high
levels of E2F1–TGFBR1–FGFR1 in bladder cancer and
E2F1–TGFBR2–EGFR in breast cancer constitute a molecular
signature that represent the most aggressive phenotype. Surpris-
ingly, the other receptors that are part of the input layers in the
models had no effect on the EMT process in our simulations. Our
results are in agreement with previous experimental ﬁndings in
bladder cancer studies where high levels of E2F114, TGFBR146,
and FGFR147 were independently associated with tumor invasion.
Similarly, in breast cancer studies, high expression of E2F148,
TGFBR249, and EGFR50 was separately observed to regulate
invasive tumor phenotypes. Furthermore, we conﬁrmed the role
of predicted signatures on the regulation of tumor invasion using
bladder and breast cancer patient survival data from independent
studies in Figs 7 and 8. For all our predicted signatures
high expression of the constituent molecules mapped to
low patient survival and vice versa. These correlations prove
that our approach is successful in identifying tumor-speciﬁc
molecular signatures regulating EMT processes and driving
invasive phenotypes.
By applying an expression signature from highly invasive
bladder cancer cells and the respective regulatory core, our model
predicted resistance to EGFR inhibition in cells overexpressing
E2F1. Indeed, treatment of UM-UC-3 with EGFR inhibitors
resulted only in a marginal reduction of cell invasion. Likewise,
exposure of RT-4 to EGF did not have any observable effect.
These results are not intuitive as we showed that UM-UC-3
express EGFR (Fig. 5b). On the basis of these results, we propose
that EGFR-targeted therapies might be ineffective in muscle
invasive bladder cancer exhibiting elevated levels of E2F1. In this
regard, it is interesting to note that the majority of completed
clinical trials using inhibitors of EGFR family RTKs do not
show an added beneﬁt over standard of care chemotherapy in
an adjuvant or second line setting51. These studies show that
treatment with chemotherapeutic agents rendered patients with
muscle invasive bladder cancer also resistant to EGFR inhibitors
for hitherto unknown reasons. Expression of EGFR is, like in our
model system UM-UC-3, detected in urothelial carcinomas of the
bladder. However, the absence of activating EGFR mutations at
exons 19 to 21 in a number of bladder cancer specimens has been
demonstrated and may contribute to EGFR inhibitor resistance52.
In contrast, aberration of FGFR1 is a frequent event in bladder
cancer contributing to rapid disease progression53. In pre-clinical
models, the presence of FGFR1 genetic alterations confers
sensitivity to FGFR inhibitors54. Respective clinical trials
are ongoing. However, molecular pre-selection (e.g., FGFR1
ampliﬁcations present or not) is the primary challenge for the
development of FGFR inhibitors. In this context, our model could
be a valuable tool to select for patients who potentially beneﬁt
from an anti-FGFR therapy through application of model-based
signatures for patient classiﬁcation such as determination of E2F1
and TGFBR1 oncogene expression. With regard to our data in
bladder cancer cell lines, we observed an opposite situation in
breast cancer cells. Although EGFR activation in less-invasive
MCF-7 or inhibition in metastatic MDA-MB231 showed a clear
regulation of cell invasion, FGF treatment, and exposure to
FGFR1 inhibitors, respectively, did not substantially alter cell
invasion. However, the FGFR signaling pathway regulates normal
mammary gland development and FGFR1 overexpression has
been associated with breast cancer progression55. A recent
study applied a pre-clinical mammary tumor model to show that
FGFR1 inhibitor treatment leads to initial rapid regression
which is, nevertheless, ﬁnally followed by tumor recurrence56.
Intriguingly, recurrent tumor tissues revealed elevated levels of
activated EGFR compensating for FGFR1 inhibition. It remains to
be seen whether or to which extent available FGFR1 inhibitors
can improve treatment of metastatic breast cancer57.
Overall, model-based treatment recommendations of E2F1-
driven tumor diseases such as advanced bladder or breast cancer,
have the potential to support cohort-speciﬁc treatment of patients
to avoid therapy resistance and cope with aggressive cancers.
Finally, we used the map to investigate E2F1-associated malignant
progression in two tumor entities, but the map and the workﬂow
proposed can also be applied to other cancer types in which E2F1
might have a similar role, as well as to uncover other phenotypes
related to this transcription factor like chemoresistance or
angiogenesis.
Methods
Data retrieval and construction of the E2F1 interaction map. For the
construction of the E2F1 interaction map, we derived, curated, and incorporated
information from the literature and publically available databases as well as E2F1
cofactors recently identiﬁed by our group. More speciﬁcally, we retrieved data on
protein–protein interactions from STRING58 (v9.1) and HPRD59 (release 9).
Transcription factors and their target genes were retrieved from databases60 and
relevant literature. Moreover, we included microRNA-target interactions, which
were extracted from the miRTarBase61 database (release 4.5). Transcription factors
of microRNAs have been extracted from the TransmiR62 database (v1.2). In
addition, we searched PubMed for publications about validated E2F transcription
factors, their post-translational modiﬁcations, molecular interactions, and
connections to certain diseases, especially to cancer. Furthermore, we
manually curated interactions (assigned directions to the interactions, i.e.,
activation/inhibition and relevant references) that were retrieved from mostly
automatically generated databases like STRING, KEGG or the EMBL-EBI
search engine PSICQUIC63 and the text mining tool iHop64 to search for more
interactions described in the literature.
The E2F1 interaction map was built with the process diagram editor
CellDesigner65 (v4.3) and visualized as a SBGN (Systems Biology Graphical
Notation) compliant diagram66. We created different regulatory and functional
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compartments based on the role of molecules in inﬂuencing E2F1 activities and
determining cell fate as follows: (i) Extra-/intracellular receptor signaling: This
compartment contains cellular receptors and ligands with known crosstalk to E2F
family pathways (e.g., FLT4, PDGFRB) and additionally, cancer-relevant receptors
that feed downstream processes like the cell cycle (e.g., growth factor receptors via
the MAPK pathway), apoptosis (like TNF/TRAIL receptors) or survival
(e.g., IGF1R for Ras and AKT signaling); (ii) E2F1 modiﬁcations: To separate the
post-translational modiﬁcations inﬂuencing its transactivation potential of target
genes from the effects that cofactors have on the latter, we consider post-
translational modiﬁers of E2F1, containing factors that regulate E2F1 protein
stability, for example, upon phosphorylation after DNA damage, including kinases
(ATM/R), acetylases (EP300), deacetylases (HDAC1) or methyltransferases
(DNMT1), and regulators of E2F1 transcriptional activity, containing protein-
binding partners that regulate the afﬁnity or speciﬁcity of E2F1 to its DNA targets
(like epigenetic modiﬁers interacting with histones and recruiting E2F1 to target
promoters, e.g., ATAD2); (iii) Cell cycle: This compartment includes cyclins,
CDKs, and MYC that regulate the cell cycle upon extracellular stimulation by
growth factors. It also harbors the regulation of expression and activity (e.g.,
inhibition by RB1) of E2F1-3 as central cell cycle regulators; (iv) Quiescence: This
compartment encloses factors involved in arresting the cell cycle (CDK inhibitors
such as p21, p14/ARF), as well as complexes that silence E2F1 targets during G0/
G1/G2-phase or quiescence (e.g., SWI/SNF complex or the DREAM complex).
DNA repair: DNA damage sensing and repair factors (e.g., BRCA1, TOPBP1) are
summarized in this compartment; (v) Apoptosis: Factors inducing and executing the
cellular apoptotic program like the TP53 family (TP53/63/73), pro-apoptotic
BCL-family inhibitors (BID, BAX), or Caspases; (vi) Survival: Factors suppressing
pro-apoptotic signaling like the anti-apoptotic BCL-family members BCL2, MDM2,
XIAP proteins, MDR-transporters, and the MYB family; (vii) EMT/invasion/
angiogenesis: Besides currently known players in EMT-like ZEB1/2, SNAI1/2, VIM,
CDH1/2, this compartment contains the CTNNB1 regulation and its inﬂuence on
CDH1 as well as angiogenesis and extracellular matrix regulating factors such as
HIF1A, MMPs, and L1CAM; (viii) Metabolism: Ion channels (KCNH11) and
metabolic enzymes (PFKFB2, MAT2A) are summarized in this compartment as there
is recent evidence indicating a regulatory role for E2Fs in the cellular metabolome.
Next, we incorporated into our map detailed text-based annotations including
HUGO name, HGNC ID, Entrez ID, and UniProt ID. We used complex formation
and dissociation information to accommodate activities of protein monomers,
dimers, and oligomers (Supplementary Data 3). By assigning web links to the
annotations in our map, we turned it into an interactive resource.
The web version of the E2F1 map was constructed using NaviCell67. In
addition, the map was translated to Cytoscape68, a format suitable for the use of
network analysis tools. For the sake of improving the visualization, the
CellDesigner map (Fig. 1) pools proteins of the same family into general terms,
whereas the Cytoscape version (Supplementary Fig. 1) contains all respective
family members and interactions among them (Supplementary Data 4), thereby
allowing the use of existing tools for data integration and network analysis. To
assure the accuracy of the network, we randomly selected ~10% of the interactions
and asked independent domain experts to cross-validate them. Over 98% of the
interactions were derived correctly.
Identiﬁcation of context-speciﬁc regulatory core network. We developed a
novel method for the identiﬁcation of the tumor entity-speciﬁc core of large
regulatory networks, which we understand as a subnetwork that is responsible for
critical systems dynamics and driver of a tumor-speciﬁc phenotype. Furthermore, we
propose a mathematical modeling-based approach for the prediction of molecular
signatures, i.e., sets of network-derived diagnostic/prognostic biomarkers. For an
illustration of the workﬂow for network reconstruction, identiﬁcation of the
regulatory core, and prediction of molecular signatures see Fig. 9.
The method for the identiﬁcation of the regulatory core and molecular
signatures involves the following steps: (i) Network analysis: The purpose is to
identify the network structure and node properties, which help in the identiﬁcation
of important nodes and network motifs. Topological and node properties were
determined using the Cytoscape plugin NetworkAnalyzer69. In particular, we
calculated for each node the degree and betweenness centrality, and for the
network the clustering coefﬁcient, diameter, radius, characteristic path length, and
average number of neighbors to understand the overall organization of the network
(Supplementary Table 1; Supplementary Fig. 2). (ii) Network motif identiﬁcation:
Feedback loops from the E2F1 interaction map were identiﬁed using Cytoscape
plugin NetDS26 (v3.0). For the identiﬁcation of feedback loops, we set the loop
length to three nodes (see “Discussion” section for detail). (iii) Motif ranking: To
identify the most important motifs with respect to the relevance for the disease
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derived by merging the top-ranked motifs. c In silico simulations of the regulatory core help in the detection of molecular signatures that are then subject to
experimental validation. d An algorithm for motif prioritization. Motifs can be prioritized based on the objective function represented in Eq. (1). This
objective function contains parameters accounting for node properties, the expression proﬁle of nodes in relevant cancer cell lines and their relatedness to
disease pathways. Weights can be assigned by giving importance to a particular parameter in a user deﬁned manner or iteratively to determine the Pareto
sets of motifs. From these sets, top-ranked motifs can be identiﬁed based on user deﬁned cutoff. e Logic-based representation of biochemical network.
Left: A toy model of biological network consisting of four nodes (X1-4), and interactions among them regulate certain phenotype. Right: Derivation of
Boolean functions (BF) and multi-valued logic functions (MF) for the toy model
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00268-2
12 NATURE COMMUNICATIONS | 8:  198 |DOI: 10.1038/s41467-017-00268-2 |www.nature.com/naturecommunications
165
phenotype under investigation, we developed a novel motif ranking scheme
(Fig. 9d). The scheme is based on: (a) Topological properties, node degree and
betweenness centrality (see “Discussion” section for detail); (b) the involvement of
the motif constituents in KEGG’s ‘Pathways in cancer’ pathway (KEGG: hsa05200);
(c) the gene prioritization score from the Cytoscape plugin GPEC25; and
(d) tumor-speciﬁc gene expression fold-changes from non-invasive to invasive
phenotypes. We used the ArrayExpress database (ArrayExpress accession number:
E-MTAB-2706)70 to ﬁnd suitable gene expression data in non-invasive and
invasive bladder and breast cancer cell lines. In particular, we used RT-4 as
non-invasive and UM-UC-3 as invasive cell lines in bladder cancer, whereas
MCF-7 as non-invasive and MDA-MB231 as invasive cell lines in breast cancer.
Differential expression analysis was performed using the DEseq R-package with
method = ‘bind’ and ﬁtType= ‘local’ (v1.22.1)71. Furthermore, we calculated the
absolute average fold-change for a motif based on the change in expression values
of each node in non-invasive to invasive phenotype. To rank the network motifs
considering all these structural and biomedical criteria, we derived the weighted
multi-objective function72 in Eq. (1).
Sij ¼
w1j
2
 hNDii
max NDð Þ þ
w1j
2
 hBCii
max BCð Þ þ w2j 
hDPii
maxðDPÞ
þw3j  hGPiimax GPð Þ þ w4j 
hjFCjii
max jFCjð Þ
ð1Þ
Here, Sij is the ranking score of each motif (i= 1…n) in different weighting
scenarios (j= 1…13) as given in Supplementary Table 2. w1j to w4j are weighting
factors pounding the importance of the chosen properties, hNDii: average node
degree, hBCii : average betweenness centrality, hDPii: number of nodes in a motif
involved in disease pathways, hGPii: average gene prioritization score, and hjFCjii :
average absolute expression fold-change of a motif i.
To give equal importance to each property, the function is normalized to the
maximum property value in all the network motifs identiﬁed (e.g., max(BC)). In
order to not over-emphasize topological properties in motif prioritization, we
assigned half of the weighting factor to hNDi and hBCi. To generate a ranking of
the motifs, we computed the value of the Sij function for every motif i identiﬁed.
The function proposed is intrinsically multi-objective and may generate a different
ranking for same motif depending on the sets of values chosen for the
weighting factors (Supplementary Methods). To approximate the Pareto set of all
non-dominated motif rankings, we iteratively modiﬁed the values of the weighting
factors, computed the Sij function for every motif and ranked them according to
their Sij values (Supplementary Data 1). Next, we selected the top 10 motifs from
each weighting scenario for further analysis (Fig. 9d). (iv) Derivation of the
regulatory core: The core regulatory network is obtained by merging the sets of the
top-ranked motifs identiﬁed using Cytoscape plugin NetDS (v3.0). In case there are
disjoint sub-networks in a regulatory core, we connect those using direct
interactions between the nodes taken from the complete regulatory network. (v)
Prediction of molecular signatures using in silico simulations: We consider a
disease gene signature as a group of molecular entities in the regulatory core, which
upon perturbation have a signiﬁcant impact on the disease phenotypes. To identify
molecular signatures, the regulatory core is translated into a logic-based model29, 73
and steady state analysis is performed using the software tool CellNetAnalyzer74.
We developed logic-based models of the regulatory cores and carried out in
silico perturbation experiments. To this end and upon the selection of the relevant
network motifs, we established the Boolean rules based on the network structure
and the inspection of the available literature about the interactions. The obtained
model contains three layers: (i) An input layer, (ii) A regulatory layer, and (iii) An
output layer representing the phenotype. In the Boolean-like logic models, nodes
X = (X1…n) of a network correspond to the Boolean variables that can have values
either 1 or 0, and edges deﬁne the type of interactions (e.g., activation or inhibition)
that can be represented by Boolean gates (ACTIVE, NOT, OR, and AND). In
Boolean models, the future state (t + 1) of a node is a Boolean function (BF) of the
current state (t) of all the nodes regulating it, i.e., Xi(t + 1)= BF(X1(t), X2(t),…,
Xn(t)) (Fig. 9e). We derived Boolean functions for signals originating from the
input layer and their propagation through nodes constituting the regulatory layer
based on network structure using Boolean gates (Supplementary Data 2).
In addition, we used qualitative information based on expression data to
approximate activation levels75. For example, in our bladder cancer model, CDH1
is inhibited by multiple molecules including SNAI1, SNAI2, TWIST1, SRC, miR-
25, and MDM2. In case of bladder cancer, the expressions of SNAI2, SRC, miR-25,
and MDM2 were downregulated, whereas SNAI1 and TWIST1 were upregulated in
the invasive cell line. It is well established that CDH1 is downregulated in the
invasive phenotype, therefore, we consider SNAI1 and TWIST1 more relevant for
the regulation of CDH1 than others (for Boolean rules, see the Supplementary
Data 2). Further, we derived multi-valued logic functions that represent the EMT
phenotype in four ordinal levels (from 0, accounting for inactive EMT, to 3,
accounting for full activation) based on the sum of Boolean states of factor 1:
[SMAD2/3/4, SNAI1, ZEB1, TWIST1], factor 2: CDH1, and factor 3: FGFR1, with
the following structure:
EMT ¼ SMAD2=3=4AND SNAI1ð ÞOR ZEB1ANDTWIST1ð Þ½ 
þ NOTCDH1ð Þ þ FGFR1
The motivation to select these factors as drivers of EMT was due to the fact that
CDH1 is a widely accepted hallmark of EMT together with SMAD2/3/4, SNAI1,
ZEB1, and TWIST124. We also considered receptor proteins as decisive factors
determining EMT phenotype whether they are present in the regulatory core,
highly overexpressed in the invasive phenotype and not connected to any of the
EMT markers (e.g., FGFR1 in bladder cancer). We validated our methodology for
predicting molecular signatures driving a speciﬁc phenotype by using an
independent TGFB1 signaling network developed by Steinway et al.34
(Supplementary Figs 3 and 4, Supplementary Table 3, and Supplementary Data 6)
Cell culture and treatment. All cell lines were purchased from ATCC (Rockville,
MD, USA) and kindly provided by Dr S. Füssel, Urology Laboratory, University of
Dresden (RT-4, UM-UC-3, HT1197, J82, T24, SW1710, and VM-CUB1 bladder
cancer cell lines) and by the Department of Obstetrics and Gynecology, University
of Rostock (MCF-7, MDA-MB231, BT549, and T47D breast cancer lines). Cells
were maintained at 37 °C and 5% CO2 in Dulbecco’s modiﬁed Eagle’s medium
(high glucose, 4.5 g/l) containing 2 mM L-glutamine, 1 mM sodium pyruvate,
supplemented with 10% FCS, 0.1 mM non-essential amino acids, 50 U/ml
Penicillin and 50 µg/ml Streptomycin. Breast cancer BT549 cells were grown in
RPMI medium with the same supplements. RT-4 and MCF-7 cells were incubated
with growth factors (EGF, FGF2, TGFB1, from R&D Systems, at 10 ng/ml) for 48 h
prior to experiments. UM-UC-3 and MDA-MB231 cells were treated with
inhibitors (EGFR inhibitor Tyrphostin AG 1478, FGFR1 inhibitor PD161570,
TGFBR inhibitor SB431542, from Santa Cruz, at concentrations ranging from 200
nM to 3 µM) for 24 h prior to Boyden chamber assays. We used non-invasive RT-4
bladder and MCF-7 breast and invasive UM-UC-3 bladder and MDA-MB231
breast cancer cell lines to model the EMT transitions. All cell lines were tested for
mycoplasma contamination prior to the experiments according to manufacturer’s
instructions (Venor GeM Classic, Minerva Biolabs).
Adenoviral transduction. RT-4/MCF-7 and UM-UC-3/MDA-MB231 cells were
seeded into cell culture plates and transduced with Ad.ER-E2F1 (MOI 5) and Ad.
sh.E2F1/Ad.sh.control (MOI 10) adenoviral vectors, respectively. After 24 h the Ad.
ER-E2F1 transduced cells were treated with 4-hydroxy-tamoxifen (4-OHT,
0.02 µM) or 70% ethanol as control.
Table 1 The effect of E2F1 and receptor molecules in
relevant combinations on the EMT phenotype in bladder and
breast cancer model
(a) Bladder cancer
E2F1 TGFBR1 FGFR1 EGFR CXCR1 RARA EMT
0 0 0 0/1 0/1 0/1 0
0 0 1 0/1 0/1 0/1 1
0 1 0 0/1 0/1 0/1 1
0 1 1 0/1 0/1 0/1 2
1 0 0 0/1 0/1 0/1 1
1 0 1 0/1 0/1 0/1 2
1 1 0 0/1 0/1 0/1 2
1 1 1 0/1 0/1 0/1 3
(b) Breast cancer
E2F1 TGFBR2 EGFR HMMR THRB IL1R1 RARA EMT
0 0 0 0/1 0/1 0/1 0/1 0
0 0 1 0/1 0/1 0/1 0/1 1
0 1 0 0/1 0/1 0/1 0/1 1
0 1 1 0/1 0/1 0/1 0/1 2
1 0 0 0/1 0/1 0/1 0/1 1
1 0 1 0/1 0/1 0/1 0/1 2
1 1 0 0/1 0/1 0/1 0/1 2
1 1 1 0/1 0/1 0/1 0/1 3
Active state of the molecule is represented by ‘1’ and the inactive state as ‘0’. The phenotype
output (EMT) can take four ordinal levels ranging from ‘0’ (non- invasive) to ‘3’ (highly invasive).
Table (a) is the summary of 64 in silico simulations of bladder cancer. Each row represents the
result of eight simulations where for the given Boolean state of E2F1, TGFBR1, and FGFR1, all eight
combinations of EGFR, CXCR1, and RARA results in the same phenotypical output. Table (b) is
the summary of 128 in silico simulations of breast cancer. Each row represents the result of
16 simulations where for the given Boolean state of E2F1, TGFBR2, and EGFR, all 16 combinations
of HMMR, THRB, IL1R1, and RARA results in the same phenotypical output
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Lentiviral transduction. For production of lentiviruses expressing shRNA against
SMAD3 (shSMAD3, TRCN0000330055), NFKB1 (shNFKB1, TRCN0000006517),
SRC (shSRC, TRCN0000038149), FN1 (shFN1, TRCN0000286357) or scrambled
shRNA (shscr), Mission shRNA plasmids (Sigma) were used. VSV-G enveloped
pseudotyped lentiviral vectors were generated by cotransfection of HEK293T cells
with plasmids pMD2.G and psPAX2 (Addgene) using calcium phosphate.
Invasion assays. For Boyden chamber assay (growth factor pretreated) cells were
seeded on an 8-μm PET membrane (BD BioCoat™ BD Matrigel™ Invasion Chamber,
6-well) covered with BDMatrigel™ Basement Membrane Matrix (BD Bioscience). Cell
invasion was triggered by a concentration gradient of FCS (2% vs. 30%) between
insert and well. After 36–48 h cells on the upper membrane surface were removed,
whereas those on the lower surface were stained with DAPI and documented by
ﬂuorescence microscopy. Migrated cells were counted using ImageJ software
(http://imagej.nih.gov/ij/). For UM-UC-3 and MDA-MB231, pretreated cells were
seeded into Boyden chambers, supplied with the according amount of inhibitor and
incubated for 36 h. For RT-4 and MCF-7, cells were pretreated with 10 ng/ml of each
growth factor (alone or in combination) prior to Boyden chamber assay. 24 h after
transduction with adenoviral vector (Ad.ER-E2F1), cells were seeded into Boyden
chambers and covered with growth factor reduced BD Matrigel™ Basement Mem-
brane Matrix (BD Bioscience) containing growth factors and 4-OHT or EtOH.
Polymerase chain reaction. For semiquantitative PCR, 1 μg of RNA was reverse
transcribed using First Strand cDNA Synthesis Kit (Thermo Scientiﬁc). cDNA was
added to Thermo Scientiﬁc PCR Master Mix and ampliﬁed with gene-speciﬁc
primers. Actin was used as loading control. The following primer sequences were
used:
EGFR Fwd: AACTGTGAGGTGGTCCTTGG, Rev: GGAATTCGCTCCAC
TGTGTT,
FGFR1 Fwd: ACCACCGACAAAGAGATGGA, Rev: GCCCCTGTGCAATA
GATGAT,
TGFBR1 Fwd: TTGCTCCAAACCACAGAGTG, Rev: TGAATTCCACCAA
TGGAACA,
TGFBR2 Fwd: CTGGTGCTCTGGGAAATGAC, Rev: CAGAAGCTGGGAA
TTTCTGG.
CDH1 Fwd: GCTTTGACGCCGAGAGCTACA, Rev: TCCCAGGCGTAGACC
AAGAAA
VIM Fwd: CTCCCTGAACCTGAGGGAAAC, Rev: TTGCGCTCCTGAA
AAACTGC
GAPDH Fwd: CACCACCCTGTTGCTGTA, Rev: CACAGTCCATGC
CATCAC.
Western blots. For western blot analysis cells were lysed using RIPA buffer
containing PhosSTOP Phosphatase Inhibitor Cocktail (Roche). Protein
concentration was determined by Bradford assay (Bio‐Rad). Protein samples were
separated by SDS-PAGE and transferred to nitrocellulose membranes (Amersham
Biosciences). The following antibodies were used: E2F1 (KH‐95; 1:500), EGFR
(1:250), FGFR1 (Flg C15; 1:1000), TGFBR1 (V22; 1:1000), TGFBR2 (L21; 1:1000),
Vimentin (V9; 1:1500), ZEB1 (H‐102; 1:1000), Snail (H-130; 1:500), SMAD2/3
(FL-425; 1:1000), and c-SRC (1:500) from Santa Cruz, E‐Cadherin (1:1500), and
NFKB1 (C22B4; 1:1500) from Cell Signaling; N-Cadherin (610921; 1:1500) and
FN1 (1:1000) from BD Bioscience, Actin (Sigma; 1:4000) and their corresponding
HRP‐conjugated secondary antibodies (Pierce; 1:2000). Detection of HRP activity
was performed with the ChemiDoc TouchTM Imaging System (BioRad) using ECL
Plus (Amersham) or Super Signal West Femto (Thermo Scientiﬁc) Western
Blotting Detection Reagents (GE Healthcare). Uncropped pictures of the
immunoblots are shown in Supplementary Figs 9, 10, and 11.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the paper and its Supplementary Information/Data ﬁles.
The web version of E2F1 interaction map is available at https://navicell.curie.fr/
pages/maps_e2f1.html. The interactions in the Cytoscape version of the map can be
found in the Supplementary Data 4. Both the CellDesigner and Cytoscape versions
of the maps in xml format, MATLAB code, Boolean models of bladder and breast
cancer regulatory core can also be downloaded from https://sourceforge.net/
projects/e2f1map/ﬁles. Equations used for logic-based model of regulatory cores
are given in Supplementary Data 2.
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A decade of successful results indicates that systems biology is the appropriate approach to investigate the
regulation of complex biochemical networks involving transcriptional and post-transcriptional regulations.
It becomes mandatory when dealing with highly interconnected biochemical networks, composed of hun-
dreds of compounds, or when networks are enriched in non-linear motifs like feedback and feedforward
loops. An emerging dilemma is to conciliate models of massive networks and the adequate description of
non-linear dynamics in a suitable modeling framework. Boolean networks are an ideal representation of
massive networks that are humble in terms of computational complexity and data demand. However, they
are inappropriate when dealing with nested feedback/feedforward loops, structural motifs common in
biochemical networks. On the other hand, models of ordinary differential equations (ODEs) cope well with
these loops, but they require enormous amounts of quantitative data for a full characterization of the
model. Here we propose hybrid models, composed of ODE and logical sub-modules, as a strategy to handle
large scale, non-linear biochemical networks that include transcriptional and post-transcriptional regula-
tions. We illustrate the construction of this kind of models using as example a regulatory network centered
on E2F1, a transcription factor involved in cancer. The hybrid modeling approach proposed is a good compro-
mise between quantitative/qualitative accuracy and scalability when considering large biochemical networks
with a small highly interconnected core, and module of transcriptionally regulated genes that are not part of
critical regulatory loops. This article is part of a Special Issue entitled: Computational Proteomics, Systems
Biology & Clinical Implications. Guest Editor: Yudong Cai.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
In cells, biological processes are driven by complex networks integrat-
ing genes, transcripts, like mRNAs and microRNAs (miRNAs), proteins
and small molecules. Concentrations and activity of these biomolecules
are continuously changing in a concertedmanner in response to internal
and external cell signals. Those changes are regulated bymultiple nested
biological circuits that may contain feedback and feedforward loops.
These non-linear biological circuits give rise to important cell features
like robustness against noise, adaptation despite environmental changes
or hysteretic responses with multistability [1]. In the last decade it has
been found that some biochemical networks are extremely large and
complex: they are commonly integrated by hundreds of compounds
and are enriched in non-linear motifs like feedback and feedforward
loops. Under these conditions, the analysis of biochemical networks
evades human intuition. However, mathematical modeling is an appro-
priate tool to help in understanding those networks [2–4]. Depending
on the features of the biochemical network under consideration and the
available experimental data, a variety of frameworks for mathematical
modeling are available. These range from simple and abstract approaches
to biologically detailed ones, from deterministic to probabilistic or from
spatio-temporal continuous to discrete ones [5].
Models in ordinary differential equations (ODEs), accounting for
the variation in time of variables representing the concentration or
activation state of biochemical molecules, have been used to describe
biological networks for decades [6]. These ODE models allow the
quantitative simulation of the concentration changes or activity proﬁles
of proteins, genes, RNAs and other molecules over time. These features
make it possible to compare the model predictions with most of the
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standard experimental measurements. When biological compartments
are considered, they can also account for a qualitative description of
spatial features [7]. Finally, ODEmodels are the almost “natural”model-
ing framework when investigating the features of biochemical net-
works containing regulatory circuits like feedback- and feedforward
loops [8]. However, a complete characterization of the model requires
to specify the values of several kinds ofmodel parameters (for example,
initial protein concentration and rate constants), which in biochemical
mid-size networks becomes a computationally intensive task that re-
quires large amounts of quantitative experimental data and sophisticated
optimization algorithms. For larger networks parameter estimation be-
comes cumbersome and difﬁculties to identify unique values for model
parameters emerge [9–11].
An alternative to the ODEmodels is the discrete modeling approach
which allows the modeling of interactions among a large number of
proteins, genes and other biomolecules to analyze system behavior
and make predictions on biologically relevant scenarios [12–14]. It
is a qualitative approach that depends only on the network structure
(i.e. parameter free) with the simplifying assumption that networks
nodes, accounting for the expression level or activation state of biolog-
ical molecules, exist only in a well-deﬁned set of possible discrete nu-
merical values [10]. Boolean models are the simplest discrete models,
in which each element of the network can have one of two possible
states at any time (1: ON, expressed or active; 0: OFF, non-expressed
or inactive). This assumption is supported by biological evidences,
e.g. when genes/proteins exhibit ON/OFF switch like behavior. This
can be adopted by assuming a reduced set of biologically meaningful
values for the model variables [15,16,10]. A number of recent papers
illustrate how discrete logic models nicely capture the behavior of
large systems where the interactions are simple [17–19]. However, in
some cases discrete logic models do not reproduce some of the time-
dependent features associated to non-linear biological circuits, like
those containing nested feedback loops.
The recent development of new experimental techniques facili-
tates high-throughput quantitative proteomics measurements and
increases the complexity of the biological networks under investiga-
tion. Therefore, it is necessary to ﬁnd suitable modeling strategies
that realize a compromise between the ability to simulate the behavior
of large biochemical networks, the complexity associated to the existence
ofmultiple regulatory loops in themand the diversity of sources of exper-
imental data. Hybrid models are mathematical and computational con-
structs that combine, in a single modeling framework, interdependent
variables that distributed over discrete/continuous or deterministic/
stochastic domains [20]. Hybrid models account, in an integrative man-
ner, for different spatio-temporal scales of the same biological phenom-
enon, which are described using different, interconnected modeling
frameworks. This approach seems especially valuable to deal with the
multifactorial and multi-level nature of biological phenomena like
cancer emergence and progression [21].
Here we propose, discuss and analyze the construction of hybrid
models, composed of ODE and logic sub-modules, as a strategy to
handle large scale, non-linear biochemical networks associated to
cancer and other complex diseases. We illustrate the construction of
this kind of models using as example a regulatory network centered
in E2F1, a key cancer-related transcription factor.
2. Material and methods
For the implementation of our hybrid modeling approach we used
built-in ODE solvers fromMatlab to simulate the dynamics of the core
regulatory module (MathWorks, MA) and CellNetAnalyzer (CNA)
to simulate the logical part of the target genes and phenotypical
read-outs [14]. To connect both subparts, we develop a Matlab script
that discretizes the values of critical variables of the core regulatory
model and uses these values as the input vector for the simulations
with CNA. The output of the model simulations (continuous and
discrete variable values) is stored in a matrix, whose content is visu-
alized using color coded surface plots.
3. Results
3.1. Methodology proposed
Here, we address the problem of modeling large biochemical net-
works involving dozens to hundreds of receptors, kinase proteins,
transcription factors, mRNAs and microRNAs. Their expression and
activity are typically regulated by multiple, cross-talking pathways
that may even contain overlapping regulatory loops. Our strategy is
to organize and divide the network into three parts with distinctive
regulatory features (Fig. 1A): 1) the core regulatory module of the net-
work, a highly interconnected subnetwork that contains the signaling
and transcriptional pathways enriched in feedback and feedforward
loops, and therefore is expected to display a high non-linear behavior;
2) the target genes module, which accounts for dozens to hundreds of
genes whose expression is directly regulated by the proteins and
transcription factors included in the core regulatory module and can
be experimentally quantiﬁed using high-throughput transcriptomics
and proteomics techniques; and 3) a set of phenotypical read-outs,
phenomenological variables accounting for relevant phenotypes trig-
gered upon activation of groups of genes in the target genes module.
Input signals external to the networks are assumed to regulate or in-
teract with key compounds of the core regulatory module; although
in some cases they could also be direct regulators of the target genes.
In our approach the core regulatory network is modeled using or-
dinary differential equations, while the target genes module and the
phenotypical read-outs are encoded using discrete logic modeling
(Boolean or multi-valued logic). Both parts of the model are connected
using a discretization interface. Given the set of continuous time-
dependent variables of the core regulatory module (Xi,C,i = 1,2,…k),
we deﬁne a set of auxiliary discrete variables (Xi,D,i = 1,2,…k) for the
discretization interface. Furthermore, we discretize the time by consid-
ering a discrete and ﬁnite set of p time points within the duration of the
simulation (tj,j = 1,2,…p). For every time point considered, the inter-
face assigns values to the auxiliary discrete variables, Xi,D(tj), following
a set of discretization rules that depend on the current values of the
continuous variables, Xi,C(tj), and ni physiologically relevant thresholds,
THi,m,m = 1,2,…ni. The number of thresholds for each continuous vari-
able deﬁnes the number of ordinal states for the auxiliary discrete vari-
ables. The structure of the discretization rules is displayed in Table 1.
To simulate the whole model, ﬁrst the core module is initialized
and simulated with a set of values deﬁned for the model inputs
(Fig. 1). At each of the p time points deﬁned, the values of the auxiliary
discrete variables, Xi,D(tj), are calculated following the discretization
rules. Those discrete values are passed as inputs to the logical module
accounting for the target genes and are used to update the values of
its discrete variables following a logical steady-state analysis. Subse-
quently, the updated values for themodel variables in the transcription-
al circuitry module are used to update the phenotypical read-outs. In
this manner and for every discrete time point (tj), the model simulation
generates: 1) a set of continuous values for the variables of the regula-
tory core module, Xi,C(tj); 2) a set of discrete values for the auxiliary
variables, Xi,D(tj); 3) values for the discrete variables accounting for
the expression of the target genes, Tgti(tj); and 4) Boolean values for
the phenotypic read-outs (Fig. 1A).
This approach has the advantage that the complex and highly reg-
ulated part of the network, which is enriched in regulatory loops is
encoded with a modeling approach that provides many computational
and analytical tools to investigate its properties [7,22]. On the other
hand, the use of logicmodeling to describe the associated target genes al-
lows the simulation of massive transcriptional networks with dozens to
hundreds of biologically relevant genes with low computational burden
[23,24]. In this line, the data produced inhigh-throughput transcriptomics
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and proteomics experiments can be discretized in the described way to
substantiate these large scale transcriptional networks.
To illustrate the functioning of the proposed hybrid modeling
approach, we derived a small model describing the regulation of the
tumor suppressor miRNA-205 by the transcription factor p73 and its
isoform DNp73, and the subsequent regulation of anti-apoptotic targets
like BCL-w (Fig. 2A) [25,26]. We have simulated this regulatory module
using a model in ordinary differential equations (Fig. 2C) and the hybrid
modeling approach here proposed (Fig. 2D). The ODE model was
extracted from our previous publication [26]. To construct the hybrid
version of the model, we conserved the ODE description of the miR-205
regulation and generated amulti-valued logic model to describe the reg-
ulation of BCL-w bymiR-205 (Fig. 2B). Furthermore, the continuous ODE
values of miR-205 (miR205con) were discretized (miR205disc) into three
possible values using the rule described in Fig. 2B. The two surface plots
generated in the model simulations clearly show that the hybrid model
preserves the non-linear nature of the BCL-w regulation for different ex-
pression values of p73 and DNp73 as displayed by the ODE model [26].
However, BCL-w expression is now represented by three ordinal states
(0: no expression, 1: low expression and 2: high expression).
3.2. Case study: regulation of chemoresistance by a regulatory network
centered around the transcription factor E2F1
3.2.1. Background
The protein E2F1 is a transcription factor. Upon stimulation with
different signals E2F1 can promote the activation and subsequent ex-
pression of different sets of genes involved in DNA replication and re-
pair, cell cycle progression, proliferation and/or apoptosis [27,28].
Activation of E2F1 by growth factor associated signals induces expres-
sion of target genes promoting cell cycle progression and proliferation
[29,30]. In addition, after genotoxic stress E2F1 regulates the expression
and transcriptional activity of the tumor suppressors p53 and p73,
promoting the expression of multiple genes related to the regulation
of apoptosis and cell cycle arrest [31–33]. Having the ability to regulate
cell proliferation and apoptosis, it is not surprising that E2F1 has been
found to be deeply involved in tumor progression and the resistance
against anti-cancer drugs [34,25,26].
Rather than isolated, E2F1 is part of a vast and complex biochemical
network involving regulation events and a transcriptional circuitry.
Subparts of this network are enriched in non-linear network motifs, in-
cluding feedback and feedforward loops. This makes the use of mathe-
matical modeling mandatory to investigate the deregulation of E2F1
in cancer. Several mathematical models have been developed to inves-
tigate the regulation of E2F1 in different biological contexts. A number
of papers published to date are devoted to the elucidation of the E2F1
role in the regulation of the mammalian G1-S cell cycle transition by
means of ODE modeling and bifurcation analysis [35,36]. Others have
investigated the mechanisms by which cellular stress (e.g. DNA dam-
age) shifts E2F1 activity to induce apoptosis, and how this mechanism
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Fig. 1. Hybrid modeling methodology. A: Sketch of a simulation, with continuous and discrete variable sets B: Structure of the model. C: Data workﬂow in the hybrid model during
simulations.
Table 1
Deﬁnition of the discretization rules. For the each of the k variables of the core regula-
tory module (Xi,C,i = 1,2,…k) at the considered time point, tj, we assign a value Xi,D(tj)
using the following discretization rules:
for i ¼ 1;2;…k
if Xi;C tj
 
≤THi;1→Xi;D tj
  ¼ 0
if THi;1≤Xi;C tj
 
≤THi;2→Xi;D tj
  ¼ 1
if THi;2≤Xi;C tj
 
≤THi;3→Xi;D tj
  ¼ 2
⋅
⋅
⋅
if THi;n−1≤Xi;C tj
 
≤THi;n→Xi;D tj
  ¼ ni−1
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is distorted in cancer cells [37–39]. The role of miRNAs in the regulation
of E2F1 has also recently been investigated via mathematical modeling
[40]. In our own previous work we developed a mathematical model to
investigate the E2F1–p73/DNp73–miR-205 regulatory circuit in the
emergence of resistance to anti-cancer drugs [26]. Taken together,
those papers investigate the regulation of small modules controlling
E2F1 in different biological contexts, but none of them has addressed
the question of how these events modulating E2F1 expression and
activity affect the expression of large transcriptional networks down-
stream of E2F1. The model here described is the ﬁrst approach to this
question with a focus on the role of E2F1 in chemoresistance.
3.2.2. Model description
The model derived accounts for the critical elements of the signal-
ing and transcriptional network regulating the activity of E2F1 in
tumor and normal cells (Fig. 3; for further details see Sup. Mat.). The
network can be divided into three parts: 1) the core regulatory module,
a signaling/transcriptional subnetwork accounting for the regulation
of the expression and activity of E2F1 by proliferative and genotoxic
stress signals, 2) the target genes, a network accounting for the E2F1
modulated expression of critical genes involved in the regulation of
cell proliferation, genotoxic drug response and apoptosis; and 3) the
phenotypical read-outs, a set of phenomenological variables accounting
for the activation of relevant phenotypes (e.g., proliferation, apoptosis,
chemoresistance) upon the expression of given genes in the target
genes (see Sup. Mat.).
The core regulatory module has been extended to account for the
regulation of p73, DNp73 and miR-205, which form together with
E2F1 a regulatory circuit in the context of the genotoxic stress re-
sponse and apoptosis initiation [25,26]. Furthermore, we included a
sub-module accounting for the activation of E2F1 via EGFR mediated
proliferative signals and the E2F1 mediated transcriptional regulation
of EGFR [29]. Both sub-modules constitute experimentally conﬁrmed
cases of feedback loops, a negative one in the case of E2F1–p73/
DNp73–miR-205 [25] and a positive one in the case of E2F1/EGFR
[29,26]. In addition, input variables regulating the dynamics of the
coremodule account for: a) the concentration of growth factors activating
EGF receptor (GF), b) the cancer-related changes in the expression rate of
E2F1 (FS), c) the expression level for the oncogene TGFβ-1 (TGFB1), and
d) the dose of genotoxic agent administered as anti-cancer drug (GxS).
A B
C D
Fig. 2. A: Graphical representation of transcriptional regulation of the oncogene BCL-w by the transcription factor p73 and its isoform DNp73. B: ODE model equations [26] and
hybrid model representation. C: ODE model simulations. D: Hybrid model simulations. In the simulations, different expression levels for p73 and DNp73 were considered and the
steady-state expression levels of miR-205 and BCL-w were computed using the two versions of the model. ODE model parameters: kdmiR = 0.029; ksmiR = 0.1010; kimir = 10.2672;
ksbclw = 0.1; kdbclw = 0.1; kiblc = 0.18; p73, DNp73 [10−1, 102].
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Wenote that TGFβ-1 exempliﬁes in ourmodel a set of proteinswhose dy-
namics is external to the coremodule, but regulate the expression and ac-
tivation of the core regulatory module compounds.
On the other hand, genes considered in the target genes module
account for: a) E2F1-regulated genes involved in cancer-related abnormal
cell proliferation (e.g., Gab2, CCND1, ANCCA); b) E2F1-modulated genes
involved DNA-damage response and apoptosis initiation (e.g., BIM,
DUSP1-3, HRK, NOXA); c) p73-regulated genes involved in apoptosis ini-
tiation (e.g., BAX, PUMA); and d) miR-205-repressed genes involved in
apoptosis repression and chemoresistance (e.g., BCL2, ABCA2). These
genes are used here as an example and represent a wider set of genes
which undergo similar regulation. With the organization proposed for
the network, the core regulatory module contains the molecules and in-
teractions that display non-linear behavior and are involved in regulatory
loops.
Following the approach proposed, we derived an ODE model to
describe the dynamics of the core regulatorymodule, whichwas extracted
and adapted from our previous publication [26]. For the target genes
we constructed a discrete multi-valued logic model, which was
connected to phenotypical read-outs using also multi-valued logic. The
core regulatory module and the target genes module were connected
using a computational interface that discretizes the values of the
model variables in the regulatory module that control the expression
of the genes in the target genes, namely, active E2F1 (E2F1p), p73,
DNp73, and miR-205. The discretization rules were established using
manual training [26]. Taken together, the model is integrated by nine
ordinary differential equations and 35 multi-valued logic functions
(Table 2).
3.2.3. Model simulations
We simulated cancer and non-cancer like cells and applied different
input vectors by tuning the values of the model inputs GF, FS, TGFB1,
and GxS (Fig. 4). We considered two sets of scenarios, characterized by
i) the presence of sufﬁcient amount of growth factor (GF = 1) to trigger
proliferation and ii) the lack of growth factor stimulation (GF = 0). Next,
we modiﬁed sequentially and systematically the values of the other
input variables, obtaining 36 biological scenarios accounting for the
effect of genotoxic drug administration on cancer and non-cancer cells
with/without abnormal overexpression of E2F1 and TGFβ-1. The hybrid
model was used to compute steady-state values of the model variables.
The effect of genotoxic drug administration (GxS) in these different bio-
logical scenarios is substantiated in the model by the emerging gene
Fig. 3. Regulatory map of the E2F1 centered biochemical network involved in resistance to anti-cancer drugs. The ﬁgure displays a CellDesigner map of the system and consists of
three parts: 1) the core regulatory module, a transcriptional subnetwork accounting for the regulation of the expression and activity of E2F1 by proliferative and genotoxic stress
signals, 2) the target genes module, a network accounting for the E2F1 modulated expression of critical genes involved in the regulation of cell proliferation, genotoxic drug re-
sponse and apoptosis and 3) the phenotypical read-outs (purple hexagons), a set of phenomenological variables that connect the transcriptional circuitry with phenotypic
responses.
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expression pattern and the triggering of any of the phenotypes consid-
ered in the model. The computation of the complete set of simulation
took approximately 1 s on a conventional workstation.
The results obtained are in accordance with those previously de-
rived from an ODE model and with other biological evidences in the
literature [26,25,29]. However, our hybrid model delivered some
Table 2
Model description.
Core regulatory module
∂EGFR
∂t ¼−k1⋅ GF þ k2⋅EGFR
ð Þ⋅EGFRþ k3⋅ E2F1kx þ E2F1
 
−k4⋅EGFR
[1]
∂EGFR
∂t ¼ k1⋅ GF þ k2⋅EGFR
ð Þ⋅EGFR−kxx⋅EGFR [2]
∂pERK
∂t ¼ k5⋅EGFR⋅ ERKt−ERKð Þ−k6⋅pERK [3]
∂mE2F1
∂t ¼ GxS⋅k7 þ FS⋅k8−k9⋅ 1þ k10⋅miR205ð Þ⋅mE2F1 [4]
∂E2F1i
∂t ¼ k11⋅mE2F1−k12⋅E2F1i⋅pERK þ k13⋅E2F1p−k14⋅E2F1i [5]
∂E2F1p
∂t ¼ k15⋅E2F1i⋅pERK−k16⋅E2F1p [6]
∂p73
∂t ¼ k17⋅E2F1p−k18⋅p73 [7]
∂DNp73
∂t ¼ k19⋅E2F1p−k20⋅DNp73 [8]
∂miR205
∂t ¼ k21⋅TGFB1
−1⋅p73⋅ 1þ DNp73
k22
 −2
−k23⋅miR205 [9]
Discretization rules
1 E2F1pD = 0 if E2F1pc b 1.15
2 E2F1pD = 1 if 1.15 ≤ E2F1pc b 12
3 E2F1pD = 2 if 12 ≤ E2F1pc
4 miR205D = 0 if miR205c b 5
5 miR205D = 1 if 5 ≤ miR205c
6 p73D = 0 if p73c b 1
7 p73D = 1 if 1 ≤ p73c
8 DNp73D = 0 if DNp73 b 10
9 DNp73D = 1 if 10 ≤ DNp73
Transcriptional circuitry
Reactions
1a E2F1p = Gab2
1b 2 E2F1p = 2 Gab2
2a E2F1p = CCND1
2b 2 E2F1p = 2 CCND1
3a E2F1p = ANCCA
3b 2 E2F1p = 2 ANCCA
4a E2F1p = MAP3Ks
4b 2 E2F1p = 2 MAP3Ks
5a E2F1p = ACTR2
5b 2 E2F1p = 2 ACTR2
6a E2F1p = EZH2
6b 2 E2F1p = 2 EZH2
7a E2F1p + GxS = EZH2
7b 2 E2F1p + GxS = 2 EZH2
8 E2F1p + 2 !EZH2 = BIM
9 E2F1p + GxS = FOXO3
10 E2F1p + GxS = DUSPx
11 E2F1p + GxS = NOXA
12 E2F1p + GxS = HRK
13 P73 + !DNp73 + GxS = BAX
14 P73 + !DNp73 + GxS = PUMA
15 !miR-205 + E2F1p = Bcl-2
16 !miR-205 + E2F1p = ABCA2
17 !miR-205 + E2F1p = ABCA5
Phenotypic read-outs
Reactions
1a Gab2 + ANCCA + CCND1 + MAP3Ks + ACTR + EZH2 = Proliferative_complex
1b 2 Gab2 + 2 ANCCA + 2 CCND1 + 2 MAP3Ks + 2 ACTR + 2 EZH2 = Proliferative_complex
2 BIM + FOXO3 + DUSPx + NOXA + HRK = E2F1_Drug_apoptotic_comp
3 BAX = p73_apop_genes
4 PUMA = p73_apop_genes
5 Bcl-2 = miR-205_reg_genes
6 ABCA2 = miR-205_reg_genes
7 ABCA5 = miR-205_reg_genes
8 Proliferative_complex + !DUSPx + !FOXO3 = Proliferation
9 E2F1_Drug_apoptotic_comp + p73_apop_genes + 2 ! EZH2 + !miR-205_reg_genes = Apoptosis
10 miR-205_reg_genes = Chemoresistance
In CellNetAnalyzer the “+” sign represents logical ‘AND’, while the “!” sign represents logical ‘NOT’.
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interesting results. For example, our model simulations for condi-
tions of non-growth factor stimulation (GF = 0) indicate that in
the case of sufﬁcient overexpression of E2F1 tumor cells may become
self-sufﬁcient in growth signals [41,42]. We link this simulation re-
sult to the existence of a positive feedback loop between E2F1 and
EGFR [29]. Furthermore, sufﬁcient overexpression of either E2F1
(E2F1 = 10) or TGFβ-1 (TGFB1 = 10) can promote resistance to
anti-cancer drugs by the repression of miR-205. This conclusion is in
agreement to the results of our previous publication. On the other hand,
a version of the model completely constructed using multi-valued logic
fails to reproduce the features associated to the existence of the indicated
feedback loops (see Sup. Mat for further details).
Furthermore, we modiﬁed the E2F1 synthesis parameter (FS) and
TGFβ-1 expression level (TGFB1) to investigate whether they can
synergize to provoke the emergence of a resistant phenotype [26].We in-
vestigated the combined effect of deregulation in E2F1 and TGFβ-1 with
our model. To this end, the values of the input variables FS and TGFB1
were iteratively modiﬁed and we simulated whether resistance to apo-
ptosis initiation (chemoresistance) after stimulation with genotoxic
drug emerged (Fig. 5). Our model simulations suggest that a combina-
tion of E2F1 and TGFβ-1 overexpressions can trigger chemoresistance.
In contrast to Boolean models, the use of a hybrid model is sufﬁcient to
determine precise thresholds of E2F1 and TGFβ-1 expressions shifting
the phenotype from chemosensitive (Fig. 5, blue area) to chemoresistant
(Fig. 5, red area).
4. Discussion
In this work we have proposed and illustrated the construction of
hybrid models, composed of ODE and logic sub-modules, as a strategy
to handle large scale, non-linear biochemical networks. Our strategy
is to organize the network into three parts: 1) the core regulatory
module, a subnetwork of signaling and transcriptional processes that
displays high interconnectivity and is enriched in non-linear regula-
tory loops, 2) the target genes, accounting for genes whose expression
is directly regulated by the signaling proteins and transcription fac-
tors included in the core module and 3) the phenotypical read-outs.
The core module is modeled using ODEs, while the target genes and
the phenotypical read-outs are described using discrete logic model-
ing. Furthermore, an interface is designed that links both parts by
discretizing the values of the variables in the core module. Although
the approach proposed seems simple, a number of questions emerge
when trying to generalize the method and make it more accurate.
In our case study, the model construction relied on the manual re-
trieval of biomedical information and integration into a regulatory
map. Real case study networks can be much more complex and exten-
sive, especially in terms of the target genes, which makes it impossible
to manually retrieve the information. One approach to predict the struc-
ture of these networks could be the systematic use of existing databases
of protein–protein interactions and transcriptional regulation [43,44,26].
Similarly, the determination of the core regulatorymodule is typically
not straightforward. It requires, for the biomedical context under inves-
tigation, to determine in a systematicmannerwhich parts of the network
display structural complexity and are enriched in non-linear regulatory
loops. A possible approach could be to employ tools from the graph-
based network analysis to detect, classify and rank non-linear network
motifs [45].
In addition, in some cases there may be feedback between the core
regulatory module and the target genes module. For example, in our
case study EGFR is a transcriptional target of E2F1 but also regulates
E2F1 activity in a system that has the structure of a positive feedback
Fig. 4.Model simulations for the effect of genotoxic drug administration on cancer and
non-cancer cells with/without overexpression of E2F1 and TGFβ-1, and with/without
growth factor stimulation.
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loop [29]. Given the consequences that this motif has on the regulation
of the system, the dynamics of the transcriptional target EGFR were in-
cluded in the non-linear core regulatory module. This idea could be
used to account for this kind of motifs in other models. In a more
advanced setup of the methodology, network biology methods would
be used to detect feedback loops between different parts of the net-
work. These motifs would then be entirely included in the non-linear
core regulatory module. In addition, the use of logical modeling would
be reserved for the linear transcriptional regulation motifs.
When modeling the core regulatory module with ODEs, two funda-
mental questions have to be addressed: the derivation of the model
equations and the estimation of model parameters. The construction
of model equations may beneﬁt from using canonical modeling frame-
works like classical kinetic or power-lawmodeling to obtain more con-
sistent, homogeneous and easy to derive equations [6,46,2]. Secondly,
the characterization of the ODE model will require adequate quantita-
tive experimental data (dose–response experiments, quantitative time
series, etc; see [2,7] for further details and example), but also adequate
methodologies for parameter estimation [11,47].
A critical element of the proposed approach is to determine the
discretization rules for the core regulatory variables that control the
target genes. These rules are the basis of the interface between the
ODE and logic modules. In our case study, the discretization rules
were derived by manual training [7], but in a real case with a larger
set of genes integrated in the target genes module a more systematic
approach will be necessary. This approach will require transcriptomics
and proteomics data from experiments, in which expression and activ-
ity of the proteins and transcription factors controlling transcriptional
programs are modulated in a dose–response fashion. Furthermore,
computational methodologies will be required to determine precise
discretization rules and gene-dependent activation thresholds for the
transcriptional factors [48].
A ﬁnal but not minor question is that of timing in the model simula-
tions. ODEmodels are continuous-timemodels, inwhich time is, at least
theoretically, a continuous variable, while in discrete logic-models also
the time is discrete per se. A more advanced version of the computa-
tional interface between the ODE and logic submodules will require
rules for time discretization. Therefore, a criterion has to be established
to re-compute iteratively in deﬁned time-intervals, the discrete values
for the regulators of the target genes (Fig. 6). This strategy could even
be enhanced by integrating time-dependent high-throughput gene ex-
pression and phenotypic data in the analysis.
In this paperwe proposed to combineODE and discrete logicmodel-
ing in computational hybrid models, which can be a useful tool for the
analysis of large scale biochemical networks. In Table 3 we compare
the performance of ODE, discrete logic and hybrid models with respect
to a number of biological and computational features, which are impor-
tant when choosing a strategy to construct a mathematical model for a
biochemical system. The table indicates that among them there is not a
perfect modeling framework, able to deal better than the others in all
the features considered. This is a conclusion that can be extended to a
wider pool of modeling frameworks and emerges after inspecting de-
cades of scientiﬁc publications on modeling of biochemical models.
Some modeling frameworks are clearly better in some features but
have a poor performance for other features. When choosing the right
modeling framework one has to think which of those features are
Fig. 6. Time series model simulation. For one of the scenarios considered previously,
we simulated the effect of pulse-like drug administration. Toward this end, the simu-
lation time was discretized (t = 0, 60, 120, 180, 240, 270 h) and the nodes of the
target genes and the phenotypes were updated at those time points.
Fig. 5. Emergence of chemoresistance upon deregulation of E2F1 and TGFβ-1 expres-
sions. The values of the input variables accounting for E2F1 synthesis rate (FS) and
TGFβ-1 expression (TGB1) were iteratively modiﬁed in an interval of physiologically
feasible values (values were normalized to the ones in the wild-type chemosensitive
cell line described in [25,26]).We simulated the systemunder genotoxic drug administra-
tion and analyzed for eachpair of values for FS and TGFB1, respectively,whether apoptosis
initiation was triggered (blue area) or the cell displays chemoresistance (red area).
Table 3
Comparison of ODE, discrete logic and hybrid models for the analysis of biochemical
networks.
models
Logic models Hybrid 
models
Biophysical realism
Accuracy
Interpretability
Encoding of non-linearity
Calibration techniques
Integrability of quantitative data
Scalability
Computability
Legend Good Acceptable Poor
ODE
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more important in the biochemical system investigated. We think that
hybrid models like the ones proposed are a good compromise between
quantitative/qualitative accuracy and scalability when considering
large biochemical networks with a small core of highly interconnected
feedback loop regulated processes and a large amount of transcription-
ally and post-transcriptionally regulated genes not intervening in those
loops.
An interesting option when using a modular representation of
regulatory networks connected to phenotypic readouts is the investi-
gation of phenotype probability distributions in heterogeneous cell
populations. This kind of approach can be used to connect single-cell
and cell-populationmodels. Toward this end, alternative to ourmethod,
other approaches based on continuous variables may be considered
(i.e., partial differential equations; see for example [49]). In the current
study, our approach was used to investigate the behavior of the signal-
ing and transcriptional machinery of single cells belonging to homoge-
nous populations, and their connection to the emergence of given
phenotypes. Thus, the discrete representation of the phenotypical
readouts remains valid. Furthermore, the hybrid approach proposed
could be integrated in more advanced methodologies accounting for
the dynamics of cell populations, like for example agent-based
models of cell populations [50]. In this case, our hybrid model ap-
proach would account for the regulatory machinery of each individ-
ual cell, which would be connected to the phenotypic parameters
controlling, in the agent-based model, the dynamics of the modeled
cell. For models of mid-size cell populations, the use of our hybrid
approach for describing the internal regulatory machinery of each cell
reduces the computational effort necessary for simulations of the
agent-based model. Statistical analysis can be further applied to the out-
put of the model simulations [51].
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Kinetic Modeling–Based Detection of Genetic Signatures
That Provide Chemoresistance via the E2F1-p73/DNp73-
miR-205 Network
Julio Vera1,3, Ulf Schmitz1, Xin Lai1,4, David Engelmann2, Faiz M. Khan1, Olaf Wolkenhauer1,5, and
Brigitte M. P€utzer2
Abstract
Drug resistance is a major cause of deaths from cancer. E2F1 is a transcription factor involved in cell
proliferation, apoptosis. and metastasis through an intricate regulatory network, which includes other tran-
scription factors like p73 and cancer-related microRNAs like miR-205. To investigate the emergence of drug
resistance, we developed a methodology that integrates experimental data with a network biology and kinetic
modeling. Using a regulatory map developed to summarize knowledge on E2F1 and its interplay with p73/
DNp73 andmiR-205 in cancer drug responses, we derived a kineticmodel that represents the network response to
certain genotoxic and cytostatic anticancer drugs. By perturbing the model parameters, we simulated hetero-
geneous cell conﬁgurations referred to as in silico cell lines. These were used to detect genetic signatures
characteristic for single or double drug resistance. We identiﬁed a signature composed of high E2F1 and low
miR-205 expression that promotes resistance to genotoxic drugs. In this signature, downregulation of miR-205,
can bemediated by an imbalance in the p73/DNp73 ratio or by dysregulation of other cancer-related regulators of
miR-205 expression such as TGFb-1 or TWIST1. In addition, we found that a genetic signature composed of high
E2F1, lowmiR-205, and high ERBB3 can render tumor cells insensitive to both cytostatic and genotoxic drugs. Our
model simulations also suggested that conventional genotoxic drug treatment favors selection of chemoresistant
cells in genetically heterogeneous tumors, in a manner requiring dysregulation of incoherent feedforward loops
that involve E2F1, p73/DNp73, and miR-205. Cancer Res; 73(12); 3511–24. 2013 AACR.
Introduction
Resistance to genotoxic drugs as the major cause of cancer
therapy failure is a serious problem for oncologists and their
patients that requires the understanding of the pivotal trig-
gering events and its evolution when cancer progresses. Che-
moresistance can be innate or acquired and may attributable
to a single agent or a class of drugs. Potential mechanisms to
counteract the therapeutic effects of DNA-damaging agents
include the reduction of effective drug concentrations via
enhanced efﬂux, detoxiﬁcation enzymes or drug sequestration,
modiﬁcation of drug targets, changes or mutation in mitotic
checkpoint signals, and hyperactivation of DNA repair
mechanisms (1).
The cellular transcription factor E2F1 is a uniquemember of
the E2F family of proteins as it regulates the tumor suppressor
Major Findings
Our model analysis indicates that tumor cells showing a
genetic signature composed of high E2F1, low miR-205, and
high ERBB3 expression can be resistant to multiple types of
anticancer drugs. Furthermore,we found that the deregulation
of E2F1 signaling can promote chemoresistance in concert
with some epithelial–mesenchymal transition signals via com-
mon miRNA targets. Our analysis shows that the E2F1 signal-
ing network is enriched in feedforward loops, the deregulation
of which can play a decisive role in the emergence of che-
moresistance. Finally, we found that in in silico heterogeneous
tumors with cells displaying different signatures for the E2F1
signaling network, genotoxic drugs can favor the selection of
subpopulations of chemoresistant tumor cells.
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p53 and its homologue p73 thereby promoting apoptosis by the
activation of a plethora of death pathways (2). One of the ﬁrst
signals recognized to induce E2F10s apoptotic activity was
DNA damage (3). Overexpression of E2F1 was shown to
increase the sensitivity of malignant cells to apoptosis upon
genotoxic treatment (4), which is critical for tumor growth
Quick Guide to Main Model Equations and Assumptions
The kinetic model is organized in four interconnected modules: a core regulatory module, transcriptional modules related
to apoptosis and proliferation, and an additional module for the tumor cell population.
The core regulatory module contains ﬁve differential equations, accounting for E2F1 mRNA and protein (mE2F1 and E2F1),
both isoforms of p73 (respectively, p73 and DNp73), and miR-205 (miR205). The most relevant equation describes the dynamics of
miR-205:
dmiR205
dt
¼ k11  TGFB11  p73  1þ DNp73k13
 2
 k12 miR205
This equation describes the regulation of miR-205 synthesis and degradation (k11, k12). Here, we assume that p73 acts as an
activator of miR-205 synthesis, whereas DNp73 plays an inhibitory role. According to the observations reported in several tumor
types, we assume that when both isoforms of p73 are overexpressed, the inhibitory effect of DNp73 dominates and cancels out p73
activation ofmiR-205. To exemplify the set of regulators ofmiR-205 that are external to the E2F1/p73/miR-205 network, we include
a term that describes the repression of miR-205 by the oncogenic signal coming from the TGFb-1 pathway (TGFB1).
The module for apoptosis-related targets includes three differential equations, accounting for the dynamics of E2F1-regulated
proapoptotic genes (represented by Hrk), p73-regulated proapoptotic genes (represented by Bax), and miR-205–repressed
antiapoptotic genes (represented by BCL2). The most representative equation for this module accounts for Hrk dynamics:
dHrk
dt
¼ k17  DS  E2F1
g
k16 g þ E2F1g
 k18  Hrk
This equation describes the regulation of Hrk synthesis and degradation (k17, k18). In this equation, we include the E2F1-
mediated expression of Hrk using a Hill function. In addition, we assume that DNA damage signals trigger acetylation and
activation of E2F1, which is required to promote Hrk expression. Drug-induced DNA damage signals are here encoded as a binary
variable (DS).
The module for targets associated with proliferation includes ordinary differential equations for the de novo inactive EGFR
(EGFR), growth factor-activated EGFR (EGFR), cytostatic drug–inhibited EGFR (EGFRI), and active ERBB3 (ERBB3). In this
module, the most important equation describes the dynamics of EGFRI:
dEGFRI
dt
¼ k30  CyD  k36  E2F1
g2
k
35
g2 þ E2F1g2  EGFR
  EGFRI
 !
 1þ ERBB3
ERTH
 1
 k31  EGFRI
The ﬁrst term accounts for the inhibition of EGFR by cytostatic drugs (CyD), which converts EGFR into inactive form (EGFRI).
Here, we assume that the expression of EGFR is regulated by E2F1, which is modeled with a Hill equation (k36, g2). We include a
power-law term accounting for the effect of ERBB3 as an inhibitor of the cytostatic drugs regulating EGFR activity (ER).
The tumor cell population module is composed of an ordinary differential equation accounting for the size of a population of
tumor cells with the considered genetic signature (TC). This equation is a phenomenological kinetic equation that connects the
components of the regulatory network to the dynamics of the tumor cell population:
dTC
dt
¼ k24  EGFR  TC  k22  Hrk  Bax  1þ BCL2k23
 1
TC
In this equation, active EGFR (EGFR) connects the proliferation of the tumor cell population to proliferative signals (k24),
whereas the representatives for pro- and antiapoptotic proteins (Hrk, Bax, and BCL2) regulate the cell death rate after genotoxic
stress (k22, k23).
In some simulations, we consider tumors composed of three subpopulations of tumor cells with different genetic signatures.
Accordingly, we construct three instances of the model, which differ in model parameter values describing the different genetic
signatures. Further details are available in the main text and Supplementary Material.
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reduction (5). In this regard, activation of p73 by E2F1 func-
tions as backup once p53 is defective to ensure that damaged
cells can undergo apoptosis (6,7). In such a scenario, high levels
of endogenous E2F1 should increase the effectiveness of DNA-
damaging agents and discriminate between tumors clinically
responsive or resistant to anticancer therapy. This is in line
with clinical surveys that associated E2F1 expression with
improved survival in patients treated with adjuvant chemo-
therapy and underscores E2F10s role as an endogenous che-
mosensitizer in patients with cancer and beyond, as a predic-
tive factor for therapeutic success and clinical outcome (8).
This beneﬁcial view on E2F1 was thwarted as other studies
showed that overexpression or ampliﬁcation of the E2F1
genomic locus in conjunction with RB1 loss frequently
observed during cancer progression is associated with meta-
static disease and chemoresistance (9). From this perspective,
aberrantly elevated E2F1 levels in high-grade tumors can be
considered as a marker for unfavorable patient survival prog-
nosis. In support of these ﬁndings, we have recently shown
that dysregulated E2F1 causes malignant progression in ther-
apy-resistant metastatic melanoma xenografts in which deple-
tion of endogenously high E2F1 levels abrogates tumor inva-
sion and pulmonary metastasis (10). According to our results,
the aggressive behavior of E2F1 in melanoma cells is partially
mediated through the induction of the EGF receptor (EGFR)
pathway.
It is well established that E2F1 stimulates the expression
of the tumor suppressor p73 and its N-terminally truncated
isoform (named DNp73) via direct transactivation of the TP73
gene (11).While full-length p73 inhibits cancer development by
inducing cell-cycle arrest and apoptosis through its ability to
bind p53 DNA target sites, DNp73 acts as antagonist of wild-
type p53 family members by either directly interfering with
DNA binding or forming inactive heteromeric complexes with
transcriptionally active p73 (12). Strikingly, in melanoma
metastases DNp73 isoforms are strongly upregulated in con-
junction with full-length p73 compared with primary tumors
(13). Because of the previous results, DNp73 exhibits antiapop-
totic activity in human melanoma cells and speciﬁc suppres-
sion of individual isoforms enhances the sensitivity towards
cytotoxic drugs (14). Investigating mechanisms responsible for
dysregulated E2F1 losing its apoptotic function in human skin
cancer, we identiﬁed miR-205 as a speciﬁc target of p73 and
found that upon genotoxic stress its expression is sufﬁciently
abrogatedby endogenousDNp73 (15). Signiﬁcantly, we showed
that metastatic cells can be rescued from drug resistance by
selective knockdown of DNp73 or overexpression of miR-205
in p73 depleted cells, leading to increased apoptosis and the re-
duction of tumor growth in vivo. These results suggest the E2F1-
p73/DNp73-miR-205 network as a crucialmechanism for chemo-
resistance and thus as a target for prevention of metastasis.
The structure of the E2F1-centered biochemical network
that mediates the potential resistance against anticancer
therapies is a complex system involving signaling and tran-
scriptional regulation. This network is enriched with network
motifs, including feedback and feedforward loops. Further-
more, these network motifs are well interconnected, overlap,
and cross-talk with other cancer-related signaling pathways
(4, 16). Networks containing several of these motifs often
show nonintuitive regulatory patterns, which require the use
of mathematical modeling to understand their function and
regulation (17,18).
In this work, we constructed a regulatory map that sum-
marizes the current literature on E2F1 signaling dysregulation
in cancer and complemented it with information about E2F1
and miR-205 targets, which have known or putative roles in
drug response. On the basis of this map, we derived a math-
ematical model and used it to investigate under which con-
ditions dysregulation of this network provides tumor cells with
resistance mechanisms against several families of anticancer
drugs. In connection to this, we further explored the conse-
quences of tumor heterogeneity in the effectiveness of these
therapies. Our results indicate that kinetic modeling under the
systems biology paradigm can be an effective method to detect
genetic signatures providing tumor cells with chemoresistance
mechanisms and thereby to design therapeutic strategies to
counteract them.
Materials and Methods
Cell culture, PCR, Western blot, and apoptosis assays
The humanmelanoma cell line SK-Mel-147 characterized by
morphology and cytogenetics was obtained from M. Soengas
(Department of Dermatology, University of Michigan, Com-
prehensive Cancer Center, Ann Arbor, MI). Tested and authen-
ticated cells were cultured as described (15). Plasmid miRZIP-
205 encoding antagomir-205 was purchased from BioCat.
Transfections were conducted with Lipofectamine 2000 (Invi-
trogen). Adenoviral vector with shE2F1 was described previ-
ously (10). Expression of hsa-miR-205 and hsa-RNU6B (for
normalization) was detected using speciﬁc TaqMan assays
(Applied Biosystems). PCR,Western blot, and apoptosis assays
were conducted as described. The wet lab data were obtained
previously and are published in (15).
Regulatory map construction
Information about the network components and their inter-
actions was extracted from relevant published reports and
databases (HPRD and STRING for protein–protein interac-
tions; TRED for E2F1 transcriptional targets; TarBase 6.0,
miRTarBase, miRecords andmiR2Disease for validated targets
of miR-205; and TransmiR for transcription factors regulating
the expression of miR-205). Putative miR-205 targets and miR-
205 transcription regulators were extracted from additional
databases (see Supplementary Materials and Methods for a
detailed description of the data retrieval process). As we were
interested in the role of E2F1 and miR-205 in pro- and anti-
apoptotic processes aswell as in drug responses, weﬁltered the
obtained set of molecular interactions based on the corre-
sponding Gene Ontology (GO) terms (GO:0043065, GO:0043066
and GO:0042493). Finally, all the information collected was
integrated into a regulatory map in Cytoscape (available in
Supplementary Materials and Methods).
Kinetic modeling
Representative interactions in the constructed regulatory
map were translated into a kinetic model based on ordinary
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differential equations. Themodel constructed accounts for the
dynamics of miRNA, mRNA and protein expression levels, as
well as cell populations in different cancer-relevant scenarios,
including tumor proliferation and genotoxic or cytostatic drug
administration. Themodel has the following general structure:
dmiRNAi
dt
¼
X
k1
Dk1 GS; Protj ;mRNAi;miRNAi
 
;
dmRNAi
dt
¼
X
k1
Fk1 GS; Protj ;mRNAi;miRNAi
 
;
dProti
dt
¼
X
k2
Gk2 GS; Proti; Protj;mRNAi
 
;
dCi
dt
¼
X
k3
Hk3 Ci; Protj
 
;
where Proti accounts for the expression level of the proteins
involved in the network, mRNAi for the messenger RNAs
mediating their synthesis, miRNAi for miRNAs repressing
expression of given proteins, and Ci for the size of proliferative,
arrested, or apoptotic cell populations. GS is an input signal
that accounts for the effect of genotoxic or cytostatic drugs in
the synthesis and regulation of proteins and mRNAs. Dk1, Fk1
and Gk2 account for the description of biochemical processes
as rate equations that depend on the expression levels of
proteins and mRNAs, or the time-dependent genotoxic stress
signal GS. Hk3 are rate equations describing the dependence of
cell population dynamics on the expression level of critical
proteins in the network. Values of the model parameters
characterizing the reaction rates were assigned following a
hybrid strategy, composed of: (i) extracting parameter values
from published information (e.g., protein, mRNA, and miRNA
half-lives); (ii) estimating a subset of parameter values by
tuning them to ﬁt published quantitative and qualitative data;
(iii) reducing some parameters by normalizing variables
around the basal, nonstressed levels of mRNA and protein.
Model equations and chosen parameter values are provided in
Supplementary Materials and Methods.
In silico cell lines. To search for genetic signatures pro-
viding tumor cells with a chemoresistant phenotype, we pro-
duced in silico (kinetic model-based) cell lines by randomly
perturbing values of selected model parameters using Latin
hypercube sampling. Thereby, we generated 105 in silico cell
lines, each one with a distinctive set of parameter values
accounting for an individual genetic background.
Model simulations
For each in silico cell line, we conducted simulations in 3
cancer relevant scenarios: (i) nonstressed growth conditions;
(ii) apoptosis under; and (iii) proliferation under cytostatic
drug administration. We investigated genetic signatures pro-
viding the tumor cells with a chemoresistant phenotype, by
randomly perturbing parameter values and simulating the
response of the model to different cancer-relevant scenarios.
We analyzed the effects of perturbations in the expression
levels of critical network components by iteratively modifying
their synthesis rate constants accounting for their induction
and simulating the behavior of the network. We assessed
the efﬁcacy of conventional anticancer treatment in in silico
cells with different E2F1-related genetic signatures by simu-
lating periodic cycles of genotoxic or cytostatic drug injection.
Model calibration, computational simulations, and data anal-
ysis were conducted using MATLAB running on a high-end
workstation Fujitsu Celsius V840, 2x CPU AMD Opteron 2214,
2.2 GHz. ECC. Complete information about the construction of
the regulatory map, as well as about the model structure,
calibration, and analysis is included in Supplementary Materi-
als and Methods.
Results
A network with multiple feedforward loops determines
the E2F1 drug response
Our recent results suggest that the E2F1-p73/DNp73-miR-
205 pathway is involved in the regulation of pro- and anti-
apoptotic genes, which confers chemoresistance (15). We
investigated whether this system is part of a wider and more
complex network regulating the response of tumor cells to
anticancer drugs. Towards this end, we constructed a regula-
torymap that contains the E2F1-p73/DNp73-miR-205 pathway
as core module and includes genes targeted by E2F1 or miR-
205, with known or putative relation to the drug response and
drug-induced apoptosis (Fig. 1A). Overall, the map unravels a
tightly interlocked regulatory system. Computational analysis
of the network (81 nodes, 194 edges) shows a robust structure
and a topology that is composed of many regulatory motifs,
especially enriched in feedforward loops (for details, see Sup-
plementaryMaterials andMethods). Interestingly, we detected
several instances of network motifs in which a direct E2F1
target gene interacts with amiR-205–repressed target. Because
E2F1 regulates miR-205 via p73, processes downstream of the
interaction between both targets are regulated by E2F1 fol-
lowing 2 independent routes and can be considered as feedfor-
ward loop (Fig 1A). Several of those loops are associated with
the efﬁcient apoptosis initiation and involve the positive
regulation of proapoptotic genes by E2F1 and the repression
of antiapoptotic genes by miR-205. For example, the E2F1
target Hrk regulates apoptosis through interaction with the
miR-205 targets BCL-2 andBCL-XL (Fig 1A; ref. 19). In addition,
we detected at least one additional instance of this motif, in
which E2F1 promotes EGFR expression andmiR-205 represses
ERBB3 (both belonging to the HER receptor family). In several
tumors, both receptors are associated with abnormal prolif-
eration and upon heterodimerization they inﬂuence sensitivity
to cytostatic drugs like erlotinib (20). Furthermore, DNp73 can
inhibit the expression of p73 transcriptional targets, including
miR-205. The expression of these targetsmay depend on a tight
trade-off between p73 and DNp73 expression and activity,
which are both transcriptionally regulated by E2F1. These
E2F1-p73/DNp73-target motifs can be considered as incoher-
ent feedforward loops. Overall, the activation of miR-205 and
therefore of its targets may depend on the interplay among
E2F1, p73, DNp73, and other regulators ofmiR-205 like TWIST1
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Figure 1. A, E2F1-p73/DNp73-miR-205 regulatorymap. This Cytoscape ﬁgure shows the targets of E2F1, p73, andmiR-205 as well as transcription factors of
miR-205 that are involved in apoptosis (gray nodes), drug response (pink nodes), or both (purple nodes) according to GO. Edges are color coded with respect
to the following processes: transcriptional regulation (dark and light blue), posttranscriptional regulation (orange), and protein–protein interaction (gray),
whereas solid lines represent validated interactions and dashed lines denote predicted interactions. B, kinetic model for the E2F1-p73/DNp73-miR-205
network. The model is composed of four modules: The core regulatory module (blue) describes the dynamics of E2F1, p73, DNp73, and miR-205. The
transcriptional targetsmodule accounts for representative apoptosis and proliferation-associated targets of E2F1, p73, andmiR-205, whichmay play a role in
drug response. The tumor cell populationmodule connects the biochemical network to the fate of a population of tumor cells. GxD accounts for genotoxic and
CyD for cytostatic drug; red-colored symbols for oncogenes and green for tumor suppressors. Twelve ordinary differential equations accounting for the
evolution in time of: E2F1 mRNA (in the model represented with the variable mE2F1) and protein (E2F1), both isoforms of p73 (respectively, p73 and DNp73),
miR-205 (miR205), E2F1-regulated proapoptotic genes (Hrk), p73-regulated proapoptotic genes (Bax), miR-205–repressed antiapoptotic genes (BCL2),
E2F1-regulated and active EGFR (EGFR), cytostatic drug–inhibited EGFR (EGFRI), and miR-205–repressed ERBB3 (ERBB3). In addition, we consider
another differential equation accounting for the population size of tumor cells with the genetic background deﬁned by our model (TC). The node size is in
accordance to its degree (i.e., number of edges connected). C, prototypical simulationmadewith themodel. Upon administration of a drug at t¼ 0, genotoxic
stress is triggered (top). This activates the E2F1-p73/DNp73-miR-205 network (middle), which in turn promotes the transcription of apoptosis-related genes
(middle). When proapoptotic genes are sufﬁciently expressed, they trigger apoptosis and the population of tumor cell decreases (bottom).
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and TGFb-1 signaling, as suggested by our regulatory map.
Because of the network complexity, mathematical modeling is
necessary to investigate nonintuitive regulation of this system
in cancer-relevant scenarios.
A modularized kinetic model to investigate E2F1-p73/
DNp73-miR-205 network chemosensivity
We set up and analyzed a kinetic model using ordinary
differential equations. To construct the model, we selected
parts of the regulatory map that are representative for the
network response to different anticancer drugs (Fig. 1B). The
model is organized into four interconnected modules: the core
regulatorymodule, twomodules of transcriptional targets, and
one for tumor cell population. The core regulatory module of
the kinetic model is composed of E2F1, both isoforms of p73
(respectively, p73 and DNp73) and miR-205 (miR-205) and
accounts for their temporal evolution under drug administra-
tion (15). We include here the transcriptional regulation of
miR-205 expression by the known oncogene TGFb-1 (TGFB1),
which exempliﬁes the set of regulators of miR-205 expression
external to the core module. The inclusion of this variable
allows for the investigation of cross-talk, via miR-205, between
E2F1 signaling and other oncogenic signals involved in the
epithelial–mesenchymal transition (EMT). EMThas been asso-
ciated with the emergence of chemoresistance (21).
In addition, the model includes a module for pro- and
antiapoptotic transcriptional targets, which are regulated by
the network components in response to genotoxic stress.
Precisely: (i) for representing the dynamics of proapoptotic
proteins whose expression is promoted by E2F1, we included a
variable accounting for Harakiri expression (22); (ii) similarly,
for proapoptotic proteins whose expression is positively reg-
ulated by p73 and negatively regulated by DNp73, a variable
accounting for Bax expression is deﬁned (23); and ﬁnally (iii)
for antiapoptotic proteins whose expression is repressed by
miR-205, we chose BCL2 as a representative and deﬁned a
corresponding variable (15). These pro- and antiapoptotic
proteins are used here as an example and represent a wider
set of proteins which undergo similar regulation. This kind of
simpliﬁcation has been successfully applied to reduce the
complexity of models of biochemical networks, for example,
in the study conducted by Aguda and colleagues (24). Further-
more, themodel includes amodule for receptorswhose activity
is regulated in response to cytostatic drugs. This module
includes variables accounting for the dynamics of EGFR,whose
expression is promoted by E2F1 (10), and ERBB3, which is
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Figure 2. A, genetic signatures of the E2F1-p73/DNp73-miR-205 network that confer chemoresistance. Box-and-whisker plots of simulated nonstress levels
for E2F1, p73, DNp73, miR-205, BCL2, TGFb-1, ERBB3, and EGFR for the different subsets of in silico cells generated: gray, entire set of randomly
generated solutions; orange, tumor cells; blue, genotoxic drug–resistant; green, cytostatic drug–resistant; red, double drug–resistant. In each bar, the central
mark is the median, the edges of the box are the 25th and 75th percentiles, the whiskers extend to the most extreme data points. The dashed
horizontal line in the plot accounts for the values in the nominal chemosensitive genetic signature. B, phenotype of the in silico chemosensitive tumor
cell line. Percentage of cells with respect to initial population. Control(0): population size at 0 hours, no drug injection; control(120): population at 120 hours,
no drug injection; CyD(120): 120 hours after cytostatic drug; GxD (48): 48 hours after genotoxic drug. C, distribution of the initial set of randomly generated
104 in silico cell lines in the different subpopulations. Percentage over the total is indicated.
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repressed by miR-205 (25,26). In several tumors the hetero-
dimerization of these receptors has been linked to abnormal
cell proliferation and changes in the sensitivity of tumor cells to
cytostatic drugs (20). Additional input variables account for the
effect of genotoxic (GxD) and cytostatic (CyD) drugs triggering
DNA damage-E2F1–mediated apoptosis and abolishment of
tumor cell proliferation, respectively (4).
Finally, the lastmodule includes a phenomenological kinetic
equation, which connects the components of the network to
the dynamics of the tumor cell population. In this equation, the
representatives for pro- and antiapoptotic proteins regulate
the cell death rate after genotoxic stress, whereas EGFR and
ERBB3 control the tumor cell proliferation rate. Taken togeth-
er, our model is able to describe the cascade of regulatory
events after drug administration including stress signals,
downstream intracellular responses, the regulation of pro-
and antiapoptotic signals (for genotoxic drugs) or proliferative
signals (for cytostatic drugs), and ﬁnally the global effect on
tumor cell population (Fig. 1C; see Supplementary Materials
and Methods for a complete description of the model).
Genetic signatures for the E2F1-p73/DNp73-miR-205
network that confer chemoresistance to anticancer
drugs
In our analysis, we considered two families of drugs: geno-
toxic drugs, like doxorubicin and cisplatin, inducing apoptosis;
and cytostatic drugs, like erlotinib and lapatinib, repressing
tumor cell proliferation. In some scenarios, it has been
observed that these drugs lose efﬁcacy when some of the
network components are dysregulated (15,27). With the help
of the kinetic model, we analyzed whether speciﬁc genetic
signatures of the core module can be linked to a phenotype
response of resistance to these anticancer drugs. We deﬁne a
genetic signature as a group of genes in a tumor cell whose
combined expression pattern is linked to a speciﬁc phenotype
(i.e., chemoresistant or chemosensitive). In line with this, we
designed a nominal in silico chemosensitive genetic signature,
inspired by that of SK-Mel-147 (15). This signature accounts for
the expression of the network components for which an in
silico cell line holds the phenotype of a chemosensitive tumor
cell; that is, abnormal proliferation but responsiveness to
genotoxic drugs (via triggering of apoptosis) and cytostatic
drugs (via inhibition of proliferation, see Fig. 2B).
To detect genetic signatures providing chemoresistance, we
generated a population of 104 model conﬁgurations obtained
by random perturbation of the model parameter values of the
nominal chemosensitive genetic signature. In the following, we
deﬁne these distinct conﬁgurations as in silico cell lines. For
each one of them, we simulate the model and obtained the
expression levels of the network components and the tumor
cell population in three cancer-relevant scenarios: (i) under
nonstress conditions, at time zero, and after 120 hours; (ii) after
genotoxic drug administration, at 48 hours; and (iii) after
cytostatic drug administration, at 120 hours. The in silico cell
lines were classiﬁed into the following groups: (i) cell lines that
show abnormal proliferation in nonstress conditions, named
as tumor cells; (ii) those resistant to genotoxic drugs; (iii) those
resistant to cytostatic drugs; and (iv) those resistant to both
genotoxic and cytostatic drugs. For each group, the data
describing the expression levels of the network components
at time zero were normalized with respect to the nominal
chemosensitive values (Fig. 2C). For the computational deﬁ-
nition of the simulation scenarios and classiﬁcation of the
resulting cell phenotypes, see Supplementary Materials and
Methods.
Our results indicate that 30% of the in silico cell lines are
resistant to genotoxic drugs (Fig. 2C). These cells display high
basal levels (at time zero, nonstress conditions) of E2F1 and
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Figure 3. The interplay between E2F1 and miR-205 promotes resistance
to genotoxic drugs. A, model simulations. For different values of the
synthesis rates for E2F1 and miR-205 (kE2F1; kmir205 2 ½101; 101), we
determined the percentage of apoptotic cells 48 hours after genotoxic
stress: Apoptotic cells¼ 100  [1- TC(t¼ 48)], where TC is the number of
surviving tumor cells at 48 hours. B, validation experiments with SK-Mel-
147 cells. The percentage of apoptotic cells wasmeasured 48 hours after
cisplatin treatment. 1, control; 2, after miR-205 knockdown; 3, after E2F1
knockdown; and 4, after miR-205 and E2F1 knockdown. Data were
extracted and processed from Alla and colleagues (15).
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DNp73, whereas miR-205 is downregulated compared with the
nominal chemosensitive tumor cell and the group of in silico
tumor cells (Fig. 2A). In addition, approximately 1% of the cell
lines display resistance to cytostatic drugs. These cells have a
genetic signature composed of much higher basal E2F1,
DNp73, and ERBB3 levels, whereas miR-205 appears strongly
downregulated and TGFb-1 is moderately upregulated. In both
cases, EGFR is expressed at itsmaximum level, but our analysis
indicates that this is a property already acquired by the group
of tumor cells as a consequence of high levels of E2F1 (see
Supplementary Materials and Methods). Finally, a small frac-
tion of the cell lines display a phenotype of double resistance
and their genetic signature is very similar to that of cytostatic
drug–resistant cells.
Taken together, our results suggest a relevant role for E2F1,
DNp73, and miR-205 in the regulation of resistance to several
anticancer drugs. To validate this model-based prediction, we
compared them with our recently published data on the
interplay of E2F1 and miR-205 under genotoxic stress admin-
istration (15). To this end, we conducted simulations in which
we iteratively perturbed the values of the parameter account-
ing for E2F1 and miR-205 induction and computed the
percentage of apoptotic cells 48 hours after genotoxic drug
administration. As shown in Fig. 3A, in silico cell lines with high
levels of E2F1 display lower percentage of apoptotic cells in
response to chemotherapy. Our previous experiments with
melanoma SK-Mel-147 cells conﬁrm the simulation results
(Fig. 3B). SK-Mel-147 cells were treated with cisplatin and high
percentage of cells became apoptotic (Scenario 1 in Fig. 3B).
Inhibition of miR-205 with antagomir-205 reduces the per-
centage of apoptotic cells after treatment (Scenario 2), whereas
selective knockdown of endogenously high E2F1 leads to a
pronounced increase in apoptosis (Scenario 3). Finally, repres-
sion of both E2F1 and miR-205 reduces the apoptotic effect of
cisplatin (Scenario 4). These experimental results conﬁrm the
model predictions displayed in Fig. 3A for the scenarios named
with the same numbers.
To verify whether dysregulation of couples of network
components affects chemosensitivity to genotoxic and cyto-
static drugs, we conducted additional simulations in which we
iteratively modiﬁed the values of the protein synthesis rates
(Fig 4). Precisely: (i) because the p73/DNp73 ratio is known to
play a major role in the aggressiveness of cancer cells
(11, 28, 29), we iteratively modiﬁed the parameters accounting
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for p73 and DNp73 synthesis; ii) given that overexpression of
E2F1 is associated with aggressiveness and chemoresistance
(4,15), we also considered iterative modulation of E2F1 and
DNp73 synthesis parameters to test whether their dysregula-
tion sufﬁces to induce resistance; (iii) considering that
dysregulation of TGFb-1 signaling promotes invasion and
metastasis (30), we modiﬁed the E2F1 synthesis parameter
and TGFb-1 expression level to investigate whether they can
synergize in the emergence of a resistance phenotype; and (iv)
given that the expression of ERBB3 associates to the resistance
to certain cytostatic drugs (20,31,32), we modiﬁed E2F1 and
ERBB3 synthesis parameters to test whether their combined
dysregulation can cause enhanced chemoresistance.
As shown in Fig. 4A, in silico cell lines with strong DNp73
and/or weak p73 synthesis display a very high percentage of
cells resisting apoptosis after genotoxic drug administration,
whereas strong p73 synthesis and reduced DNp73 induction
provide efﬁcient cell death. Furthermore, our kinetic simula-
tions suggest that very strong E2F1 induction alone is sufﬁcient
to provoke chemoresistance to genotoxic drugs and can there-
fore compensate low DNp73 levels (Fig. 4B). In addition, high
induction of TGFb-1 reduces the level of E2F1 required to
induce resistance. Taken together, strong E2F1 synthesis can
synergize with strong induction of DNp73 and TGFb-1 to
provide genotoxic drug resistance (Fig. 4A). When analyzing
the emergence of resistance to cytostatic drugs through the
considered network, our analysis indicates that strong ERBB3
and E2F1 induction can synergize to achieve chemoresistance
(Fig. 4B). Taken together, the results suggest that resistance to
both genotoxic and cytostatic drugs can emerge with strong
ERBB3 and E2F1 induction. We summarized our results in a
qualitative manner in Fig. 4C, which lists possible genetic
signatures conferring chemoresistance. We note that in our
model, the regulation of antiapoptotic genes like BCL-2 and
ERBB3 by E2F1, p73/DNp73, and TGFb-1 is mediated via miR-
205. Therefore, we hypothesize that the coregulation of miR-
205 by its transcriptional regulation can foster chemoresis-
tance (Fig. 4D).
Conventional genotoxic drug treatment favors selection
of chemoresistant cells in genetically heterogeneous
tumors
It is a well-established fact that cell populations with dif-
ferent genetic signatures inﬂuencing cancer hallmarks coexist
in malignant tumors (33). In line with this, we used our kinetic
model to investigate how tumor heterogeneity (i.e., coexistence
of several populations with different genetic signatures) affects
the efﬁcacy of conventional anticancer therapy (Fig 5). In our
analysis, we focused on genotoxic drugs. Towards this end, we
reformulated our model to consider two kinds of tumors: (i)
tumors with homogeneous expression of E2F1 and (ii) tumors
with heterogeneous expression of E2F1. In our simulations,
heterogeneity in E2F1 expression is modeled by making 90% of
cells with a deﬁned E2F1 level, 5% cells with 0.5-fold down-
regulation, and 5% cells with 2.5-fold upregulation of E2F1. In
accordance with our previous simulations, we considered two
biologic scenarios: E2F1 overexpression (101, represented by
E2F1~) and extreme overexpression (102, represented by
E2F1~~).
We used the model to simulate the effect of an anticancer
treatment composed of periodic injections of a conventional
genotoxic agent. In a tumor with homogenous E2F1 over-
expression, our results indicate that the tumor is abolished
after several injection cycles (Fig. 5 top left). However, in a
Figure 5. Effectivenessof genotoxic
drug treatment in tumors
with homo- and heterogeneous
genetic signatures for E2F1. We
simulated the effect of an anticancer
treatment composed of periodic
injections of a conventional
genotoxic agent, twice aweekduring
20 weeks (see Supplementary
Materials and Methods for details).
The size of the tumor was assumed 1
(n.u.) at time zero.Plots in theﬁrst row
illustrate the treatment-dependent
tumor growth for tumors with
homogeneous E2F1 levels, whereas
the second row accounts for tumors
with heterogeneous E2F1 levels.
First column accounts for scenarios
with E2F1 overexpression (101,
represented by E2F1~) and the
second column shows extreme
overexpression (102, represented by
E2F1!!).
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tumor with homogenous E2F1 extreme overexpression, our
simulation suggests that the tumor is resistant to the therapy
and recovers fast growth afterwards (Fig. 5 top right). Inter-
estingly, in a tumor with heterogeneous E2F1 overexpression,
the tumor becomes virtually abolished after several cycles of
drug injection, but the tumor reemerges after the drug injec-
tions are discontinued (Fig. 5 bottom left). Finally, for a tumor
with heterogeneous E2F1 extreme overexpression, model
simulations indicate that the tumor is fully drug resistant with
continuous proliferation (Fig. 5 bottom right).
We further analyzed the scenario of heterogeneous E2F1
overexpression and found that in our simulations during the
treatment, the composition of the tumor shifts from one of
predominantly chemosensitive cells at time point zero (Fig. 6A,
dark blue curve) towards a composition of entirely genotoxic-
drug resistant cells at twenty weeks (Fig. 6A, red curve). This
suggests that the genotoxic drug treatment can induce selec-
tive pressure on tumor cells. This is because chemosensitive
cells undergo apoptosis during treatment, whereas cells with
the resistant genotype withstand and continue proliferating.
Therefore, the tumor reemerges after discontinuation of the
treatment after 20 weeks (Fig. 6B). Our simulations indicate
that during treatment the genetic signature of E2F1 and miR-
205 in the tumor shift from that of chemosensitive cells to the
one in chemoresistant cells (upregulation of E2F1 and down-
regulation of miR-205, Fig. 6C). Strikingly, we were able to
conﬁrm our prediction with experiments, in which we stim-
ulated SK-Mel-147 cells with iteratively increasing levels of
cisplatin (1–50 mmol/L) and measured E2F1 and miR-205
expression before and after the treatment with this genotoxic
drug (respectively and in Fig. 6C; ref. 15).
Discussion
E2F1-p73/DNp73-miR-205 network mediates
chemoresistance
We developed a kinetic model to investigate the emergence
of chemoresistance in tumor cells, mediated by a network with
a core module composed of E2F1, p73, DNp73, and miR-205. In
previous efforts, mathematical modeling was applied to
address the role of E2F1 and other network components in
cancer and cell proliferation (24, 34–36). However, to our
knowledge, this work is the ﬁrst modeling-based analysis of
E2F1-mediated chemoresistance.
Our results suggest that dysregulation of this network can
provoke chemoresistance to multiple anticancer drugs. In line
A B
100
80
60
40
20
0
2
1.5
1
0.5
0
2
1.5
1
0.5
0
E(–)
E(tc)
E(+)
Model prediction Experimental data
1.5
1
0.5
00 10 20 30
Time (wks) 0 10 20 30
Time (wks)
E2F1 miR-205 E2F1 miR-205
Tu
m
or
 c
om
po
si
tio
n 
(%
)
S
iz
e 
(a
.u
.)
E
xp
re
ss
io
n 
(n
.u
.)
E
xp
re
ss
io
n 
(n
.u
.)
C
Figure 6. Selection of chemoresistant clones after conventional genotoxic drug treatment in tumors with heterogeneous genetic signature for E2F1. We
simulated the effect of periodic injections of a conventional genotoxic agent over an in silico tumor, with a heterogeneous genetic signature for
E2F1. TheaverageE2F1expression level, E2F1av, is similar to that in the in silico chemosensitive tumor cell line; 90%cells displayE2F1E2F1av; 5%cellswith
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treatment). C, normalized E2F1 and miR-205 levels before and after injection of repeated cycles of genotoxic drug as predicted by our model. Bottom
right, SK-Mel-147 cells stimulatedwith increasing levels of cisplatin (1–50mmol/L). E2F1 andmiR-205 levelsweremeasuredbefore and after treatment.
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with this, our model unraveled several genetic signatures of
tumor cells that can promote chemoresistance. Regarding
genotoxic drugs, we found a signature of high E2F1 and low
miR-205 expression that promotes resistance. Downregulation
of miR-205 in this signature can be mediated by an imbalance
in the p73/DNp73 ratio or by the dysregulation of other cancer-
related pathways like TGFb-1 signaling, whose components
positively or negatively regulate miR-205 expression (37,38).
With respect to the imbalance in the p73/DNp73 ratio, our
simulations predict that tumors with high E2F1 and normal/
high DNp73 expression show a higher percentage of surviving
cells after genotoxic stress than tumors expressing high E2F1
and low DNp73. This supports the idea that DNp73-mediated
repression ofmiR-205 is amechanismbywhich drug resistance
is achieved. Because DNp73 is promoted by E2F1, high levels of
E2F1 can induce chemoresistance via the E2F1-DNp73-miR-
205 axis due to the negative regulation of miR-205 by DNp73
(Fig. 7A). However, DNp73 is upregulated in melanomametas-
tases with a concomitant rise of the full-length p73, a positive
regulator of miR-205 (13). Taken together, this module has the
structure of an incoherent feedforward loop. This suggests that
the speciﬁc ratio between both p73 isoforms expression and
activity determines the functional outcome of E2F1 and cell
fate upon genotoxic treatment. This ratio is regulated in
malignant melanoma by as yet unknown factors involved in
alternative splicing of p73 pre-mRNA, possibly independent of
E2F1 (39). In tumor cells with high E2F1 induction, our analysis
indicates that downregulation of DNp73 and/or upregulation
of p73 can restore chemosensitivity, which emphasizes the
importance of the p73/DNp73 ratio.
When constructing the network, we found that some pro-
teins involved in the epithelial-to-mesenchymal transition
(EMT), like TGFb-1, BMP, or TWIST1 can regulate miR-205
expression in some tumors (38,40). Furthermore, our simula-
tions indicate that when E2F1 is upregulated, high levels of
TGFb-1 or other EMT-related signals regulating miR-205,
external to the E2F1 network, can provoke genotoxic drug
resistance in cancer cells. This suggests an intriguing hypoth-
esis, in which E2F1 signaling cross talks and synergizes with
some EMT-related signals, and their regulation of common
miRNAs can mediate this synergy in the context of chemore-
sistance (Fig. 7B).
Moreover, our analysis gives additional insights into the
resistance to cytostatic drugs that inhibit the activation of
HER receptor family members. We found a genetic signature
composed of high E2F1, low miR-205, and high ERBB3 that
can render tumor cells insensitive to cytostatic drugs. As
cited before, miR-205 posttranscriptionally represses ERBB3.
Interestingly, recent results suggest that tumor cell lines
sensitive to erlotinib show high levels of miR-205 and other
miRNAs (41), which supports our predictions. According to
our model analysis, tumor cells with E2F1 overexpression
and miR-205 downregulation do not show cytostatic drug
resistance, but synergy with high ERBB3 gene activation is
required to acquire this feature. In addition, the simulations
suggest that in most of the cases, this genetic signature can
lead to double resistance, this means the tumor cells become
insensitive to some genotoxic and cytostatic drugs at the
same time, a feature that may have important consequences
in the design of personalized cancer treatments. The under-
lying molecular mechanism providing this double resistance
is to be further elucidated.
Taken together, our results indicate that differences in the
expression of some of the proteins in this network are critical
for tumor cells to become chemoresistant, and that this
resistance is substantiated through regulatory loops including
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miR-205. We note that the predictions we made are based on
qualitative modeling, similar to those made in the studies
conducted by Aguda and colleagues and Yao and colleagues
(28,39). Tomake the predictions of our model quantitative, the
model should be further reﬁned in iterative cycles of experi-
mentation and model calibration (17,18).
In the model parameterization analyzed, the feedback loop
between E2F1 and miR-205 has minor effects in the dynamics
of the network. Our previous results of modeling miRNA
regulation of cancer-related genes suggest that the strength
ofmiRNA regulation is context-dependent andmay be affected
by the coregulation of other miRNAs or proteins (42). Thus, we
hypothesize that this feedback loop could be negligible in the
scenarios investigated in this article, but still crucial in other
biologic contexts which have not been investigated in this
paper. In this way, miR-205–mediated repression of some
antiapoptotic targets in our networkmay be affected by similar
coregulation. Our modeling results complement those of
Aguda and colleagues (24) and others (43) who also used
kinetic modeling to investigate the role of miRNA regulation
on E2F1 in cancer. Aguda and colleagues (24) found that the
coupling between the E2F/Myc positive feedback loop and the
E2F/Myc/miR-17-92 negative feedback loop is crucial to reg-
ulate a bistable on–off switch in E2F/Myc protein levels, a
feature that is critical in the dysregulation of E2F1 activity
during cancer progression. We here claim that E2F1-mediated
regulation of miRNAs may as well be critical to explain the
emergence of chemoresistance.
Finally, our simulations indicate that tumor heterogeneity
in terms of the genetic signature of the E2F1-p73/DNp73-
miR-205 network can affect the efﬁcacy of anticancer ther-
apy. In addition, our simulations suggest that the therapy
can induce selective pressure on tumor cells favoring those
showing chemoresistance. Other authors have suggested
that under conditions of tumor genetic instability, hetero-
geneous tumors contain populations of one or more resis-
tant clones (44, 45). These resistant subpopulations can be
residual compared with other clones in a pretreated tumor
due to the phenotypic cost associated with chemoresistance,
but could get favored when the anticancer therapy is
applied (46). This hypothesis is supported by our results.
In our analysis, we only considered the role of the E2F1-p73/
DNp73-miR205 network in developing chemoresistance.
However, these molecules interact with additional genes
involved in the regulation of other phenotypic responses
and therefore display pleiotropy (4,16). Thus, it is possible
that some features of the resistant phenotype here described
may have negative effect on other cancer-associated traits,
which are out of the scope of this article. In a more realistic
case, one could enrich the analysis by expanding the network
with interaction partners representative of these other phe-
notypes and conducting a more extensive analysis.
Design principles underlying chemoresistance
Our analysis indicates that the network under investigation
is enriched in feedforward loops. Most of these motifs are
central to the efﬁcient apoptosis initiation after genotoxic
stress and therefore their dysregulation can cause chemore-
sistance (47,48). Previous publications have emphasized the
important role of feedforward loops regulating the transient
dynamics of biochemical pathways (49). We here support the
hypothesis that these loops may further control important
features of the long-term response in signaling and transcrip-
tional systems. The paradigmatic case is the regulation of miR-
205 by p73 (positive) andDNp73 (negative), two transcriptional
targets of E2F1. This system is a canonical case of an incoher-
ent feedforward loop. Several publications suggest that the
regulation and activity of p73 and DNp73 is nonlinear and
varies for different levels of E2F1 expression (28,50). Under
these conditions, our simulations indicate that the incoherent
feedforward loop allows a single protein (e.g., E2F1) to non-
monotonically regulate components downstream of the loop
(e.g., miR-205; see Fig. 7A). Thus, for an interval of E2F1
expression levels the incoherent feedforward loop is dominat-
ed by the p73-mediated positive branch and promotes expres-
sion of miR-205. However, for higher expression of E2F1, the
negative, DNp73-mediated branch predominates and the
downstream target is repressed (Fig. 7A). This suggests that
incoherent feedforward loops can be active structures of
regulation when the different branches of the loops get dis-
tinctively regulated.
Furthermore, we identiﬁed several network motifs with the
structure of incoherent feedforward loops, in which a compo-
nent downstream the network is regulated by a direct E2F1
target gene and a miR-205–regulated target. In our study, we
focus on apoptosis-related targets (e.g., BCL-2 and HRK,
see Fig. 7B). As we mentioned before, miR-205 expression is
regulated by other cancer-related signals, external to the E2F1
network (e.g., EMT-related signals). Therefore, changes in the
activity of those external signals may alter the activation status
of the antiapoptotic branch and as a consequence the balance
between pro- and antiapoptotic signals is also altered (Fig. 7B).
In addition, miR-205 regulates proteins downstream the EMT
signaling, like E-cadherin, and some members of the BCL2
family are regulated by E2F1. This suggests the existence of
additional feedforward loops which were not investigated in
this work (25). Taken together, feedforward loops involved in
chemosensitivity can be considered active regulatory struc-
tures, whose activation status may depend on the cross-talk
with other cancer-related signals.
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